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LIST OF ABBREVIATIONS 
AAP: atypical antipsychotic drug 
ALR: average logarithmic ratio 
AP: antipsychotic drug 
CNS: central nervous system 
CNT: control 
DG: dentate gyrus of the hippocampus 
DMEM: Dulbecco’s modified Eagle medium 
DMSO: dimethyl sulfoxide 
FBS: fetal bovine serum 
G * E: geneenvironment interaction 
GAL: galactose-enriched, glucose-deprived medium 
GFAP: glial fibrillary acidic protein 
HDF: human dermal fibroblast 
HL: haloperidol 
HPA: hypothalamic-pituitary-adrenal axis 
iNC: induced pluripotent stem cell-derived neural cell 
iPSC: induced pluripotent stem cell 
MAP2: microtubule associated protein 2 
MD: major depression 
mGluR2 and mGluR7: metabotropic glutamate receptor 2 and 7 
NEUROD1: Neural differentation 1 
NPC: neural progenitor 
OL: olanzapine 
PBS: phosphate-buffered saline 
qPCR: quantitative polymerase chain reaction 
RL: lipid-reduced medium 
RP: risperidone 
STD: standard 
TAP: typical antipsychotic drug 
VGLUT1: vesicular glutamate transporter 1 
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1 INTRODUCTION 
1.1 MODELING MENTAL DISORDERS 
As mental disorders are exclusively human conditions and their pathophysiology can 
not be directly analyzed in the dysfunctioning organ in vivo, investigating and modeling these 
conditions raises several problems and necessitates compromises. Animal models provide 
valuable information on the behavioral disturbances and associated structural and functional 
brain alterations but obviously have their limitations and validation difficulties
1
. Hence, 
human biospecimens and experimental model systems are indispensable in studying complex, 
multifactorial neuropsychiatric disorders. 
Postmortem observations might be biased by various artifacts related to in vivo effects, 
applied treatment, cause of death or postmortem interval
2
. Brain banks provide great sample 
sizes, standardized methodology and detailed clinical information. However, they cannot 
counterveil that postmortem samples are not appropriate for functional assays evaluation of 
gene * environment (G * E) interactions, maladaptation, or drug response and have limited 
utility in establishing diagnosis and aiding therapeutic approaches which would be one of the 
greatest clinical advantages of etiology and biomarker studies.  
Thus, high effort is taken to develop easy-to-gain and -maintain living subjects for 
functional, translational and heritability studies in psychiatric disorders. Considering that 
molecular abnormalities, contributing to neural dysfunction (e.g. mitochondrial, metabolic 
changes, antioxidant potential, intracellular signaling, geneexpression regulation) are common 
among cell types and the majority of psychiatric disorders have a heritability between 40-
90%, they can be studied in vitro
3
. Patient derived cellular functional assays enable a system-
oriented view, in which mental disorders are the manifestation of the donor’s individual 
genetics and perform functional assays to map G * E and G * G interactions. 
In my thesis, I introduce two research projects which aimed to examine the 
diathesis‒stress model of depression in patient-derived dermal fibroblast cultures (Study 1) 
and the effect of antipsychotic drugs on induced pluripotent stem cell (iPSC) -derived 
differentiating neurons (Study 2). 
1.2 STUDY 1 – DIATHESIS‒STRESS IN FIBROBLASTS 
Selye suggested that stress response follows an evolutionary conserved scheme via 
activating the neuro-immuno-endocrine system, independently from the source or parameters 
of the stressor
4
. After danger passes, the reaction settles down and the body starts to restore 
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the reserves. Yet in some cases, the same external stimulus provokes prolonged, inadequate 
stress response and results in maladaptive disorders, such as major depression (MD).  
In 2012, MD was the leading cause of disability worldwide (WHO
5
) affecting almost 
every 5th people. It is a multifactorial disorder, with a heritability of 36-70%, suggesting 
complex (epi)genome * environment interactions in the background
6
. Despite decades of 
active research, the exact pathomechanism of MD remains unclear. Candidate gene, linkage 
and genome-wide association (GWA) studies failed to identify the genetic background of the 
disorder
7 , 8
 underpinning the polygenic heterogeneity model. According to this, common 
genetic variants alone cause minor phenotypic changes, but in certain constellations, their 
effects sum up and results in decreased individual resilience
9,10,11
.   The diathesis-stress model 
claims that this genetic sensitivity interacts with the environment and may result in the 
development or remission of clinical symptoms through the life9,10. Thus, genetic load often 
manifests only when a stress occurs and anomalies of the adaptation system are heightened. 
This G * E based approach of MD is supported by clinical data: there is a well-known 
association between stressful life-events and the development of depressive symptoms. 
Chronic stress disposes to immunological and mental disturbances and the inflammatory 
response modulates the hypothalamic-pituitary-adrenal axis (HPA axis), affective and 
cognitive functioning. Therefore, HPA-axis and inflammatory system dysregulation are the 
most studied and proved somatic factors of MD
12,13,14
. The theory is also plausible in a 
neurobiological contexts, described in the inflammation–neurodegeneration model of MD.  
MD is also referred to as metabolic syndrome type II, a complex endocrine - metabolic 
disorder. Stress hormones, vasopressin, enteroendocrine factors (insulin-like growth factor, 
ghrelin, cholecystokinin) show significant alterations in MD patients
15
. Furthermore, 
metabolic dysregulation might be associated with depressed mood and cognitive 
impairment
16
. Thus, it is plausible that G * E caused cellular malfunction manifests not only 
in affective/cognitive disturbances in the CNS, but in immune and metabolic alterations in the 
peripheral tissues also.  
1.2.1 Human dermal fibroblasts in psychiatric research 
In the recent 5 years, there has been growing literature on human dermal fibroblasts 
(HDFs) as potential model systems or biomarker resources in psychiatric disorders. They 
were used to investigate disease-related metabolism, redox homeostasis, membrane transport, 
apoptotic susceptibility, transcriptome, circadian rhythm or pharmacology in schizophrenia, 
attention deficit and hyperactivity disorder, MD, and bipolar depression.  
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HDFs are relatively easy to obtain from minimal invasive skin biopsies
17
. Their 
maintenance does not require significant resources and they can be easily propagated for long 
periods of time without genetic manipulation or external growth factors
18
. The cultures consist 
of mitotic and post-mitotic, uniform fibroblast cells
19
 and retain genetic stability for 15-20 
passages
20
. After 4-5 passages, cell lines thought to be free of pre-sampling in vivo effects, 
such as health state, diet, medication and environmental factors
21,22
. The gene expression, 
signaling pathways and receptor profile of fibroblasts are similar to cells of neuro-ectodermal 
origin
23
. Moreover, they proved to express neuron and glia specific markers
24
.  
All these considerations make HDF cultures an appealing, cost-effective experimental 
model for studying neuropsychiatric disorders. They can be used for directly studying the 
naive pathophysiology, maladaptation and epi(genetic) regulation; and may be potential 
subjects of controlled, reproducible, ‘individualized’ in vitro experiments with the patient’s 
genetic background.  
1.2.2 microRNAs: tuning mega-regulators 
Adaptation requires a quick, accurate, coordinated reaction on systemic and cellular 
level. MicroRNA-mediated transcription regulation meets these criteria. MicroRNAs are 
small (18-24–nucleotid–long), single-stranded, non-coding RNAs, key regulators of gene 
expression. More than 2000 mature microRNAs modulate nearly 60% of the human genes 
with a high degree of pleiotropy and functional redundancy. They dampen the gene 
expression and suppress its intrinsic variations to help the maintenance of homeostasis
25
. 
Intriguingly, growing body of evidence indicates that microRNAs may exert paracrine and 
endocrine-like effects after secreted into the interstitium and various biospecimens (e.g. 
plasma, saliva, tear, or urine)
 26,27,28
.  
MicroRNAs link to a complementary sequence in the 3′-untranslated region (UTR) 
and evoke the degradation, destabilization, storage or transport of the target mRNA, thus 
induce the permanent or temporary repression of local or cell-wide protein synthesis. 
However, the presence of a microRNA is not automatically enough to predict its silencing 
effects. For instance, if the complementarity between the microRNA and the target site is not 
perfect, the partial hybridization (temporalily) prevents translation but does not lead to mRNA 
decompose
29
. After the detrimental effect ceases, mRNAs are rehabilitated from the stress 
granules and translated for rapid recovery
30
. Moreover, recent observations suggest that 
miRNAs do not have exclusively negative effect on translation: the target genes can be 
enhanced by direct gene activation, mRNA stabilization, or mRNA de-repression
31,32
. Thus, 
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microRNA-driven mRNA metabolism is essential in the protection of the future enzyme sets 
and reserve capacities
33
. This remarkable dynamicity and complexity enables microRNAs to 
fine-tune the overall cell transcriptome or local protein sets (e.g. during synapse formation).  
Fifty percent of the known human microRNAs are expressed in the CNS
34
. Some 
microRNAs show restricted tissue distribution but most of them are widely expressed 
although their appearance and function might be specific to the cell type and developmental 
stage
35,36
. They are implicated in multiple processes associated with cell cycle, apoptosis, 
differentiation, regeneration, metabolic adaptation and synaptic plasticity
37,38
. We assume if 
there is a dysregulated microRNome background of the maladaptive stress reaction in the MD 
brain, and this microRNA signature might be detectable in other cells of the body.  
Compared with other types of RNAs, microRNAs exhibit higher stability even under 
harsh conditions, i.e. long storage at room temperature
39
 and in extreme pHs
40
. Postmortem 
and animal studies revealed microRNA alterations in the brain, blood and cerebrospinal fluid 
(CSF) in MD
41
, anxiety
42
, bipolar disorder
43
, and schizophrenia
44 , 45 ,
. Furthermore, 
microRNAs are involved in the gene expression and behavior modulatory effects of stress, 
psychotropic and antidepressant drugs
46,47
. These suggest that microRNAs can be used to 
assess and monitor the body's pathophysiological state
48
. However, the results are 
controversial and the association between the brain and peripheral microRNA changes is 
poorly understood. 
1.3 STUDY 2 – A PSYCHOPHARMACOLOGICAL ASSAY 
1.3.1 Human induced pluripotent and neural cells in psychiatric research 
In 2007, Yamanaka and Takahashi showed that human postmitotic somatic cells can 
be reprogrammed into induced pluripotent stem cells (iPSCs) and further differentiated into 
all three germlines
49
. Since then, iPSC-research is apparently the most rapidly developing 
field of bioscience with exceptional possibilities in in vitro disease modeling, regenerative 
medicine and drug development. Numerous reprogramming protocols have been published 
differing in the applied factors, delivery method and culturing condition
50
. Summarising, a set 
of transcriptional factor genes can be transfected into the cells via integrating (lenti- and 
retroviral) or non-integrating (adenovirus, episomal vector, synthetic mRNA) vectors or direct 
protein delivering tools 
51,49,52
. After initial induction, endogenous NANOG, SOX2 and OCT-4 
expression indicate pluripotency of iPSCs which can be maintained for theoretically unlimited 
time or differentiated into committed cell lines, such as neural progenitors (iNPC) and mature 
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neurons (iNC). These provide opportunity to study neuropathophysiology grounded by the 
patients’ individual genotype. 
The differentiation of iPSCs is thought to follow in vivo spatio-temporal 
developmental pathways
53 , 54
 with highly conserved milestones among embryonic, early 
postnatal and adult neurogenesis
55
. Remarkably, a combination of growth factors/small 
molecules is sufficient to evoke high neurotransmitter specificity: GABAergic cortical 
interneurons
56,57
; dopaminergic midbrain neurons 
58,59
; or glutamatergic cortical neurons
60
.  
1.3.2 Modeling hippocampal neurogenesis 
Neurogenesis, defined here by the generation of mature neurons from precursors, 
continues lifelong in two brain regions: the subventricular zone (olfactory bulb migratory 
pathway) and the subgranular zone of the hippocampus
61
. In the latter, proliferating radial and 
non-radial precursors give rise to neuroblasts through intermediate progenitor cells, an 
estimated number of 500-1000 neurons per day. New, immature neurons migrate into the 
inner granule cell layer and differentiate into glutamatergic dentate granule cells, grow axons 
and dendrites and integrate into efferent pathways and the local dentate gyrus ‒ CA3 circuitry 
(i.e. mossy fibers)
62
.  
In 2014, Yu et al. produced hippocampal glutamatergic granule neurons from iPSCs 
using key developmental cues specific to the dentate gyrus (DG) identity and opened the 
doors to model adult CNS neurogenesis in vitro
63
. The generated neural cells expressed 
mature DG neural marker PROX1 and TBR1, established functional synapses and were able 
to incorporate into mouse DG in vivo.   
Adult neurogenesis plays inevitable role in learning and memory
64
. It is a dynamic, 
fine-tuned process containing several stages such as proliferation, fate determination, 
selective death/survival and maturation. It is modulated by various intrinsic and extrinsic 
stimuli from neural, glial and vascular cells or the endocrine system
64
. This complexity and 
inimitability makes neurogenesis so ambitious subject of in vitro researches. Dysfunctional 
neurogenic patterns are indicated in psychiatric disorders (recently reviewed by Apple et al
65
). 
For instance, the neurogenic rate is reduced in stress, MD or schizophrenia which might be 
reversed by antidepressant and atypical antipsychotic (AAP) medication
66,67
.  
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2 STUDY OBJECTIVES 
We hypothesize that MD is a systemic, maladaptational disorder with a genetic 
background, thus it can be studied in peripheral cells on a transcriptome level, particularly 
after stress treatment. We aimed to answer the following questions:  
(1) How metabolic stress alters the mRNA and microRNA expression of HDFs (in other 
words: the manifestation of stress-response in the transcriptome level)?  
(2) Are there any differences between the mRNome and microRNome of HDFs of MD and 
control subjects (i.e. the footprints of diathesis on the transcriptome of peripheral cells)? 
(3) Are there any differences in the stress response of MD and control HDFs (the 
maladaptation-associated mRNA and microRNA-profiles, in effect)?  
In Study 2, we aimed to investigate how various antipsychotics (APs) affect the gene 
expression of differentiating and maturing hippocampal granule cells in vitro. Thus, we set up 
an in vitro pharmacological assay using neural cells originated from human iPSCs and 
treating them with typical AP haloperidol (HL) or with atypical olanzapine (OL) and 
risperidone (RP) at two different concentrations. 
3  MATERIALS AND METHODS 
3.1 STUDY 1 – DIATHESIS‒STRESS IN FIBROBLASTS  
3.1.1 Skin biopsy and fibroblast cultures 
 Skin biopsy was obtained from 16 patients with MD (12 females and 4 males) and 16 
healthy control subjects (CNT) matched in age, race and gender (Table 1). The diagnosis of 
current MD episode was established according to the Structured Clinical Interview for DSM-
IV-TR (SCID). Exclusion criteria were any other current or past diagnosis on DSM primary 
axis I or any medical state which could contraindicate the skin biopsy (including bleeding 
disturbances, lidocaine hypersensitivity, pregnancy or lactation). The punch biopsy was 
performed on the lateral side of the upper arm as previously described by Manier et al.
68
. The 
skin was cleaned with iodine and alcohol prep, local anesthesia was induced by 1% lidocaine 
injection. The Vanderbilt University Institutional Review Board (IRB, Nashville, TN, USA) 
approved the study and written informed consent was obtained from all study participants 
before any procedures were conducted. 
The 1x2 mm skin biopsy sample was transferred in a culture flask containing standard 
Dulbecco’s modified Eagle medium (DMEM; Mediatech) without serum and processed the 
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same day. The biopsy was cut into 
pieces and incubated in trypsin/ 
collegenase mix at 37°C for 1 
hour. Standard DMEM (25 mM 
glucose, 1 mM sodium pyruvate) 
supplemented with 2mM L-
glutamine (Mediatech), 10% fetal 
bovine serum (FBS; Thermo 
Scientific) and penicillin/ 
streptomycin (MediaTech) was 
added and the cells were pelletted. 
They were resuspended in standard 
medium and placed in 60 mm 
tissue culture plates. 
 
All fibroblasts were cultured with 
standard medium at 37°C in a 
humidified atmosphere containing 5% CO2
105
. The medium was changed 3 times per week. 
Cells were cultured simultaneously, inspected daily by microscopy and subcultured using 
0.05% trypsin/0.02% EDTA solution (Invitrogen)
69
. The samples were subcultured for 5-10 
passages to minimize in vivo effects. After 2-3 weeks, between passages 5-10 the cultures 
reached confluency, cells were trypsinized, collected and counted.  
3.1.2 Metabolic stress treatment 
Three plates were initiated from each single cell line (1.2 x 10
6 
cells per plate). After 
overnight adherence, the medium was changed with two different metabolic stress conditions: 
(1) glucose deprived, galactose-containing (GAL) medium: DMEM deprived of glucose 
(Mediatech), supplemented with 10 mM galactose (Sigma-Aldrich);  (2) reduced lipid (RL) 
medium: DMEM containing 25 mM glucose, supplemented with lipid-reduced FBS (Thermo 
Scientific); and (3) standard (STD) medium: DMEM with 25 mM glucose (Figure 1).  
  All cultures were grown for seven days; the medium was changed 3 times per week. 
Cell growth and proliferation were not affected by GAL or RL treatment. After one week the 
cells were washed with ice-cold phosphate-buffered saline (PBS) twice, trypsinized, pelleted 
(700 g for 8 min on 18°C) and stored at -80 °C until RNA isolation.  
Table 1 Study subjects of Study 1  
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3.1.3 RNA isolation 
Total cell RNA and small RNA 
fractions were isolated from the 
frozen samples using the 
mirVana miRNA isolation Kit 
(Ambion) according to 
manufacturer's instructions. In 
brief, the cell pellet was 
suspended in 600 ml 
Lysis/Binding Solution, then 60 
ml Homogenate Additive was 
added. After 10 minutes 
incubation 1.25 volume of 100% ethanol was added to the aqueous phase for total RNA 
isolation. The supernatant was purified using the proprietary solutions provided by the 
manufacturer. For small RNA isolation, we added 0.33 volume of 100% ethanol to the 
aqueous phase and two-third volume of 100% ethanol to the flow-through. The total RNA and 
small RNA species were collected with 100 ml Elution Solution and quantified by NanoDrop 
ND-2100 (Thermo Scientific). Agilent 2100 Bioanalyzer was used to determine the quality 
and size distribution of the RNA. All samples showed an RNA Intergity Number (RIN) > 8.0. 
The samples were stored at -80°C until used. 
3.1.4 mRNA expression assessment with DNA microarray 
Complementary DNA (cDNA) was generated using 2 μg of total RNA. cDNA 
synthesis, amplification, and labeling were performed using the Enzo Life Sciences Single-
Round RNA Amplification and Biotin Labeling System. Biotin labeled, fragmented, 
amplified RNA (5 μg) was hybridized to an Affymetrix GeneChip HT HG-U133_PM Array 
Plate at the Vanderbilt Microarray Shared Resource facility. Segmented images from each 
microarray were normalized and log2 transformed using GC-robust multi-array analysis
70
. 
After standard image segmentation of the microarray images, RMA normalization was 
performed using GenePattern software. Average expression values for each group (MD or 
CNT samples; GAL, RL or STD conditions) were calculated for each gene probe. The 
magnitude of expression change was determined by the average logarithmic ratio (ALR) 
using the below described formulas. 
Figure 1. Experimental plan of Study 1 
C1STD C1GAL C1RL C2STD C2GAL C2RL C3STD C3GAL C3RL C4STD C4GAL C4RL
microRNA profiling with miRNome qPCR arrays in pooled groups
qPCR validation of mRNAs and microRNAs in individual samples
pathway and correlation analyses
study subjects
NCNT= 16
NMD= 16
STD
GAL
RL
fibroblast cultures
pooled groups
mRNA changes with DNA microarray in individual samples
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1. To measure the stress induced gene expression changes in CNT or MD fibroblasts: 
ALR= mean(CNTGAL) - mean(CNTSTD) or ALR= mean(CNTGAL) - mean(CNTSTD). 
2. To analyze the transcriptome differences between the MD and CNT samples: 
ALR= mean(MDSTD) - mean(CNTSTD). 
Student’s paired and grouped two-tailed p-values were used as indicators for 
significant change. A gene was considered to be differentially expressed when it met the dual 
criteria of ALR >0.585 (50%) and both pairwise p-value and groupwise p-value ≤0.05. 
3.1.1 mRNA profiling data validation by quantitative polymerase chain reaction 
In order to validate our mRNA data, we measured relative mRNA levels of selected 
genes by quantitative polymerase chain reaction (qPCR).  First, based on our pathway 
analyses we selected a panel of 10 genes involved in lipid biosynthesis in the CNT GAL-, RL-
treated samples (n=16-16): stearoyl-CoA desaturase (SCD); fatty acid binding protein 3 
(FABP3); 7-dehydrocholesterol reductase (DHCR7); insulin induced gene 1 (INSIG1); 
quinolinate phosphoribosyltransferase (QPRT); 3-hydroxy-3-methylglutaryl-CoA reductase 
(HMGCR); 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1); low density lipoprotein 
receptor (LDLR); fatty acid desaturase 1 and 2 (FADS1, FADS2) and 2 housekeeping genes: 
actin beta (ACTB) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). cDNA was 
synthesized from total RNA (500 ng) using RT2 First Strand Kit (Qiagen) according to the 
manufacturer’s instructions. The 96-well custom-designed RT2 Profiler PCR Arrays (Qiagen) 
were assayed on the real-time cycler ABI Prism 7300 System (Applied Biosystems). The 
exported Ct values were analyzed using SABiosciences PCR Array Data Analysis Template 
Excel and compared using a paired experimental design. 
For validation of the mRNA data from the STD-treated MD and CNT samples we 
measured 13 genes by qPCR: heparin-binding EGF-like growth factor (HBEGF); major 
histocompatibility complex, class II invariant chain (CD74); glutathione S-transferase theta 1 
(GSTT1); major histocompatibility complex class II DR alpha; DQ beta 1; DP beta 1 ; DQ 
alpha 1; DP alpha 1 (HLA-DRA; -DQB1; -DPB1; -DQA1, -DPA1);  interleukin 11 (IL11); 
Met proto-oncogene (MET); protocadherin 10 (PCDH10); S100 calcium binding protein B 
(S100B); tumor necrosis factor receptor superfamily, member 19 (TNF19), and a 
housekeeping gene (glyceraldehyde-3-phosphate dehydrogenase (GAPDH)). cDNA was 
generated with random primers using High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). Primers with efficiency >85% were used in SYBR Green based PCRs 
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(Life Technologies). Each sample was tested in four technical replicates on an ABI Prism 
7300 thermal cycler (Applied Biosystems). The Ct(GAPDH) was used for normalization. 
3.1.2 microRNA expression assessment with PCR 
From small RNA samples cDNA was prepared with miScript II RT Kit (Qiagen) using 
miScript HiSpec Buffer. The DNA was quantified with Nano Drop ND-1000 
spectophotometer, yielding 693–839 ng/ml. After reverse transcription, the individual sample 
cDNAs were pooled into four groups in equal proportions based on the gender and age. Each 
group contained material from 4 individuals (Table 1). The relative amounts of 1008 
microRNAs were measured with Human miRNome miRNA PCR Arrays using miScript 
SYBR Green PCR Kit (Qiagen) according to the manufacturer's instructions. For microRNA 
expression quantification comparative Ct method was used with SNORD61, SNORD68, 
SNORD72, SNORD95, SNORD96A and RNU6-2 as housekeeping genes. A microRNA was 
considered differentially expressed if it showed a |ΔΔCt| ≥ 0.3785 (at least 30% difference 
between the average ΔCt values) and p-value of ≤0.05. 
3.1.3 microRNA data validation by individual PCR 
Twenty-two microRNAs were selected for follow up on the 16 individual, not-pooled 
samples (hsa-miR-146b-5p, hsa-miR-550a, hsa-miR-129-3p, hsa- miR-214, hsa-miR-21, hsa-
miR-22, hsa-miR-132, hsa-miR-376c, hsa-miR-19a, hsa-miR-195, hsa-miR-181a, hsa-miR-
486-5p, hsa- miR-377, hsa-miR-424, hsa-miR-542-3p, hsa-miR-22, hsa-miR-103a, hsa-miR-
376b, hsa-miR-29b, hsa-miR-185, hsa-miR-564, hsa-miR-34a). The assays were identical to 
the one used on the pooled samples described above: Human miRNome miRNA PCR Arrays 
using miScript SYBR Green PCR Kit (Qiagen). 
3.1.4 mRNA and microRNA data analysis  
The differentially expressed genes were subjected to a two-way hierarchical clustering 
analysis using GenePattern software (Broad Institute). For mRNAs, this was performed using 
the RMA normalized log
2 gene expression values, while for the microRNAs the ΔCt values 
were used. Correlations were calculated in MS-Excel 2010 using Pearson coefficient. In 
addition, gene set enrichment analysis (GSEA) was carried out with the GenePattern software 
based on the BioCarta defined molecular pathways (San Diego). The calculated normalized 
enrichment score (NES) reflects the degree to which a gene set is overrepresented in the 
ranked list of genes.  
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To reveal the correlations between the mRNome and microRNome alterations, we 
searched the miRDB online database (based on miTarget2 dataset) for the target genes of the 
significantly changed microRNAs
71
. Pathways potentially altered by the significantly changed 
microRNAs were identified with DIANA-mirPath software. This a priori, in silico 
computational tool combines Targetscan 5.1 and KEGG pathways. First, it calculates the 
union of targeted genes of the selected microRNAs, than performs an enrichment analysis. 
DIANA-mirPath was set to use to identify possible mRNA targets
72 , 73
. Gene sets were 
considered significantly differentially expressed at p≤0.05. 
3.2 STUDY 2 – A PSYCHOPHARMACOLOGICAL ASSAY 
3.2.1 iPSC and NPC cultures 
Human iPSCs were differentiated into Prox1 positive hippocampal granule neurons 
according to the protocol published by Yu et al. (2014)
63
. All the cell cultures were grown 
under standard conditions (37°C, 5% CO2) on 6-well-plates except those for further 
immunocytochemistry, which were loaded into confocal imaging chambers. All media were 
supplemented with combined antibiotic-antimycotic (Life Tech.).  
hiPSCs (line 6/2/F, provided by the Laboratory of Genetics, Salk Institute for 
Biological Studies, CA USA) were cultured feeder-free with mTeSR media (Stemcell Tech.) 
on matrigel (BD Biosciences) coated plates.  The media was changed daily and the clumps 
were subcultured via mechanical dissociation after collagenase pre-digestion.  
- Day 1: after mechanical dissociation, whole colonies were transferred onto ultra-low 
adherence dishes for free-floating embryoid body (EB) formation. Differentiating media 
contained N2B27 media (DMEM/F12-Glutamax plus N2 and B27; Invitrogen), 
anticaudalizing factors DKK1 (0.5 µg/ml; PeproTech), Noggin (0.5 µg/ml; Life Tech.), 
SB431542 (10 µM; Sigma) and Cyclopamine (1 µM; Merck). Medium was changed twice a 
week.  
- Day 20: EBs were plated onto poly-L-ornithine and laminin (PORN/L; Sigma) coated plates 
in N2B27 media supplemented with laminin (1 µg/ml, Life Tech.). Medium was changed 
three times per week. 
- Day 27-30: adhered neural rosette-containing EBs were manually collected, washed twice 
with PBS and dissociated with accutase (Life Tech.). Cells were plated onto PORN/L dishes 
with NPC media (N2B27 media plus bFGF2 (20 ng/ml) and laminin (1 µg/ml)) changed 3 
times/week. NPCs were subcultured using accutase after reaching confluency about 70-90%. 
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 - After gaining enough experimental material, P2 NPCs were subcultured onto PORN/L 
6-well plates (1.7 x 10
5
 cells/well; 3 wells/treatment) or confocal imaging chambers. On the 
following day, NPC medium was replaced with differentiating medium containing APs. 
3.2.2 Neural differentiation and treatment with antipsychotics 
We aimed to differentiate NPCs into hippocampal granule neurons and treat the 
differentiating cells simultaneously with APs. In details, NPC proliferation was arrested by 
bFGF2 withdrawal and hippocampal granule cell differentiation was provoked by N2B27 
media supplemented with ascorbic acid (200 nM, Sigma), dibutiryl-cAMP (500 mg/ml, 
Sigma), laminin (1mg/ml), BDNF (20 ng/ml, R&D), Wnt3a (20 ng/ml, R&D), and 1% fetal 
bovine serum (FBS, Fisher Scientific). 
Haloperidol (HL), olanzapine (OL), 
and risperidone (RP) were solved in dimethyl 
sulfoxide (DMSO) and added to the 
differentiating medium (Table 2). The 
control cells were treated with the same 
differentiating medium containing the equal 
amount of DMSO. The culturing media was 
changed 3 times per week for 19 days. 
Notably, we found only 4 previous studies which applied APs on human, postmitotic 
neural cultures. HL was used at concentrations of 0.1-5.0 µM for 5 days74; 1µM (4 days)75; or 
3µM (minutes)76. RP was administered at 0.1-10 µM for 5 days74, while OL was used at 1-
3 µM for 48 hours77. Because we planed to apply these drugs for 19 days and HL reported to 
have neurotoxic effects in higher concentrations, we were especially cautious about the 
dosages. For instance, Post et al. found that HL reduced cell viability by ∼20% at a 
concentration of 1 μM among mouse hippocampal neurons after 20 min78. 
3.2.3 Cell characterization 
To investigate the pluripotency hallmarks of 6/2/F hiPSCs, we used fluorescence 
activated cell sorting (FACS)
79
. Single cell suspensions were prepared by collagenase pre-
digestion and mechanical dissociation. Cells were washed with PBS containing 0,5% BSA 
and incubated with directly labeled anti-human SSEA4-PE mouse monoclonal antibody at 
37 °C for 30 min. Dead cells were labeled with Zombie.  For cell sorting, we used an 
Attune™ NxT flow cytometer.  
group treatment concentration 
HLlow 
haloperidol 
10 ng/ml 0,003µM 
HLhigh 100 ng/ml 0,03 µM 
OLlow 
olanzapine 
50 ng/ml 0,16 µM 
OLhigh 500 ng/ml 1,6 µM 
RPlow 
risperidone 
100 ng/ml 0,24 µM 
RPhigh 1000 ng/ml 2,4 µM 
CNT DMSO 0,2 µl/ml 
Table 2. Treatment groups in Study 2 
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For immunostaining iPSC and 
differentiated neural cultures were washed 
gently twice with DPBS and fixed in 4% 
PFA at room temperature for 30 min. The 
samples were rinsed in DPBS 3 x 5 min 
and blocked with DPBS++ (3% normal 
serum in DPBS with 0,1% Triton-X) for 
30-60 min. After overnight incubation with 
primary antibodies (Table 3) at 4°C, samples were washed with DPBS twice and blocked in 
DPBS++ for 30-60 min. The secondary antibodies (Alexa Fluor conjugated anti-mouse, anti-
goat or anti-rabbit antibodies) were diluted with DPBS++ and incubated at room temperature 
for 2-3 hours.  
 
3.2.4 RNA isolation, reverse transcription  
After 19 days of differentiation and psychopharmacon-treatment, total cell RNA was 
isolated with Trizol (Invitrogen) following the manufacturer’s protocol. Briefly, cells were 
washed in ice cold PBS and lysate directly in 1 ml of ice cold Trizol Reagent. The samples 
were stored at -80°C until usage. For RNA isolation, 200 µl chloroform was added to the 
unmelted samples, vortexed and incubated at room temperature for 2-3 minutes. After 
centrifuging (12000g, 4°C, 15 mins) the upper aqueous phase was transfered and diluted with 
500 µl isopropyl alcohol and 1 µl glycogen sol. (1 mg/ml). Following 10 minutes incubation 
at RT, samples were spinned down (12000g, 4°C, 15 mins) and the supernatant was removed. 
The pellet was washed with 1 ml 75% ethyl alcohol, centrifuged (12000g, 4°C, 15 mins), air-
dryed and resuspended into 20 µl RNAse free water. The quality of the RNA samples were 
assessed with Nanodrop 2000 Spectrophotometer (Thermo Scientific). 
Complementary DNA (cDNA) synthesis was carried out using the Promega Reverse 
Transcription System. 1 µg total cell RNA in 9.5 µl RNase free water was incubated at 70°C 
for 10 minutes than chilled on ice.  The reaction mix contained 4 µl MgCl2, 1 µL of random 
hexamer primers (0.5 mg/ml), 2 µL 10x reaction buffer, 1 µL recombinant RNasin RNase 
Inhibitor (20 U/µL), 2 µL 10 mM dNTP Mix, 1 µL AMV Reverse Transcriptase (15 U/µL). 
The incubation lasted 10 min at RT, followed by incubation for 60 min at 42°C and 
termination of the reaction (90°C, 5 min). Samples were stored at −20°C until further usage. 
antibody company dilution 
stem cell markers 
NANOG (goat polyclonal) R&D 1:50 
OCT3/4 (mouse monoclonal) Thermo Fisher 1:50 
neural markers 
PROX-1 (goat polyclonal) R&D 1:100 
MAP2 (mouse monoclonal) Sigma 1:500 
Table 3. Antibodies for cell typisation 
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3.2.5 Real-time quantitative PCR and data analysis 
For real-time quantitative polymerase chain reaction (rt-qPCR), we used the following 
TaqMan PCR probes to analyze the gene expression changes (Thermo Fisher): metabotropic 
glutamate receptor 2 (mGluR2 or GRM2, Hs00968358_m1); metabotropic glutamate receptor 
7 (mGluR7 or GRM7, Hs00356067_m1); vesicular glutamate transporter 1 (VGLUT1 or 
SLC17A7, Hs00220404_m1); microtubule-associated protein 2 (MAP2, Hs00258900_m1); 
neuronal differentiation 1 (NeuroD1 or BETA2, Hs01922995_s1); glial fibrillary acidic 
protein (GFAP, Hs00909233_m1). We chose large ribosomal protein P0 (RPLP0, 
Hs99999902_m1) for endogenous control to normalize the variations in cDNA quantities 
from different samples recommended by
80,81
. Each reaction was performed in triplicate for 
every well (9 reactions per gene per treatment group). 
The reactions were performed according to the manufacturer’s instructions: 5 µL 
template cDNA was used in a final PCR reaction volume of 20 µL, containing 10 µL TaqMan 
Master Mix, 1 µL of 20x forward and reverse primer and probe and 4 µl bidestillated water. 
The conditions for the PCR included 2 min denaturation at 94°C followed by 40 cycles of 
PCR (10 min at 94°C, 15 s at 52°C, 60 s at 60°C). mRNA changes were measured in the 
StepOnePlus real-time PCR System (Applied Biosystem) using the StepOne v2.1 program.  
 Ct was determined manually from the amplification plots. We calculated the 
normalized gene expression level with the ΔΔCt method: average ΔCt (treated) – average ΔCt 
(control). Statistical significance was tested with unpaired two-sample t-test. A gene was 
considered differentially expressed if |ΔΔCt| ≥ 0.3785 (≥ 30% difference) and p-value ≤0.05. 
4 RESULTS 
4.1 STUDY 1 – DIATHESIS‒STRESS IN FIBROBLASTS 
4.1.1 How fibroblasts adapt on transcriptome-level? 
In order to examine the cellular stress response in peripheral tissues we measured the 
mRNA and microRNA levels after 1 week metabolic stress treatment in fibroblast cultures 
obtained from healthy, CNT subjects.  
GAL-treatment, a mitochondrial and oxidative stress resource affected the expression 
of 2063 genes compared to STD condition. 1117 genes were overexpressed (54.1%). Many of 
these are known to be involved in cell cycle, apoptosis, inflammation, mRNA metabolism and 
metabolic adaptation.  
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 The lipid reduced, cholesterol 
deprived (RL) treatment also resulted in 
mRNome changes: 984 gene products 
were significantly altered, 640 of these 
were increased (65.0%) (Figure 2). 
BioCarta pathway analysis 
revealed enrichment of 19 gene sets in 
the GAL-treatment and 15 in the RL-
treatment (3 of them repressed). Notably, 
4 pathways were found to be 
overexpressed in both stress conditions 
(Table 4A and B).  
A. GAL-affected B. RL-affected C. microRNA-modulated 
pathways NES  p-value pathways NES p-value KEGG pathways p-value 
RACCYCD* 1.93 0.000 PPARA* 1.80 0.000 ErbB signaling 0.000 
CELLCYCL 1.83 0.000 P38MAPK 1.56 0.010 Regulat. of actin cytosk. 0.000 
SRCRPTP 1.70 0.000 VIP 1.60 0.010 Dopaminergic synapse 0.001 
P53 1.70 0.002 BAD 1.48 0.016 Osteoclast differentiation 0.001 
TEL 1.73 0.011 CHREBP2* 1.64 0.023 Chagas disease  0.001 
STATHMIN 1.57 0.012 RACCYCD* 1.65 0.028 Axon guidance 0.002 
CFTR 1.65 0.012 GCR 1.46 0.038 Insulin signaling 0.002 
CERAMIDE 1.67 0.012 HSP27* 1.49 0.041 MAPK signaling 0.004 
ATRBRCA 1.60 0.016 CD40 1.58 0.044 FcγR-mediated phagocyt 0.004 
G2 1.59 0.026 LYM 1.37 0.048 FcεRI signaling 0.004 
HSP27* 1.47 0.027 TNFR2 1.53 0.049 GnRH signaling 0.004 
CARM_ER 1.61 0.027 TALL1 1.52 0.049 Protein processing in ER 0.006 
PLCE 1.47 0.031 IL22BP -1.56 0.021 Wnt signaling  0.006 
CHREBP2* 1.61 0.031 DNAFRAGM. -1.51 0.030 Lysine degradation 0.008 
AKAPCENT 1.53 0.032 AHSP -1.59 0.043 Circadian rhythm 0.009 
CHEMICAL 1.56 0.033       Hepatitis B 0.015 
RB 1.53 0.034   Chemokine signaling   0.026 
ATM 1.58 0.045 
 
TLR signaling 0.037 
PPARA* 1.43 0.036 
 
Melanogenesis 0.043 
     
Cytokine-cytokine R 
interaction 0.046 
     
Neurotrophin signaling 0.000 
     
Adherence junction 0.000 
Table 4A. and B. Metabolic stress affected pathways in HDFs derived from control subjects.  
*Commonly upregulated in GAL and RL. 4C. Pathways regulated by the overlapping 4 metabolic 
stress-induced microRNAs. (NES: normalised enrichment score) 
 
(NES: normalised enrichment score) 
 
Figure 2. Metabolic stress-induced transcriptome 
changes in HDFs derived from CNTs. 
microRNAmRNA
1117↑
946↓
640↑
344↓
GAL RL
CHREBP2, PPARA, 
RACCYD, HSP27
24↑
21↓
7↑
27↓
GAL RL
miRNA ddCt(GAL) ddCt(RL) 
miR-146b-5p 1,058 1,487
miR-129-3p 0,949 1,108
miR-543 0,659 0,610
miR-550a -1,054 -1,236
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These pathways might be essential for the physiological adaptation independently 
from the type of stressor: (1) Peroxisome proliferator-activated receptor alpha (PPARA) is a 
lipid activated pathway which regulates several genes involved in metabolism, energy 
homeostasis, oxidative stress response, and anti-inflammation. PPARA agonists proved to 
have protective features in neurodegenerative disorders
82 , 83
. (2) Carbohydrate-responsive 
element-binding protein-2 (CHREBP2) pathway. CHREBP is a glucose-sensing, lipogenic 
transcription factor enabling the cell to adopt to extracellular glucose concentrations. Loss of 
function mutation results in fatty acid synthesis deficit, and impaired insulin homeostasis
84
. 
(3) Influence of Ras and Rho proteins on G1 to S transition (RACCYCD) pathway which 
describes the induction of cyclin D1 expression and cell cycle progression
85
. (4) Stress 
induction of heat shock protein 27 (HSP27) regulation. HSP27, a class I small-HSP has a 
chaperon-like activity; it acts as a cytoskeleton stabilizer, anti-oxidant, anti-apoptotic agent, 
and cell cycle regulator
86
.  
 Interestingly, both GAL and RL-treatment modified the expression of a set of genes 
associated with lipid biosynthesis. We validated our microarray data with 10 from these. 
According to the qPCR data 9 of the 10 genes were significantly altered by both GAL and 
RL-conditions (HMGCR mRNA levels showed the same direction but did not reach statistical 
significance). The qPCR and microarray findings showed high correlation (r(GAL)=0.92; 
r(RL)=0.72) (Table 5). 
 GAL-treatment modulated 45 microRNAs and RL-condition changed the expression 
of 34 microRNAs compared to STD culturing. The overlap between the two different 
metabolic stresses were 4 microRNAs: hsa-miR-146b-5p, hsa-miR-129-3p, hsa-miR-543 
were elevated, while miR-550a was downregulated (Figure 2). DIANA mirPath pathway 
analysis suggested that these 4 microRNAs participate in the regulation of 57 KEGG 
pathways. Thirty-nine percent of the pathways (22) are controlled by all 4 microRNAs, and 
16 of these are intracellular signaling pathways (Table 4C).  
 Although, the list of the GAL and RL-treatment affected microRNAs differed from 
each other, when we correlated the GAL-modified microRNAs with their expression in the 
RL-treatment, we found significant correlation (r=0.71, p<0.001). Similarly, data of RL-
affected microRNAs correlated with the levels measured in GAL (r=0.65, p<0.005). These 
indicate that the most affected microRNAs were not identical in the different conditions but 
the metabolic stresses resulted in a similar overall microRNA pattern in the CNT cells.  
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 Since microRNome PCR assays 
were conducted on pooled samples 
which could bias the results, we 
measured 22 microRNAs in the 
individual, not-pooled samples using the 
same PCR assays to validate our data. 
Our data suggest, pooling of the samples 
did not skew artificially the microRNA 
pattern observed in GAL and RL. 
 We were also curious how the 
microRNA changes present on the level 
of mRNAs. To determine the crosstalk 
among these transcripts, we listed the 
potential target genes of the 
4 overlapping microRNAs and analysed their expression data. According to the miRDB 
online database, miR-129-3p, miR146b-5p, miR-550a and miR-543 have 211, 243, 129 and 
921 putative target genes, respectively. Notably, 9.3% of these genes were differentially 
expressed under stress (140 out of 1504) and several of them showed transcription alterations 
in both GAL and RL-treatment. This rate meets our expectations since literature suggests that 
10% of the predicted genes reflect to the regulator microRNAs depending on the cell type, 
developmental stage and environment.  
4.1.2 Manifestation of MD diathesis in fibroblasts 
We compared the mRNA and 
microRNA profile of fibroblasts from MD 
patients and CNT subjects in STD culturing 
conditions. First, we measured the mRNA 
levels with DNA microarray: 162 genes were 
differentially expressed in the MD samples. 
Remarkably, 114 genes were downregulated, 
which indicate rather loss-of-fuction genetic 
dysregulation than gene induction in the 
disorder (Figure 3). The most prominent decreases were observed in genes associated with 
cell-to-cell communication and adhesion, such as protocadherin 10 (PCD10, ALR=1.73); 
Table 5. Validation of microarray data with qPCR 
(NS: no significant change) 
Gene 
GAL vs. STD RL vs. STD 
microarray qPCR microarray qPCR 
ALR -ΔΔCt ALR -ΔΔCt 
SCD 2.02 2.66 1.82 2.23 
FABP3 1.86 2.80 1.89 3.10 
DHCR7 1.18 1.42 1.82 2.49 
INSIG1 1.43 1.79 1.61 2.16 
QPRT 1.42 2.03 1.96 2.71 
HMGCR 0.70 0.43 1.50 NS 
HMGCS1 1.17 1.20 1.64 2.40 
LDLR 1.08 1.46 1.55 2.35 
FADS1 1.08 1.36 1.22 1.57 
FADS2 1.00 1.84 1.51 2.50 
correl r
2
=0.84 r
2
=0.63 
Figure 3. Transcriptome alterations of MD 
fibroblasts compared to CNT cells in 
standard conditions  
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tenascin XB (TNXB, ALR=1.30); periplakin (PPL, ALR= 1.34); and hepatocyte growth factor 
(HGF) receptor (ALR=1.21).  
According to the gene set enrichment 
analysis 6 BioCarta pathways were 
upregulated and 4 were downregulated. 
These are known to play role in: apoptosis, 
cell-to-cell communication and adhesion, 
and immune functions (Table 6). These 
mRNA and pathway analysis data concur 
with peripheral and postmortem brain tissue 
studies that the genetic background of MD 
may manifest in immune and 
(neuro)development related gene set 
disturbances.  
We chose 14 immune-related genes 
and determined their expression with qPCR 
to validate our microarray data (genes listed 
in Materials and Methods). The microarray-
reported ALR and qPCR-given ΔΔCt values showed high correlation (r=0.84), and 12 of the 
14 transcripts were significantly changed in the qPCR data also. 
The MET/HGF intracellular signaling pathway attracted our attention for its trophic 
roles. Under normal conditions, the pathway is silent but during development, stress and 
regeneration, MET tyrosine kinase receptor promotes motility, proliferation, morphogenesis 
and protects cells against hypoxia and serum deprivation caused dysfunction through the 
PI3K-Akt and ras-MAPK pathways in neurons
87
 and peripheral cells as well
88
. Paradoxically, 
HGF (scatter factor) proved to be identical with fibroblast-derived tumor cytotoxic factor (F-
TCF) and MET activation can provoke apoptosis in tumor cells
89
 and myofibroblasts
90
. This 
dual, cell-type specific antiapoptotic and proapoptotic property may be essential in 
regeneration
91
. The pathway participates also in neurodevelopment, and in the prevention of 
post-stroke neuron death. Serum HGF level was found to correlate with the presence, severity 
and progression of symptoms in a subgroup of MD patients
92
. Interestingly, Arakaki et al. 
found that the proapoptotic, antimitotic effect of MET can be suppressed by enhanced GSH 
production
93
. According to Gibson et al., MD fibroblasts exhibit impaired redox homeostasis 
and decreased glutathione-regeneration reserve capacity
105
. 
Table 6. Differentially expressed pathways in  
MD fibroblasts compared to CNT cells 
Pathway NES p-value function 
Akt signaling -1.61 0.018 
ap
o
p
to
si
s 
TCAPOPTOSIS: HIV 
induced T-cell apoptosis 
1.53 0.036 
ARF: Arf inhibits 
ribosomal biogenesis 
-1.55 0.044 
CLASSIC: classical 
complement 
-1.49 0.026 
im
m
u
n
e 
 f
u
n
ct
io
n
s 
COMP: complement  -1.42 0.047 
ASBCELL: antigen 
dependent B-cell activ. 
1.49 0.006 
CSK: activation of Csk by 
PKA 
1.51 0.013 
TCR activation by Lck 
and Fyn tyrosine kinases 
1.43 0.033 
CTLA4: co-stimulatory 
signal during T-cell activ. 
1.44 0.037 
co
m
m
. 
an
d
 
ad
h
es
io
n
 
NKT: selective expression 
of chemokine receptors 
1.52 0.038 
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 Hence, we decided to compare the expression of genes involved in the MET/HGF 
pathway in MD and CNT fibroblasts. From the overall 37 pathway-genes 16 were 
differentially expressed: HGF; phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1); 
GRB2-associated binding protein 1 (GAB1); son of sevenless homolog 1 (SOS1); Rap 
guanine nucleotide exchange factor 1 (RAPGEF1); signal transducer and activator of 
transcription 3 (STAT3); protein tyrosine phosphatase, nonreceptor type 11 (PTPN11); 
p21/Cdc42/Rac-activated kinase 1 (PAK1); mitogen-activated protein kinase 1 (MAPK1); v-
crk sarcoma virus CT10 oncogene homolog-like (CRKL); jun oncogene (JUN); 
phosphoinositide-3-kinase, catalytic, alpha polypeptide (PTEN); member of RAS oncogene 
family (RAP1A); mitogen-activated protein kinase kinase 1 (MAP2K1); and v-Ha-ras Harvey 
rat sarcoma viral oncogene homolog (HRAS). 
According to our PCR results, nearly 50% of the measured microRNAs were 
expressed in the fibroblast cultures (561 out of 1008). The microRNA profile of MD 
fibroblasts differed in 38 microRNAs from CNT (more than 30% change, p<0.05). 17 were 
downregulated and 21 showed higher expression levels (Figure 4).  
The microRNA levels were 
determined in pooled groups 
(4 individuals/group). To exclude 
any adverse effect of pooling, we 
measured the expression of hsa-
miR-21*, hsa-miR-377, hsa-miR-
193a-3p, hsa-miR-542-3p, hsa-
miR-22, hsa-miR103a, and hsa-
miR-185. microRNA expression 
levels showed high correlation 
between the pooled and individual 
sample assessments (R
2
=0.93,  p<0.001) (Figure 5). Thus we can assume that grouping and 
mixing the RNA samples did not reduce the reliability of our PCR array results.  
To uncover the possible functional consequences of the MD-specific microRNA 
profile, we conducted pathway analysis by DIANA mirPath with the 38 differentially 
expressed microRNAs. According to the results, 19 pathways are controlled by at least 85% 
of these microRNAs. Some of them are universal intracellular signaling pathways (e.g. 
calcium signaling; ubiquitin mediated proteolysis pathway), and others are related to cell 
cycle (PI3K-Akt signaling; MAPK signaling pathway), cell-to-cell communication and 
Figure 4. Correlation of microRNA levels in pooled and 
individual samples 
pooled sample ΔΔCt (MD-CNT) 
in
d
iv
id
u
al
 s
am
p
le
s 
Δ
Δ
C
t 
(M
D
-C
N
T)
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adhesion (Wnt; chemokine signaling; focal adhesion pathway), immune functions (Jak-STAT 
signaling; endocytosis pathway), and neural functions (neurotrophin signaling; long-term 
potentiation; cholinergic synapse pathway). 
We wanted to know if the microRNA 
alterations could explain the mRNA profile of MD 
fibroblasts. Thus we searched miRDB for the 
predicted targets of the 38 microRNAs, and noted 
if the particular mRNA showed MD-specific 
expression. Our search revealed that 51% of the 
differentially expressed mRNAs were potential 
target molecules. This rate meets our expectations, 
since literature suggests that 40-60% of the human 
genes are under microRNA regulation. 
Interestingly, 16% of the changed microRNAs did 
not leave fingerprint on the mRNome; and further 
10% had changed in the same direction as the 
regulated mRNAs. These results suggest that the 
mRNA signature of MD is appreciably influenced 
by the microRNome and there is a remarkable 
interaction on the transcriptomic level. However, considering that 64% of the differentially 
expressed mRNAs are targeted by more than one microRNA, and microRNAs can either up- 
or downregulate the same gene depending on the cellular and external environment, we can 
only establish hypotheses on the exact cause-effect relationships.  
4.1.3 Stress vulnerability of MD-fibroblasts 
We aimed to examine whether genetically determined impaired adaptational potential 
of MD patients can be demonstrated in stress-exposed peripheral tissues. Hence, we measured 
the metabolic stress induced transcriptome changes in fibroblasts obtained from MD patients. 
We found that galactose (GAL) substitution of glucose in the medium resulted in robust 
transcriptome changes in the MD fibroblasts: 1196 mRNAs were affected, 975 of these 
upregulated. Comparing the stress response of the MD and CNT cells we found, that 26% of 
the GAL-altered genes (310) were MD-specific (Figure 6). Twenty-one pathways participated 
in the GAL-stress reaction, 9 of them were activated only in the MD samples (Table 8A). 
Table 7. Pathways regulated by at least 85% 
of the MD-related microRNAs 
 Pathway p-value 
Neurotrophin signaling <0.0001 
Pathways in cancer <0.0001 
PI3K-Akt signaling <0.0001 
MAPK signaling <0.0001 
Jak-STAT signaling 0.008 
Ubiquitin mediated proteolysis <0.0001 
Endometrial cancer <0.0001 
HTLV-I infection <0.0001 
Focal adhesion <0.0001 
Osteoclast differentiation <0.0001 
Hepatitis B <0.0001 
Insulin signaling <0.0001 
Endocytosis <0.0001 
Calcium signaling  <0.0001 
Non-small cell lung cancer <0.0001 
Cholinergic synapse <0.0001 
Chemokine signaling <0.0001 
Long-term potentiation <0.0001 
Wnt signaling <0.0001 
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The RL-treatment had 
mostly activating effect on the 
geneexpression pattern in the 
MD cells (262 upregulated 
mRNAs from the overall 
affected 312). The RL 
induced stress response of 
MD cells significantly 
differed from the CNTs: 
33.4% of the mRNA changes 
were exhibited only in the 
MD, and not in the CNT 
groups (103 genes) (Figure 5). Comparison of pathway analysis data revealed that 10 of the 
19 RL-modified gene sets are MD-specific (Table 8 B).  
The overlap between the stress induced pathway signatures of MD cells were: HSP27, 
CHREBP2, BAD and ARF which are known to control apoptosis and cell cycle phase 
transition. Although, the pathways induced by GAL and RL were different, both condition 
required cell cycle (e.g. RB, TFF, G2), apoptosis/survival (P53, TRKA, SPRY), migration, 
immune function (ECM, CDMAC, IL-7, IL-10), metabolism (GLYCOLYSIS) related gene 
set adaptations. 
According to our qPCR array data, 63 microRNAs participated in the GAL-treatment 
induced stress response of the MD fibroblasts. 81% of the detected microRNA pattern was 
MD-specific. The RL-condition resulted in more robust microRNA changes: 147 microRNAs 
were differentially expressed compared to the STD, 90% of these were observed only in the 
MD cells (Figure 5).  
Searching the literature for previous data on the GAL and RL-affected microRNAs, 
we found that 38% are related to metabolism control, 60% have role in proliferation and 
apoptosis, and 30% participate in cell motility. It is noteworthy, that significant proportion of 
the changed microRNAs are regulated by tumorsuppressor P53 (GAL: 13%, RL: 33%). P53, 
best known for its role in DNA damage response, is also an important regulator of 
metabolism, suppress the glycolytic pathway, increases mitochondrial metabolism
94
. Several 
studies have identified microRNAs as regulators of P53 activity as well as its downstream 
effectors. For instance, the oncogenic role of miR-122, miR-7 or miR-32 loss has been 
attributed to the (in)direct regulation of P53
95,96
. These and our results might demonstrate that 
 Figure 5. Stress induced transcriptome changes in HDFs 
 from MD patients. Parenthetic percentages show the ratio of MD 
specific mRNA and microRNA changes.  
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the ARF/p53 pathway enhancement may have a strong regulatory effect on the overall gene 
expression pattern via modulation of certain microRNAs.  
The overlap between the GAL and RL-induced miRNome stress response were 23 
microRNAs (listed in Figure 5). Six of them were already dysregulated under STD conditions 
in contrast with CNT samples, which might underpin our hypothesis that the dysregulated 
microRNA profile in MD contributes to the stress response. Considering the notable 
differences between the transcriptome of MD and CNT samples, we might assume that the 
MD cells can reach the required metabolic changes via non-physiological ways which might 
result in increased vulnerability. 
 
 
 
 
A. GAL-affected B. RL-affected C. microRNA-modulated 
Pathway NES  p-value Pathway NES p-value KEGG pathway p-value 
TEL  1.98  0.000  RACCYCD  1.90  0.004 PI3K-Akt signaling* <0.0001 
SRCRPTP  1.73  0.002  TFF* 1.88 0.006 Regul. of actin cytosk. <0.0001 
PTC1* 1.73 0.000 CD40  1.78 0.010 Focal adhesion* <0.0001 
G2  1.66 0.002 TRKA* 1.74 0.008 Neurotrophin signaling <0.0001 
CARM_ER  1.66  0.005 ECM* 1.67  0.023  Pathways in cancer* <0.0001 
HSP27  1.65 0.011 PPARA  1.63 0.006 ErbB signaling <0.0001 
RB  1.62 0.006 HSP27  1.62  0.017 MAPK signaling <0.0001 
CERAMIDE  1.60  0.021 GH* 1.60 0.020 T cell R signaling* <0.0001 
P53  1.58  0.022 GLEEVEC* 1.58  0.036 Chemokine signaling <0.0001 
SET* 1.58 0.032 ARF* 1.54 0.046 HTLV-I infection* <0.0001 
CHEMICAL  1.58 0.024 EXTRINSIC* 1.53 0.014 
  ATRBRCA  1.57  0.008 CHREBP2* 1.53 0.024 
  MPR* 1.56 0.041 CDMAC* 1.52 0.035 
  CELLCYC.  1.56 0.030 BAD 1.48 0.011 
  AKAP95* 1.56 0.046 SPRY* 1.45 0.041 
  CHREBP2  1.56 0.022  FEEDER* -1.53  0.023  
  IL10* 1.53 0.032 DNAFRAG.  -1.54 0.048 
  ARF* 1.50 0.038 AHSP  -1.56  0.035 
  PLCE  1.47 0.030 GLYCOLYSIS* -1.63 0.004 
  IL7* 1.46 0.025 
    BAD* 1.43  0.013      
Table 8A. and B. Pathways involved in the stress response of MD fibroblasts. 8C. Pathways might be 
targeted by >85% of those microRNAs which were commonly changed in both GAL and RL-treatment. * 
MD specific changes. The highlighted pathways were upregulated in both metabolic stresses.  
(NES: normalized enrichment score) 
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Our results suggest that the two 
different stress conditions required not 
identical, but very similar gene 
expression pattern modifications from 
the CNT cells which phenomena can be 
explained by the evolutionary 
conserved, general rules of cellular and 
systemic adaptation. Whereas GAL and 
RL-environment resulted in different, 
stress effect-specific transcriptome 
changes in the MD cells. RL-medium 
showed to be especially greater 
challenge. Understanding why these metabolic stresses represent altering challenges in MD 
may help to get closer to the genetic background of maladaptation. 
To validate the microarray-detected mRNA changes, custom qPCR arrays were used 
to detect the mRNA expression level of 10 stress-affected genes involved in lipid metabolism. 
The statistical significance of the microarray-detected expression changes for all 10 genes was 
confirmed by qPCR. Additionally, the microarray and qPCR gene expression data showed a 
high correlation with in both GAL vs. STD and RL vs. STD comparisons (Table 9).  
Validation of the miRNome analyses on pooled samples was performed with custom 
qPCR array of 14 microRNAs on individual samples. Both GAL- and RL-induced miRNA 
response demonstrated high correlation between pooled and individual samples (rGAL=0.92 
and rRL=0.79, p<0.001) and 85% of the miRNA changes in the individual samples were 
significantly different in the predicted direction (p≤0.05), providing a strong validation for the 
miRNome data.  
4.2 STUDY 2 – A PSYCHOPHARMACOLOGICAL ASSAY 
4.2.1 Characterizing iPSCs and iNCs 
We differentiated hippocampal granule cells from iPSCs according to the protocol of 
Yu et al. which was developed on the basis of in vivo and in vitro observations on the 
hippocampal dentate gyrus identity and development
63
. Yu et al. proved that the 
Table 9 Validation of microarray data with qPCR.  
 All results were significant (p <0,05). 
 
  
  
Gene 
GAL vs. STD RL vs. STD 
microarray qPCR microarray qPCR 
ALR -ΔΔCt ALR -ΔΔCt 
SCD 2.13 2.37 1.71 2.21 
FABP3 1.88 3.33 1.55 3.36 
DHCR7 1.24 1.76 1.99 2.57 
INSIG1 1.44 1.76 1.59 2.41 
QPRT 1.67 2.07 2.02 2.65 
HMGCR 0.75 0.98 1.50 1.96 
HMGCS1 1.21 1.46 1.73 2.30 
LDLR 1.24 1.75 1.70 2.44 
FADS1 1.08 1.36 1.23 1.58 
FADS2 0.76 1.78 1.27 2.34 
correl r=0.78 r=0.43 
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differentiation protocol resulted in glutamatergic (85%) and GABAergic (15%) neurons, 
assembling the electrophysiological, receptorial and transcriptional profile of in vivo neurons. 
Pluripotent and differentiated cells were characterized by morphology, FACS and ICC.  
6/2/F iPSCs showed stem cell like phenotype in their morphology, surface marker and 
pluripotent-specific transcription factor expression. Namely, FACS and ICC revealed that 
more than 95% of the cells expressed the stem cell surface antigen SSEA4
97
 and the colonies 
consisted of OCT3/4 and NANOG
98
 positive cells (Figure 6). The pluripotency of the hiPSCs 
was also tested in vitro when we induced free-floating EB formation.  
 
Figure 6 (A) DAPI, (B) OCT3/4, and (C) NANOG staining of iPSC cell cultures (20x; scale bar 100 µm) 
EBs were plated onto adherent plates and treated with N2B27 media to induce 
neuronal cell fate. Neural rosette-forming EBs were subcultured and treated with 
anticaudalizing factors (DKK1, Noggin, SB431542) and cyclopamine to provoke dorsal 
forebrain neural progenitor formation. Hippocampal granule cell differentiation was induced 
by Wnt3a and BDNF administration. After 19-21 days, cells exhibited Prox1 and MAP2 
positivity (Figure 7B and C). MAP2 is a neural marker
99
; Prox1 is thought to be specific and 
essential for the survival and commitment of the DG neuronal progenitors and descendent 
neurons
100,101
.   
 
Figure 7 (A) DAPI, (B) PROX1, and (C) MAP2 staining of differentiated cultures (20x; scale bar 100 µm) 
 
 
A B C 
A B C 
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4.2.2 Gene expression alterations 
We aimed to examine the effect of APs on differentiating neurons; thus, we treated 
developing hippocampal granule cells with haloperidol (HL), olanzapine (OL) and risperidone 
(RP) at two different concentrations for 19 days. The expression of NEUROD1, MAP2, 
GFAP, vGLUT, mGLUR2, mGLUR7 genes were determined with real-time qPCR.  Relative 
mRNA levels in the different treatment groups compared to DMSO treated control cells are 
represented on Figures 9-11 (note that plots demonstrate –ΔΔCt).  
According to our data, NeuroD1 expression was significantly increased in the RP 
treated cells compared to CNT neurons, independently from the concentration (RPlow and 
RPhigh). NeuroD1 mRNA was elevated in the OLhigh and HLlow conditions (p<0.001). 
Interestingly, HL had reverse effect at higher concentration: it lowered NeuroD1 mRNA 
levels compared to HLlow (p=0.02) (Figure 9).  
The qPCR results showed that MAP2 transcription was augmented by HLlow treatment 
compared to CNT, while haloperidol exerted opposite effect at higher concentration (p<0.05). 
MAP2 mRNA levels were not modulated by RP or OL (Figure 9). 
 
Figure 9. The relative NeuroD1 and MAP2 mRNA levels in the AP-treated cells 
Interestingly, the effects of olanzapine and risperidone on GFAP gene expression were 
inverse at different concentrations. The AAPs enhanced GFAP transcription at low 
concentrations, while OLhigh and RPhigh depressed it compared to DMSO (RPhigh-DMSO 
p=0,091). The GFAP mRNA levels were not affected by the 19-day-long HL treatment 
(Figure 10). 
vGLUT transcription was decreased by HLlow, RPlow and RPhigh treatments, but not 
altered by OL (Figure 10).   
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Figure 10. The relative GFAP and vGLUT mRNA levels in the AP-treated cells 
Furtherly, we aimed to measure the expression levels of two metabotropic glutamate 
receptors, known to be expressed by hippocampal granule neurons. mGluR2 and mGluR7 
were both upregulated in HLlow and suppressed in HLhigh. The HLhigh evoked gene expression 
alteration was not enough powerful in comparison with control cells but proved to be 
statistically significant compared to HLlow. Additionally, mGluR2 was underexpressed in 
OLhigh treatment and mGluR7 in the RPlow group (Figure 11).  
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Figure 11. The relative mGluR2 and mGluR7 mRNA levels in the antipsychoticum-treated cells 
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5 DISCUSSION 
5.1 STUDY 1 – DIATHESIS‒STRESS IN FIBROBLASTS 
Molecular profiling studies of body fluids and peripheral cells, together with 
postmortem findings, have already provided robust evidence for abnormalities in the 
immunologic/inflammatory, metabolic, hormonal, and growth factor systems in MD 
patients
102
. These findings support the concept that MD is not just a disease of the brain but 
instead should be viewed as a systemic disorder with molecular changes detectable across 
various peripheral tissues. Therefore, HDF culture might be an easily available model system 
with the patients individual genetic constellation.  
5.1.1 Metabolic stress response of control HDFs 
First, we analyzed the stress reponse of HDFs obtained from control subjects using 
two different metabolic stress conditions. We found widespread, correlating mRNA and 
miRNA changes. 
Galactose-treatment is a widely used oxidative stress model in vitro and in vivo
103
. 
Glucose depleted, galactose supplemented (GAL) medium evokes mitochondrial stress; since, 
in the absence of glucose, metabolism shifts toward oxidative phosphorilation which becomes 
the main energy source of the cells instead of glycolysis. The mitochondrial ATP synthesis 
maximizes and oxygen consumption doubles, resulting in elevated reactive oxygen species 
(ROS) levels and compensatory overproduction of antioxidant glutathione
104
. Notably, 
glutathione regeneration requires effective adaptation and NADPH production and might be 
impaired by chronic nutrient depletion
105
.  
Our observations are congruous with these since GAL-treatment provoked the 
activation of DNA repair and checkpoint pathways (9 of the 19 pathways, i.e. ATM, 
ATRBRCA, P53, RACCYD, SRCRPTP, G2, RB, HSP27, PPARA) and further cell-cycle 
related gene sets (STATHMIN, AKAPCENTROSOME). 
RL-treatment (lipid reduced, cholesterol depleted medium) forces cells to synthesize 
their lipid and cholesterol necessities de novo, and overload the cell metabolism
106
. 
Cholesterol and other lipids are essential for the cells. Composing lipid rafts, they bias the 
physical characteristics of the membrane; modulate receptors, signaling pathways, influence 
intramembrane proteolysis and the transciption of lipid-genes
107
. Lipids can also act as 
signaling molecules or second messengers
108
. The lack of exogenous cholesterol intake might 
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lead to the dysfunction of these essential, sensitive phenomena. Interestingly, contrary to 
GAL, RL-treated samples exhibited a positive enrichment of immune (TALL1, LYM, CD40) 
and protein or cellular regeneration related pathways (AHSP, IL22BP, TNFR2, HSP27, 
P38MAPK). 
According to our results, while the most significantly changed mRNAs and 
microRNAs showed variation, the overall transcriptome changes across the two metabolic 
stress conditions showed considerable similarity. Based on the findings we propose that 
metabolic stress, regardless of the type of the insult, might have a common miRNome and 
mRNA signature, representing a non-specific resilience response. We identified 4 metabolic 
stress-related transcript pathways (PPARA, CHREBP2, RACCYCD, and HSP27) upregulated 
in both GAL and RL-exposed cultures, and 4 significantly changed microRNAs (miR-129-3p, 
miR-146b-5p, miR-543 and miR-550a) that are likely to be important mediators of metabolic 
stress. These common molecular consequences might originate from the same starvation-like 
state caused by glucose deprivation or RL. Note that in RL, cells has to increase de novo lipid 
synthesis, thus acetyl-CoA is used up for lipid synthesis, instead of energy 
production
109,110,111
.  
Further, the changes in microRNA expression contributed considerably to altered 
mRNA expression profile in both the GAL and RL conditions. The 4 commonly changed 
microRNAs alone appeared to be able to regulate the mRNA expression of 52 target genes, 
arguing that microRNA regulation of the transcriptome might be a significant contributor to 
metabolic stress-induced cellular responses. mir-129-3p is located next to a CpG island and 
modulated by DNA de-methylating drugs
112
. Hence, its expression change might indicate that 
(metabolic) stress alter microRNA signature through epigenetic modifications.  
5.1.2 MD-specific transcriptome 
When we compared the transcriptome profile of the MD patient derived HDFs to 
matched CNT fibroblasts, we found prominent changes in molecular networks associated with 
immune response and cell-cell interactions. According to the neurodegeneration–
inflammation model of MD the neuropathological alterations are resulted from immune 
activation and inflammation. Immune and cytokine dysregulation was detected on a molecular 
and tissue level in MD patients not only in the CNS but also in the periphery
113,114
. 
However, it is also clear that the immune-related genes are only partially responsible 
for the genetic vulnerability of MD. The other significant component of the disease might be 
the disruption of intercellular communication, migration, cell cycle, apoptosis, thus 
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(neuro)development
115,116
.  Genetic elements regulating growth and organ development might 
also represent vulnerability factors.  Our findings, i.e. enrichment of development-related 
gene sets, are also congruent with this view and might refer to genetically determined 
susceptibility since most of the epigenetic changes, environmental influences and drug effects 
are likely to disappear over time, as the fibroblasts continuously divide in the culture
69
. 
However, our experiments cannot exclude the possibility that some of the extremely stable, 
cell-division-resistant epigenetic factors might also contribute to the observed changes
117,118
. 
An unexpected and interesting finding of our study was the strikingly different level of 
expression of approximately half (16 of the 37 genes) of the HGF/cMET signaling pathway. 
Eighty percent of the affected genes were decreased, which allow us to assume the genetically 
determined deficit of this pathway. c-MET is highly expressed by neurons. Hepatocyte 
growth factor (HGF), the ligand of c-MET receptor tyrosine kinase, is a multifunctional 
cytokine involved in immune regulation, neurodevelopment, adult neurogenesis and long term 
potentiation, processes involved in MD
119 , 120
. Previous results suggest that ischaemia-
provoked HGF production has neuroprotective effects and moderates the memory deficits
121
; 
however, the proapoptotic, antimitotic effect of MET can be suppressed by enhanced GSH 
production
93
.  Yet, the inhibition of HGF synthesis leads to depression and anxiety-like 
behavior in animal model
122
. Arnold et al. found that among plasma metabolite levels, HGF is 
the best predictor of the incidence and evolution of depressive symptoms in patients with age 
above 55 years
123
. Our hypothesis, that the deficit of the HGF/MET signaling pathway might 
preclude the beneficial effects of this compensatory elevated HGF, might be the subject of 
further researches. 
The patients’ fibroblasts showed altered expression in a panel of 38 miRNAs. The 
MD-specific microRNA and mRNA profile appeared to be functionally connected, as many 
of the mRNAs were predicted targets of the microRNAs and changed in the opposite 
direction. Practically, 50% of the gene expression changes could be explain by the 
microRNome alterations.   
The role of microRNAs in the pathophysiology of MD is under active investigation 
(recently reviewed in ref. 124). Depressed individuals show notable brain microRNA changes 
some of which are also detectable in the blood. Further, antidepressants and electroconvulsive 
therapy also proved to alter microRNAs. Therefore, profiling of microRNAs in peripheral 
samples might be potential diagnostic and therapeutic biomarkers
124
.  
Noteworthy, at least 8 of the 38 differentially expressed microRNAs have been 
previously associated to neuropsychiatric disorders: miR-132 was previously related to 
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BDNF-induced (patho)physiology and activity-dependent hippocampal arborisation
125,126
 and 
found to be upregulated along with decreased BDNF levels in MD patients in correlation with 
the disease’s severity126. miR-22 regulates BDNF, serotonin receptor 2C (HTR2C) and 
monoamine oxidase A (MAO-A)
127
;  miR-16 participate in the regulation of serotonin 
transporter (5HTT), mediating the SSRI antidepressant treatment response
128
. miR-33a-3p, 
and miR-425-3p were altered in the blood of MD patients
129
; while miR-32 and miR-22 in a 
postmortem bipolar dataset
130
. Furtherly, miR-185 was related to suicidal behavior
131
; miR-
196 and miR-7 was indicated in schizophrenia
130,132
. miR-429 is downregulated in response to 
repeated stress in rat brain
133
. Finally, miR-107 might be associated with accelerated disease 
progression in Alzheimer’s disease134. 
As microRNAs are considered to be potential biomarkers, more workgroups measured 
the microRNA levels in the blood or peripheral mononuclear blood cells (PMBCs) of MD 
patients. Some of our findings are congruent with these results, as HDFs exhibited MD-
specific expression of miR-132, miR-103, miR-22
135
, miR-107, miR-132
126
.  
However, the microRNAome has a poorly understood, tissue and gene expression 
pattern specific overall effect with notable pleiotropy and redundancy. Thus, predicted 
pathway analysis is elemental to contextualize the detected microRNA signature. For 
instance, Fan et al. detected the microRNA signature in PBMCs of MD patients and identified 
22 neural function associated pathways
136
. Although, our diseased HDFs showed different 
microRNA pattern, 18 of these were also indicated in our samples (e.g. axon 
guidance, glutamatergic synapse, Wnt signaling pathway, ErbB signaling pathway, mTOR 
signaling pathway, VEGF signaling pathway, long-term potentiation, etc.).  
These observations remind us to the multidimensionality of MD, i.e. the disease 
affects not only the CNS, and molecular anomalies are detectable in peripheral tissues.  
Hence, examination of fibroblasts gained from MD patients have conceptual implications for 
our understanding of the pathophysiology. 
5.1.3 Metabolic stress response of MD fibroblasts 
Several clinical and experimental data proved that MD and stress reaction has striking 
similarities on the level of organism, tissues and molecules; and stress can evoke depression 
in genetically vulnerable persons
9-15
. On the base of the diathesis–stress hypothesis of MD, we 
presumed that the gene expression studies could be more informative if we challenge the MD 
fibroblasts. In this way these molecular clues refer to the presence of genetically determined 
stress vulnerability even if the disordered phenotype is not detectable in STD.  
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Our results demonstrate that the metabolic challenge result in robust changes of 
mRNA and microRNA expression. A substantial fraction of the mRNA changes, 26% (GAL) 
and 33% (RL) were observed only in MD, but not in CNT. The characteristic response of MD 
fibroblasts was even more pronounced on the microRNA level: 81% (GAL) and 90% (RL) of 
the total microRNA changes were MD-specific. Some of the enriched molecular pathways 
were already identified in the STD condition; however, metabolic stress uncovered other MD-
associated impairments in the control of metabolism, energy production (FEEDER, 
GLYCOLYSIS) and cell migration (SPRY, ECM). Furthermore, 38% (GAL) and 17% (RL) 
of the enriched gene sets (PTC1, MPR, ACAP95, ARF, HSP27, SET, BAD, IL7, TRKA, 
CDMAC, SPRY, TFF) and approximately 50-60% of the microRNAs were implicated in 
survival, proliferation and apoptosis. These data provide an overwhelming support for the 
aberrant engagement of mechanisms regulating cell proliferation and survival by MD 
fibroblasts when exposed to metabolic challenges. 
GAL and RL treatments elicited common responses in MD fibroblasts. The 
CHREBP2, HSP27, BAD and ARF were the commonly enriched pathways. Three of them 
(CHREBP2, HSP27, and BAD) were acivated by GAL and/or RL in the CNT cells also and 
Arf inhibiting ribosomal biogenesis (ARF) pathway was enhanced already in STD-treated 
MD cells. 
Both of the applied metabolic stress treatments induce starvation-like, oxidative states 
in the cells
105
. It is not surprising, that one third (GAL: 38%, RL: 37%) of the genes involved 
in the stress response of the MD-fibroblasts regulates the metabolism and energy homeostasis 
and both metabolic stress treatments induced miR-424 and miR-495 expression. These 
microRNAs are overexpressed under hypoxia and play a role in the metabolic switch from 
oxidative physphorilation to anaerob (glycolytic) energy production
137,138
.  
Additionally, the RL-stress response of the MD samples varied in the expression of 
8 lipid metabolism related microRNAs from the CNT samples. This fits into our previous 
knowledge: (1) lipid deficit is an extreme metabolic overload for cells via the forced lipid de 
novo biosynthesis
106
. (2) the dysfunction of lipid metabolism, e.g. FFA metabolism 
dysregulation, is a long-investigated and documented, but still poorly understood phenomena 
in MD
139
. According to our results, the RL-environment exaggerates the adaptational deficits 
observed in MD. We found intriguing that it induces primarily negative changes in the 
microRNA profile which refers to the increase of the translation and appearance of new 
enzyme set.  
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Another interesting fact revealed only in RL-environment is the presence of six 
hypoxamirs. HypoxamiRs have been identified as microRNAs essential in the adaptation to 
oxidative stress contributing to mitochondrial respiration arrest, thus decreased production of 
ROSs in a low oxygen environment
140,141
.  In our study, CNT fibroblasts upregulated six 
hypoxamirs (let-7b*, miR-192, miR-26a, miR-98, miR-23a and miR-7) in response to RL, 
whereas MD fibroblasts downregulated them. This particular difference further supports the 
notion of mitochondrial dysfunction in MD.  
According to the microRNA target pathway analysis, both the stress-induced and MD-
specific microRNA profiles are likely to affect the glutamergic synapse pathway. Evidence 
indicates a glutamate dysregulation in chronic stress and MD, which contributes to the 
neurodegeneration. Interestingly, when Gottshalk et al. investigated the protein expression 
profile in the prefrontal cortex of MD patients, they found that glutamate neurotransmission 
and energy metabolism related pathways are the most affected by the disorder
142
.  Glutamate 
is a key intermediate product of energy metabolism and glutamate neurotransmission is highly 
linked to cellular energy metabolism (glycolysis, ATP synthesis). Our findings suggest that 
this in vitro stress and MD model could help us to understand the genetic and molecular 
background.  
To prove the validity of the presented metabolic stress functional assay in the 
identification of MD-related gene sets, we look through the pathways which were predicted to 
be targeted by the stress- and MD-affected microRNAs pathways. As Figure 12 shows, the 
majority of MD-specific pathways (green) were also modulated by the challenge-evoked 
microRNA signature. 
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Figure 12. Majority of the stress-induced and MD-associated microRNome target pathways. 
(green indicates MD-specific target gene sets in standard conditions; yellow highlightes the stress-
induced pathways in CNT; purple signes the challenge-induced pathways in MD cells) 
An important question is whether the changes we detect in peripheral tissues are 
relevant to a disease process that takes place primarily in the brain. Searching previous 
literature, we found that the challenge-induced transcriptome changes of MD cells can be 
linked to neural functions. For instance, genes important for neurite outgrowth, 
neurodevelopment and synaptic plasticity were identified: actin-related protein 2/3 complex, 
subunit 5 (ARPC5)
143
, ArfGAP, ankyrin repeat and PH domains 2 (ACAP2)
144
 and beta-1,3-
glucuronyltransferase 2 (B3GAT2)
145
.  Multiple important roles in the CNS are associated 
with the microRNA stress-response signatures as well. Indeed, 31% (GAL) and 47% (RL) of 
the stress-affected microRNAs are indicated as regulators of neuropathophysiology or 
biological markers associated with psychiatric disorders. miR-7
146
, miR-26a
147
, miR-
34a
148
, miR-134
149
 and miR-132
150
 participate in neurite outgrowth and synapse formation.  
miR-25
151
,  miR-34a
152
, miR-497
153
, miR-196a and miR-376a are involved in cell cycle, 
apoptosis and neural differentiation
154
. miR-7 and miR-370
155
 regulate brain morphogenesis; 
while miR-23a influences myelination
156
. Furthermore, we detected some microRNAs which 
were previously named as biomarkers in schizophrenia (miR-132, miR-564 and miR-382
157
); 
Alzheimer's disease (hsa-let-7g, miR-15b
158
); Huntington’s disease (miR-1285, miR-34a and 
miR-34b
159
). A number of miRNAs that respond to different stressors in the CNS: miR-34b, 
which affects the degree of oxidative stress and survival of dopaminergic 
neurons
160
; miR-296-5p, which responds to oxidative stress in mouse hippocampal neuronal 
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cultures
161
; miR-199a, which reacts to hypoxia in rat cortical pericytes
162
; and miR-98, which 
is elevated in the brains of newborn rats experiencing prenatal stress
163
.   
Taken together, the information gives confidence to the relevance of our observations 
in fibroblasts to the MD disease state. We can conclude that presenting metabolic challenges 
were instrumental for defining distinct MD mRNA and microRNA response signatures that 
might also contribute to patients' aberrant responses to life stressors. 
5.1.4 Never-ending limitations 
Considering study design; utility of HDFs in psychiatric research; or difficulties of 
transcriptome studies, several limitations have to be acknowledged when evaluating our 
results. Although our sample size was determined to ensure enough statistical power for 
microarray screening and we performed repeated measures, our results would require 
validation in larger cohort of MD patients to regard the detected transcriptome changes as 
potential biomarkers.  
Expanded literature suggests that MD is a heterogenous systemic disease without 
clear, consensual subtyping. Several (epi)genetic, neurobiological, neuroimaging 
characteristics were found only in a subset of patients hence the differences could be masked 
in the total depressive patient population, underscoring the value of diagnostic 
subclassification (e.g. serotonin signaling pathway – melancholic depression68). 
There are several drawbacks that should be considered when using the HDF 
experimental model. Several research groups investigated the in vivo and in vitro cellular 
aging-related changes in HDFs. They revealed that mRNA, miRNA and protein levels
164
, 
DNA methylation
165
, intracellular calcium levels, mitochondrial function and cell size
166
 are 
all influenced by the age of the donor. These findings necessitate careful casecontrol age 
matching and/or use of senescence markers.  
Furthermore, matching the number of passages is equally important to avoid 
consequences of in vitro cellular ageing i.e. mitotic rate, telomere length, DNA methylation
20
, 
proteome and protein phosphorylation
167
 changes that occur after the P15 in HDF cultures. 
The cells enter replicative senescence between P21 and P40
20
. Additionally, the early 
generations might also undergo significant transcriptome and epigenome remodeling during 
the adaptation to the culturing conditions
168,169
.  
Even though HDFs are thought to lose most of the epigenetic footprints after 
5 passages
69
; and Fournier et al. underpinned that body mass index (BMI), smoking and 
medication do not influence the metabolome of HDF cultures past several passages
22
, we 
41 
 
decided to perform our experiment on HDFs between P5-P10. For microRNome analysis, we 
pooled the samples regarding age and gender and the results were validated with individual 
samples. However, we cannot exclude the possibility that the lack of clinical information (i.e. 
received medication) might hinder clear conclusions. 
Lastly and obviously, HDF cells are not brain cells: they are much more robust, stress-
resilient with self-renewal capacity
18
. The energy homeostasis of neurons relies on lactate 
oxidation thus, they live in a symbiotic relationship with glial cells
170
. Additionally, neurons 
are specialized to rapid cell-cell communication, while HDFs are primarily stromal cells with 
a prominent role in immune response and regeneration
171
. We have to be aware all these 
differences when putting our results in context of the diathesis‒stress model of MD. 
There are several problematic issues on microRNA-studies as well. First of all, target 
mRNAs are identified with computational methods and not necessarily 
validated in vitro or in vivo. Since microRNAs bind to target mRNAs via imperfect 
complementarity, understanding exactly which target mRNAs are recognized by which 
specific miRNAs is challenging
172
. The mechanism, how microRNA regulates protein 
synthesis is not as simple and obvious as previously thought (a simple negative effect)
29,31
. 
Additionally, translation regulation is not the only biological function of these pleitropic 
molecules: they also serve as paracrine, endocrine signaling molecules
26
. Thus, further efforts 
are needed to establish connections between microRNA and mRNA expression data, improve 
target gene and pathway prediction. In regard of these and the huge amount of data, we 
carried out pathway analysis to get a clue what are the overall consequences of the detected 
transcriptome profile changes in MD and CNT HDFs.  
5.2 STUDY 2 – A PSYCHOPHARMACOLOGICAL ASSAY 
We used a special differentiation protocol resembling adult hippocampal neurogenesis 
and resulting in granule cells to study the AP-induced gene expression changes. Importantly, 
the same model system was recently applied in a Lithium-response assay
52,173. Hippocampal 
neurogenesis is mandatory for the maintenance of normal cognition through the life. Exogen 
factors impairing it (e.g. chronic stress or radiation) have detrimental effects on cognition and 
mood
174
. Thus studying neurogenesis during AP treatment have implications for the large 
community of patients who take these medication for years or decades. 
Haloperidol (HL) is a typical antipsychotic drug (TAP) acting primarily on D2 
dopaminergic receptors with lower activity at D1, D3, D4, 5-HT2A serotonergic, and α1 
adrenergic receptors (pharmacodynamics of APs reviewed in: ref. 175). In addition, it alters 
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NMDA binding and glutamate transporter expression thus exert a hyperglutamatergic 
effect
176,177
. In contrast, olanzapine (OL) and risperidone (RP) are atypical antipsychotics 
(AAPs) which operate primarily as 5HT2A antagonists and relatively weak D2 antagonists. 
Furtherly, they block with moderate affinity several other serotonergic, dopaminergic, 
histaminergic and alfa-adrenergic receptors
178
. Clinical studies suggested that treatment with 
AAPs, may slow the progressive changes in brain structure in patients with schizophrenia
179
. 
We have to take into account that APs might have poorly known off-target effects.  
For example, HL can block L- and T-type calcium channels, enhance voltage-gated sodium 
channel expression thus affect the generation and propagation of action potentials
180 ,181
. 
Similarly, we must not forget that deducing from in vitro data to clinical implications is 
possible only a very limited way and has to be done cautiously.  
5.2.1 Neuronal differentiation 1 (NEUROD1) 
According to our results, low and high concentration RP and high dosage OLtreatment 
increased the expression of NeuroD1. HL exerted augmenting effect on the gene at lower 
concentration, but not at higher.  
 NeuroD1 is a transcription factor, key regulator of vertebral neurodevelopment. 
NeuroD1 expression diminishes as the brain matures except in the cerebellum and 
hippocampus where it controls the differentiation of granule neurons throughout adulthood 
via activation of E-box containing gene promoters (e.g. IGF1, NCAM and TrkB)
182 , 183
. 
NeuroD1 activation or transfection is used to induce neural fate in pluripotent cell cultures 
and forced expression of  NeuroD1  alone have promoting effects on neuronal 
differentiation
184
. Hsieh et al. found that NeuroD1 overexpressing  NPCs differentiated into 
neurons (>75%) and reduce their ability to develop oligodendrocytes and astrocytes
185
. 
Agents (e.g. retinoic and valproic acid) increasing NeuroD1 levels are known to promote 
neural differentiation and inhibit astroglia and oligodendroglia development
185,186
.  
We have to consider that NeuroD1 elevation in the treated versus untreated cultures 
can be indicative of accelerated neurogenesis or augmented survival as well, in general. 
However, the bFGF deprivation from the first day of AP-treatment had to arrest proliferation; 
thus, we assume that APs facilitated cell survival only at certain concentrations. These 
findings are aligned with the previous literature. The beneficial effect of APs have been 
attributed partially to their capacity to increase neurogenesis/survival; however, the results are 
often inconsistant especially in case of HL (reviewed in ref. 187 and 188).   
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On the whole, OL administration repeatedly proved to increase the number of 
newborn cells with neural fate in the rodent dentate gyrus
189
 and improve memory 
performance via increasing brain-derived neurotrophic factor (BDNF) levels in the 
hippocampus
190
. Others suggested neuroprotective rather than proliferative effect of OL
191
.  
Most of the studies were not able to detect any consequences of RP and HL-treatment 
on hippocampal cell proliferation
187,188
. On one hand, RP and HL both found to promote the 
survival of young neurons in the hippocampus by anti-apoptotic BCL-2 and VEGF 
induction
192
, on the other hand significant body of data suggests detrimental effect of 
HL
193,194,195  
and several publications discussed the neuroprotective potential of AAPs above 
the TAPs (usually OL>RP>HL)
 195,196,197
. One possible mechanism of the dual HL-effect is 
dose-dependency
193, 198
 what was confirmed in our results also: there was a significant 
difference between HLlow and HLhigh. 
This great diversity of data might be due to differences in the dosage, application 
regime, examined brain areas and animal models
192
. For instance, Green et al. reported that 
OL increased cell proliferation in the prefrontal cortex and subventricular zone but not in the 
dentate gyrus
199
.  There might be major variaties within circuits since the depletion of neural 
transcription factors (NeuroD1, neurogenin 1, 2 or 3) induces massive apoptosis of DG 
granule cells but does not affect CA regions seriously
182
.  
The effects of AP treatment on neurogenesis/survival is especially worthy of further 
research: schizophrenia can be referred to as a neurogenesis deficit disorder since 
neurodevelopmental and/or adult neurogenesis, in particular, DG neural stem cell 
proliferation might be deficient
200
.  
5.2.2 Microtubule-associated protein 2 (MAP2) 
We found that MAP2 expression was altered in the differentiating neurons only by 
haloperidol: the 19-day-long HLlow-treatment increased the relative mRNA levels, while 
AAPs did not affected it. 
MAP2, as other microtubule associated proteins, promotes microtubule assembly, 
polymer stabilization and regulate organelle transport. Since it is predominantly expressed in 
neurons, it is used as an (early) neural differentiation marker in stem cell neural differentiation 
assays
201
. More importantly, MAP2 represents a specific neurite outgrowth marker also 
participating in dendrite spine formation and neuronal plasticity in vivo and in vitro
202, 203
. 
MAP2 expression alterations are usually evaluated as increased synaptic plasticity, and 
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thought to reflect functional and/or structural changes in the dendritic tree
204
. Accordingly, 
our findings suggest that HLlow treated cells exhibited active synaptic dynamics. 
Large body of data underpins that APs alter synaptic morphology and expression of 
several presynaptic genes in addition to their classic receptorial mechanism. In deed, 
enhanced neural plasticity and synaptic remodeling thought to be important detail of their 
therapeutic mechanism
205 ,204
. However, notably few study examined the postsynaptic 
molecular effects of APs
204
.  
Lidow et al. showed increased MAP2 phosphorilation after long-term haloperidol 
treatment in primate cortex but did not detected expression changes
206
. An other study 
measured the effects of 14-day-long HL, RP and OL on the cortical and hippocampal MAP2 
mRNA levels. The gene expression was increased in the rat cortex by HL and RP and in the 
dentate gyrus by RP and OL but remained unchanged in CA1-3
204
.  
Yet, it is worthy of note that gene expression is only one part of MAP2 function 
regulation: the binding and activity of MAPs depend on their phosphorilation state and MAP2 
serves as substrates for most of protein kinases and phosphatases present in neurons (PKA, 
PKC, ERKs, CAMKII, GSK3, CDK, MARKs)
203
. Hence, our observation that RP and OL do 
not modulate the gene expression itself is not in contradiction with previously detected AP-
induced plasticity, arborisation changes. 
Contextualizing our results, we must also not forget that synaptic changes are 
modulated on a network level which is per se much more complex in vivo than in vitro. Our 
study implies that RP and OL does not influence directly the MAP2 expression in cultured 
neurons contrary to HL. This is aligned with previous findings, suggesting that TAPs and 
AAPs regulate differentially the dendritic spines and postsynaptic plasticity
207
. Appreciating 
the known dendritic pathology in schizophrenia (e.g. decreased hippocampal MAP2 levels
208
, 
209
, but see 
210
), these molecular consequences are worthy of further investigations. 
5.2.3 Glial fibrillary acidic protein (GFAP) 
Interestingly, we found that AAPs exerted inverse effects on GFAP expression at 
different concentrations: OL and RP elevated GFAP mRNA levels at low concentration but 
repressed it at higher dosages.  
GFAP is the major intermediate filament of mature astrocytes and has been widely 
used as an astrocyte differentiation marker
211
. Elevated GFAP level can refer either to 
astrocyte activation or increased number of glial elements
212
. The phenomenon that 
differentiating neural cultures can develop glial cells spontaneously was evidenced by several 
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research groups who detected non-neuronal cells in stem cell-derived neural cultures using 
various differentiation protocols (data vary between 6-50%
213,214,215,216
). These cells include 
neural and glial precursors, oligodendrocytes and GFAP positive astrocytes
213
.  
Even though, alterations in levels of GFAP may reflect pathological regulation of 
neuronal function, survival, as well as synaptogenesis and neurotransmission, studies on 
astrocytes in context of psyciatric disorders are underrepresented in neuroscience. For 
instance, directed differentiation of glial cells from human PSCs has not been paid sufficient 
attention since glia are regarded as supporting cells and appearance of glia in the 
differentiating neural cultures as a by-product default consequence of differentiation
217
. 
However, astrocyte abnormalities have been detected in schizophrenia, depression and bipolar 
disorder in various brain regions
218,219
. Among these, the most commonly reported gene 
expression alteration is reduced level of  GFAP
218,187, 220
 which is further modified by 
antidepressant and AP-medication
221,222
. 
Despite of these, surprisingly few study aimed to investigate the effect of APs on the 
expression of GFAP: searching PubMed for haloperidol OR olanzapine OR risperidone AND 
GFAP, we found 6 relevant papers. Importantly, the results suggest that GFAP-modulatory 
effect of APs might be human and subregion specific
223,222
. For instance, Radomska et al. 
found that GFAP expression of human primary astrocytes were increased by 6h HL-treatment 
in vitro
223
; and others detected OL-induced GFAP upregulation and proliferation suppression 
in human glioblastoma cells
224
. The workgroup suggested that the mediator might be a 
human-specific Quaking (QKI) -binding element in the gene promoter
223
. This might explain 
the negative findings in rodent models after HL, RP and OL treatments
225,212,226
.  
The effect mechanism of APs on glial cells is poorly known. Notably, astroglia 
response to antidepressants and thought to be key factors of their beneficial effects on 
neurogenesis
227
. They express wide range of neurotransmitter receptors in a brain region-
specific manner (reviewed in ref. 228 and 229). For instance, hippocampal astrocytes were 
reported to express serotonine (5HT1A, 2A, 2B, 2C), glutamate (AMPA, mGluR1-8 except 
mGluR7), GABAA and GABAB, muscarinic, beta adrenergic, histamine, and somatostatine 
receptors; more of them modulated by APs. In addition, several signaling molecules proved to 
influence the transcription of GFAP, e.g. circulating cytokines, endocrine hormones, neuron-
released glutamate and TGF-ß. 
Overall, while our findings and previous data support a role for GFAP in 
pathomechanism of APs, the exact nature of this, and the pathological implications of these 
findings remain unclear. 
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5.2.4 Metabotropic glutamate receptors (mGluR2 and mGluR7) 
We found that the effect of APs on mGluR2 and mGluR7 genes depended on the 
dosage: both receptors were upregulated by HL at low concentration. In contrast, mGluR2 and 
mGluR7 mRNA levels were decreased by OLhigh and RPlow, respectively.  
Metabotropic glutamate receptors (mGluRs) have various modulatory functions on 
neurotransmission and synaptic plasticity especially in hippocampal learning and memory 
processes
230
. The eight mGluR subtypes are classified into three groups: group I 
(mGluR1/mGluR5) coupled to inositol phospholipid hydrolysis, group II (mGluR2/mGluR3) 
and group III (mGluR4/mGluR6/mGluR7/mGluR8) linked to inhibition of the cAMP 
cascade
230
. Group II and III mGluRs restrain glutamate release by inhibiting pre-synaptic 
voltage-dependent calcium channels and/or interfering with the release-system
231,232
.  
mGluR2 is predominantly expressed in dentate granule cells and distributed 
specifically on the mossy fibers at the preterminal zone or presynaptically
231
. It is an actively 
studied new therapeutic target in schizophrenia
233
, anxiety, depression
234
, and substance use 
disorders
235
.  
According to animal and human postmortem data, chronic RP, OL and clozapine 
treatment, but not haloperidol, downregulates mGluR2 expression
236,237
.  Importantly, the 
silencing effect of AAPs is modulated by the decrease of histon H3 acetylation and enclosing 
the promoter of mGluR2 among other genes
237
.
 
Furtherly,
 
this repressive histon modification 
proved to be serotonin 2A receptor (5HT2A) dependent unravelling the ineffectivity of HL: 
HL is a silent agonist of 5HT2A, while AAPs (as RP and OL) are high affinity 
antagonists
237,238
. 5HT2A was detected in the granular layer of dentate gyrus and pyramidal 
cell layer of CA1–CA3 of the hippocampus 239 . Our data suggest that HL might evoke 
mGluR2 overexpression through an other, currently unknown mechanism in a concentration-
dependent manner what could be interesting subject for further investigations. 
Further, the glutamatergic hypothesis of schizophrenia, clinical and preclinical 
observations suggest that mGluR2 activating drugs represent potentially new AP medications 
233-235, 240
. Therefore, some speculate that mGluR2 downregulation might restrain the 
therapeutic effects of existing AAP drugs
237
.  
Genetic association studies identified mGluR7 as a candidate gene for schizophrenia, 
bipolar disorder and other psychiatric disorders
241 ,242
. The schizophrenia-linked genotype 
might result in lower mGluR7 expression; although, studies on mGluR7 levels in patients 
have not been reported
243
.  Recently, the receptor gained significant attention when proved to 
be more than an inhibitory presynaptic autoreceptor
244,245
. Indeed, mGluR7 is also expressed 
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presynaptically on the GABA-neurons of the hippocampus and basal ganglia. It suppresses 
GABA transmission thus enhances LTP in the hippocampus and disinhibits the nigrostriatal 
dopaminergic pathways
245, 246
. Additonally, agonists may have neuroprotective effects in 
ischaemia and excitotoxicity
247
. As a consequent, it is hypothesized that lower expression of 
mGluR7 may increase risk of developing schizophrenia, have potential therapeutic 
implication in cognitive impairment and extrapyramidal movement disorders, especially those 
originating from AP-induced dopamine depletion
248,249
. 
Notably, despite of its potential involvement in neuropsychiatric disorders and the 
active research on novel mGluR7 acting drugs
250,247
, we did not find any publications about 
the effects of HL, RP, OL or other APs on mGluR7 expression or function. 
5.2.5 Vesicular glutamate transporter 1 (VGLUT1) 
We found that HL at low concentration and RP at both concentrations decreased the 
expression of VGLUT1. This protein, encoded by the SLC17A7 gene, orchestrates the 
synaptic vesicle cargos: its expression pattern directly influences glutamate release (i.e. 
glutamate quantal size)
251
 and correlates with learning and memory processes
252
. Accordingly, 
VGLUT1 plays a pivotal role in glutamate release, synaptic plasticity, postnatal 
neurodevelopment and learning
253 , 254
. Downregulation is implicated in the cognitive 
symptoms of affective and neurodegenerative disorders
254
. Further, VGLUT1 is a pre-
synaptic marker of excitatory neurons in the cortex and hippocampus
255
.  
Importantly, VGLUT1 expression modulation might be region, furthermore cortical 
layer specific and age-dependent, thus published results are often inconsistent
256 , 257
. In 
general, postmortem and animal studies revealed altered glutamate neurotransmission and 
VGLUT1 expression in MD, bipolar disorder
256,258
, and schizophrenia
259,257
. Uezato et al. 
reported that HL interferes with VGLUT1 in the temporal cortex of rats but not in the 
hippocampus
256
; while others found no effect of HL on VGLUT1
257
. Clozapine (AAP), 
lithium and antidepressants raised VGLUT1 in the cortex and hippocampus
260
. Notably, we 
found no previous data on the effect of RP or OL on VGLUT1.  
5.2.6 Limitations and future directions 
Although, iPSC/iNC cultures are probably the most promising tools in brain-research, 
they have considerable shortcomings. First of all, even if the cell lines can be initiated from 
easily obtainable biospecimens, the reprogramming, culturing and differentiation is labor-
intensive and requires notable expertise
261
. Proliferating iPSCs exhibit genetic instability 
which may result in population diversity and biases in genetic assays
262,263
.  
48 
 
Although, the hereby used monolayer technique thought to be the most efficient way 
to synchronize and control NPC development in vitro
264
. However, iPSC-derived neural 
cultures always contain progenitors, glial cells and mature or immature neurons with different 
neurotransmitter and receptor profiles and varying electrophysiological properties
213
. For 
instance, Yu et al. reported that the above described protocol resulted in predominantly 
glutamatergic neurons (>85%) with low occurrence of GABAergic neurons (<15%). 
Additionally, we detected GFAP-response to AP-treatments which would be impossible in a 
neural culture theoretically. On one hand, this resembles better the physiological, in vivo 
conditions suggesting more natural cell functions. On the other hand, it might necessitate 
single-cell molecular-biology approaches
213
. 
Using iNCs, we aimed to study the effect of APs on neurogenesis and differentiating 
hippocampal granule cells. However, we have only limited knowledge of how far can we 
mimic in vivo embryonic or adult neurodevelopment. NPCs and new neurons need a special 
niche, surrounded by glia, blood vessels, and ependymal cells
55
. They follow a stereotypic 
process for network integration in close interactions with hundreds of cells and different 
excitatory and inhibitory signals
265
. Still, the maturation process (i.e. reaching 
electrophysiological, neurochemical properties similar to adult neurons) might last for 6-10 
weeks
 
in vitro
52
 that can be shortened by growing the neurons on feeder astrocytes
266
. In 
conclusion, when we decided to use poor, monolayer neuronal cultures, we compromised 
between subideal techniques considering pros and contras and resourcements. 
Importantly, epigenetic effects of APs and other psychiatric medications are under 
active research. iNCs might be key approaches of these studies as iPSCs undergo epigenetic 
rearrangement during reprogramming and differentiation. This might be a notable advantage 
since cells are likely to lose in vivo effects, e.g. lifestyle or medication. However, the inherited 
and early epigenetic effects are also erased from the functional assays. Furthermore, iPSCs 
exhibit a considerably high number or epigenetic abberrations
267
. 
One of the weakest point of our experiment might be the concentration of AP-
treatments. When choosing the dosage, we had to consider two major issues: we aimed to 
model in vivo circumstances (i.e. the therapeutically-relevant serum concentrations) and gain 
results comparable with previous data. Yet, contextualizing our results might be problematic 
due to difficulties in establishing dose equivalences between APs, poor information on real 
brain concentrations and disputed dosage in animal studies
268 , 269
. Correlating receptor 
occupancy in vitro and in vivo might improve the validity of these pharmacological assays
269
.  
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5.3 OUR MAJOR FINDINGS 
In the first study, we aimed to set up and test an in vitro functional assay for modeling 
MD in the diathesisstress aspect. Here, we suggest that the above presented results 
correspond with the hypothesis that MD is a genetically determined, systemic maladaptational 
disorder.  
(1) First, we wanted to know how metabolic stress-response manifests on the level of 
mRNAs and microRNAs in HDFs? Our results suggest that metabolic stresses resulted in 
similar, but not identical, robust transcriptional changes affecting gene sets implicated in cell 
cycle, apoptosis, inflammation, and metabolic adaptation. The microRNA signature 
contributed considerably to the mRNA stress-response.  
(2) Next, we examined if there are any differences between the MD and CNT samples 
in the mRNA and microRNA profile? We found a functionally interconnected microRNA–
mRNA network disturbance in MD cells: namely, a loss-of-function genetic dysregulation 
with most prominent decreases in genes related to cell communication, adhesion, immune 
functions and apoptosis.  
(3) Finally, we compared the stress response of MD and control HDFs. These data 
underpin our hypothesis that the dysregulated microRNA profile in MD contributes to the 
maladaptation. We can also assume that MD cells can reach the required metabolic changes 
via non-physiological ways what result in increased vulnerability. Contrary to CNT cells, RL-
medium showed to be greater challenge for MD cultures. Understanding this phenomena and 
investigating the MD-specific stress response might help to get closer to the genetic 
background of maladaptation. 
In Study 2, we established an in vitro pharmacological assay using neural cells 
originated from human iPSCs and treating them with typical AP haloperidol or with atypical 
olanzapine and risperidone. As far as we know, we are the first who examined the effect of 
APs on iPSC derived neural cells during differentiation and maturation.  
AAPs increased the expression of NeuroD1, indicative of accelerated neurogenesis 
and/or augmented neural survival. MAP2 transcription was elevated by HLlow suggesting 
increased synaptic plasticity, and functional‒structural changes in the dendritic tree. Our 
results call attention to the existing, but different effects of APs on the expression of mGluRs, 
which are actively studied new therapeutic targets in psychiatric disorders and implied in 
hippocampal LTP. Similarly, the RP and HLlow-attenuated VGLUT1 expression might 
contribute to the understanding of cognitive aspects of long-term AP-treatment. Interestingly, 
GFAP was modulated by AAPs which can be remarkable subject of further research.  
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6 CONCLUSIONS 
On the basis of our observations, we argue that in vitro model systems have potency in 
psychiatric research.  
First, we worked with the classic, but still valid patient-derived HDFs which have 
been utilized in psychiatric studies since 1978
270
. We presented that the mRNA and 
microRNA profile of the cells gained from MD and CNT subjects are different and reflect to 
the known MD-specific CNS and peripheral pathophysiological phenomena. Previously HDF 
cultures were used to study the signal transduction alterations, oxidative stress in MD
271,272
. 
However, we are the first, who used these peripheral cells to get familiar with the (epi)genetic 
regulation of stress reaction and MD. Our research might serve as a base to develop a new 
stress model, which allows us to discover the (epi)genetic risk factors and G * E in the 
background of maladaptational disorders, such as MD.  
Second, we used iPSC-derived neural cells, one of the most promising models in 
current neuropsychiatric research. We found AP-induced gene expression alterations in 
differentiating hippocampal granule neurons. Considering our and previous results, we have 
to acknowledge that APs exert complex, poorly understood modulatory effect on the gene 
expression and cell pathophysiology in a brain region- and cell type-specific manner; 
therefore, these cannot be studied in peripheral cells.  Understanding these mechanisms might 
have direct consequences in clinical and experimental pharmacology.   
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Abstract
Metabolic and oxidative stresses induce physiological adaptation processes, disrupting a finely
tuned, coordinated network of gene expression. To better understand the interplay between the
mRNA and miRNA transcriptomes, we examined how two distinct metabolic stressors alter the
expression profile of human dermal fibroblasts.
Primary fibroblast cultures were obtained from skin biopsies of 17 healthy subjects. Metabolic
stress was evoked by growing subcultured cells in glucose deprived, galactose enriched (GAL) or
lipid reduced, cholesterol deficient (RL) media, and compared to parallel-cultured fibroblasts
grown in standard (STD) medium. This was followed by mRNA expression profiling and
assessment of > 1,000 miRNAs levels across all three conditions. The miRNA expression levels
were subsequently correlated to the mRNA expression profile.
Metabolic stress by RL and GAL both produced significant, strongly correlated mRNA/miRNA
changes. At the single gene level four miRNAs (miR-129-3p, miR-146b-5p, miR-543 and
miR-550a) showed significant and comparable expression changes in both experimental
conditions. These miRNAs appeared to have a significant physiological effect on the
transcriptome, as nearly 10% of the predicted targets reported changes at mRNA level. The two
distinct metabolic stressors induced comparable changes in the miRNome profile, suggesting a
common defensive response of the fibroblasts to altered homeostasis. The differentially expressed
miR-129-3p, miR-146b-5p, miR-543 and miR-550a regulated multiple genes (e.g. NGEF,
NOVA1, PDE5A) with region- and age-specific transcription in the human brain, suggesting that
deregulation of these miRNAs might have significant consequences on CNS function. The overall
findings suggest that analysis of stress-induced responses of peripheral fibroblasts, obtained from
patients with psychiatric disorders is a promising avenue for future research endeavors.
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INTRODUCTION
Postmortem brain studies of psychiatric disorders show complex transcriptome profile
changes that encompass both miRNA and mRNA disturbances [1,2]. Yet, these studies face
considerable confounds, limiting mechanistic and molecular investigation into the causality
of the observed changes. The uniquely human occurrence of major psychiatric disorders and
the absence of bona fide animal models [3,4,5] underscore the need for analyzing human
tissue. However, the usefulness of post-mortem brain tissue is limited primarily to static
measures, such as gene expression analysis. Patient fibroblasts, due to their abundance,
availability, and neuron-like receptor and protein expression are appealing alternative in
vitro models for functional analysis of brain disorders [6,7].
Stress is a strong modulator of gene expression [8]. In vitro, glucose-depleted, galactose-
supplemented medium is a widely used metabolic stress treatment in fibroblast cultures [9]:
glucose depletion increases the level of reactive-oxygen species (ROS), which results in
elevated, compensatory glutathione production [7]. Yet, over a prolonged time starvation
results in reduction of NADPH, limiting the efficacy of the glutathione protection to the
cells. In contrast, reduction in the exogenous cholesterol is a different kind, but related
metabolic stress: to maintain their membrane structure and survive, fibroblasts are forced to
synthesize their own cholesterol, stressing their metabolic machinery [10]. These two
metabolic stress models are likely to share common characteristics: there is an increased rate
of glucose incorporation into lipid when cells are switched into lipid-deficient medium [11]
and C14 galactose incorporates into galactolipids [12]. Therefore, both would be expected to
manifest common disturbances in the gene expression machinery.
Micro-RNAs (miRNA) are 18-22 nucleotide long fine-tuning regulators of gene expression
and protein production [13]. Thousands of miRNAs are encoded in the human genome,
controlling the function of approximately 50% of our genes. miRNA expression is tissue,
environment and individual specific [14]. A single miRNA can regulate the expression of
hundreds of mRNAs, cause their degradation, destabilization, stocking or transport.
The present study was aimed to answer three questions. First, do the different metabolic
stressors alter the miRNA expression profile of human fibroblasts? Second, are the miRNA
expression profiles similar between two different metabolic stressors? Finally, do the
miRNA expression changes result in changes at the mRNA level? Importantly, these studies
provide critical baseline data for similar experiments that will be performed on fibroblasts
from patients with schizophrenia, major depression and bipolar disorder.
MATERIALS AND METHODS
ETHICS STATEMENT
The Vanderbilt University Institutional Review Board (IRB) approved the study and written
informed consent was obtained from all study participants before any procedures were
conducted.
HUMAN FIBROBLAST CELL CULTURES
Specimens for fibroblast cultures were obtained by skin biopsies (~ 1 × 2 mm) from 17
healthy subjects (4 males and 13 females) (Supplemental Material 1) as described previously
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[15]. Exclusion criteria included any DSM-IV diagnosis [16] or any medical condition that
would preclude the biopsy.
All fibroblast samples used in this experiment were cultured between passages 5 and 10
using Dulbecco’s modified Eagle’s medium™ (DMEM; Mediatech, Manassas, VA, USA)
containing 25mM glucose, 1 mM sodium pyruvate supplemented with 2 mM L-glutamine
(Mediatech), 10% fetal bovine serum (FBS; Thermo Scientific HyClone, Logan, UT, USA)
and antibiotic/antimycotic solution (A/A; Invitrogen) at 37 °C and 5% CO2. The cells were
cultured simultaneously under same conditions until reaching confluence, trypsinized and
counted.
A single cell line from each individual was divided into three plates (plating density 1.2×106
cells/plate) and after overnight adherence, the medium was changed into 3 different
conditions. All cultures were grown for 7 days, with a media change every 2 days. (Figure 1)
and were grown in: 1) lipid reduced (RL) medium (DMEM supplemented with lipid reduced
FBS (Thermo Scientific HyClone, Logan, UT, USA)); 2) galactose-containing (GAL)
medium (DMEM deprived of glucose (Mediatech) supplemented with 10mM galactose) and
3) standard, glucose-containing (STD) medium. The medium was changed three times a
week. Cell growth and proliferation were not affected by GAL or RL treatment. After one
week the cells were washed with ice-cold PBS twice, trypsinized, pelleted (700g for 8 min
on 18 °C) and stored on −80 °C until the RNA isolation.
RNA ISOLATION
Total cell RNA and small RNA fractions were isolated from the frozen samples using the
mirVana miRNA isolation Kit (Ambion, Austin, TX) according to manufacturer’s
instructions. In brief, the pellet was suspended in 600 μl Lysis/Binding Solution, than 60 μl
Homogenate Additive was added. After 10 min incubation time for total RNA isolation
1.25× volume of 100% ethanol was added to the aqueous phase and the supernatant was
purified using the proprietary solutions provided by the manufacturer. Finally the total RNA
was collected with 100 μl Elution Solution. For small RNA isolation we added on-thrid
volume of 100% ethanol to the aqueous phase and two-thrid volume of 100% ethanol to the
flow-through. The small RNA specied were collected from the filter with 100 μl Elution
Solution. Agilent 2100 Bioanalyzer was used to determine the quality and size distribution
of the total RNA and small RNA fractions. All samples showed a RNA Intergity Number
(RIN) >8.0. The samples were stored on −80 °C until used.
DNA MICROARRAY and miRNome PCR ARRAY
mRNA expression—mRNA levels were examined with the GeneChip HT HG-U133+
PM Array Plate (Affymetrix, Santa Clara, CA, USA). cDNA synthesis from total RNA,
IVT, labeling and hybridization were performed according to manufacturer’s protocol.
miRNA expression—From small RNA samples cDNA was prepared with miScript II RT
Kit (Qiagen, Valencia, CA, USA) using miScript HiSpec Buffer. The DNA was quantified
with NanoDrop ND-1000 spectophotometer, yielding 693-839 ng/μl. After reverse
transcription, the individual sample cDNAs were pooled into four groups based the gender
and the age. Each group contained material from 4-5 individuals. Group 1: males age of
30-48; group 2: females age of 20-25; group 3: females age of 27-40; group 4: females age
of 44-52 (Supplemental Material 1). The relative amounts of 1008 miRNAs were measured
with miRNome miRNA PCR Arrays using miScript SYBR Green PCR Kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s instructions.
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VALIDATION OF mRNA FINDINGS
Based on our pathway analyses we selected a panel of 10 lipid biosynthesis genes, and
validated the mRNAs using qPCR on the individual control, GAL-treated and RL-exposed
samples (n=18). Total RNA (500 ng) from each sample was reverse transcribed to cDNA
using RT2 First Strand Kit (Qiagen) using the instructions of the manufacturer. Custom-
designed RT2 Profiler PCR Arrays (Qiagen) were provided in 96-well plate format and
contained primer assays for 10 focused genes (SCD, FABP3, DHCR7, INSIG1, QPRT,
HMGCR, HMGCS1, LDLR, FADS1, FADS2) and 2 housekeeping genes (ACTB and
GAPDH). RT2 Profiler PCR Arrays assays were performed on the real-time cycler ABI
Prism 7300 System (Applied Biosystems). The exported Cts were analyzed using
SABiosciences PCR Array Data Analysis Template Excel software and compared across
STD-RL and STD-GAL groups using a paired experimental design.
VALIDATION OF miRNA FINDINGS
22 miRNAs were selected for follow up on the 17 individual samples (hsa-miR-146b-5p,
hsa-miR-550a, hsa-miR-129-3p, hsa-miR-214, hsa-miR-21, hsa-miR-22, hsa-miR-132, hsa-
miR-376c, hsa-miR-19a, hsa-miR-195, hsa-miR-181a, hsa-miR-486-5p, hsa-miR-377, hsa-
miR-424,hsa-miR-542-3p,hsa-miR-22, hsa-miR-103a, hsa-miR-376b, hsa-miR-29b, hsa-
miR-185, hsa-miR-564, hsa-miR-34a). The assays was identical to the one used on the
pooled samples described above.
DATA ANALYSIS
Differential expression—For the mRNA studies, after standard image segmentation of
the microarray images, RMA normalization was performed using GenePattern software
[17]. At the individual level, the gene was considered to be differentially expressed if it
showed an absolute average log ratio |ALR| ≥ 0.378 and p-value ≤ 0.01 between the
experimental and control conditions. Pathway analyses were performed using GenePattern –
Gene Set Enrichment Analysis (GSEA) [18] and its BioCarta Database.
For miRNA expression quantification comparative Ct method was used with SNORD61,
SNORD68, SNORD72, SNORD95, SNORD96A and RNU6-2 as housekeeping genes. A
miRNA was considered differentially expressed if it showed a |ΔΔCt| ≥ 0.583 and both a
groupwise and pairwise p value of p ≤ 0.05 between the experimental and control condition.
These parameters were chosen based on previously analyzed datasets [17,18], and followed
up by qPCR validation.
Hierarchical clustering and calculation of correlation—For both the mRNA and
miRNA data two-way unsupervised clustering using Euclidian distance was performed
using the GenePattern software package [19]. For mRNA, this was performed using the
RMA - normalized log2 gene expression values from each individual sample, while for the
miRNA the ΔCt values were used. Correlations were calculated in MS-Excel 2010 using
Pearson coefficient.
Identification of miRNA targets—To identify the potentially affected mRNAs by the
four miRNAs that were changed in both the GAL- and RL-exposed cultures (miR-129-3p,
miR-146b-5p, miR-543 and miR-550a), we searched the miRDB online database [21] and
established the list of their potential targets.
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COMPARISON TO BRAIN EXPRESSION
To test the relevance of our fibroblast findings in context of human brain disorders, we
examined the mRNA expression of putative miR-129-3p, miR-146b-5p, miR-543 and
miR-550a targets in the developing human brain [33].
RESULTS
METABOLIC STRESS-INDUCED mRNA CHANGES
Our mRNA expression profiling revealed 2063 differentially expressed genes in the GAL
group compared to the matched controls. Of these, 1117 (54.1%) were up-regulated
(Supplemental Material 2A), while 946 (45.9%) showed downregulation. These regulated
gene products were involved in cell cycle, apoptosis, inflammatory response and mRNA
processing related pathways, and in metabolic adaptation. RL treatment had also a
widespread effect on the transcriptome. 984 gene transcripts were affected by the RL
treatment, with 640 mRNAs increased (65.0%) and 344 (35.0%) transcripts repressed
(Supplemental Material 2B). Two-way unsupervised hierarchical clustering provided a good
separation of samples based on the treatment condition (Supplemental Material 3AB).
Pathway analysis with BioCarta classification revealed enrichment of 18 groups of
transcripts in the GAL condition (Table 1A), while in the RL condition, the analysis
revealed enrichment in 12 pathways and transcript repression in 3 pathways (Table 1B).
Notably, 4 of these pathways were commonly upregulated in both the GAL and RL
condition: peroxisome proliferator-activated receptor α (PPARA), carbohydrate response
element binding protein 2 (CHREBP2), influence of Ras and Rho proteins on G1 to S
Transition (RACCYCD) and stress induction of HSP regulation (HSP27). As there was a
significant enrichment of lipid biosynthesis genes in the fibroblast as a result of exposure to
RL and GAL conditions, we decided to validate a panel 10 commonly upregulated genes
(SCD, FABP3, DHCR7, INSIG1, QPRT, HMGCR, HMGCS1, LDLR, FADS1, FADS2).
qPCR assessment of expression validated 9 out of 10 transcript changes in both RL and
GAL conditions (all except HMGCR, which showed the same directionality and magnitude
of change, but did not reach statistical significance) (Supplemental Material 4) and revealed
a high correlation between the microarray and qPCR results (GAL-STD comparison: r=0.92;
RL-STD comparison: r=0.72) (Figure 2).
miRNA EXPRESSION IN RESPONSE TO METABOLIC STRESS
We found that in human fibroblasts 45 miRNAs were differentially expressed due to the
GAL treatment (Table 2 A,B) (|ΔΔCt| ≥ 0.583; p≤0.05), with approximately same number of
miRNAs increased and decreased (24 miRNAs and 21 miRNAs, respectively). The RL
treatment affected 34 miRNAs, with more prominent downregulation than upregulation (27
and 7, respectively). When compared to the control cultures, four miRNAs showing
significant differential expression overlapped in the two metabolic stress conditions (GAL,
RL) (Figure 3). However, the overall pattern of miRNA profiles between the two stressors
was strong: the differentially expressed miRNA’s in the GAL condition, when correlated
with their expression level in the RL condition, showed a significant correlation (r=0.71,
p<0.001) (Figure 4A). Similarly, the expression levels of differentially expressed miRNA’s
in the RL condition were correlated with the expression levels observed in the RL condition
(r=0.65, p<0.005) (Figure 4B). Furthermore, the combined list of these miRNA expression
changes, when subjected to a two-way unsupervised hierarchical clustering, perfectly
separated out the CNT, GAL and RL conditions (Figure 5). Thus, while the most changed
miRNAs were not identical between the GAL and RL, the overall pattern suggested a
comparable miRNA response between the two very different metabolic stressors.
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As the initial screening was performed on 4 pools of samples which could theoretically bias
our data, we wanted to validate the expression of 22 miRNAs on our 17 individual samples.
In this follow-up study the initial miRNA findings on the pooled samples showed the
expected expression pattern on the individual experimental samples (Figure 6).
CORRELATION OF miRNA WITH mRNA EXPRESSION
To establish how metabolic stress-induced miRNAs affect the mRNA transcriptome, we
focused our attention on the four significantly changed miRNAs that overlapped between
the GAL- and RL-treatment: miR-129-3p, miR-146b-5p, miR-543 and miR-550a. To
identify the target mRNAs of these miRNAs we established the list of their potential targets
using the miRDB online data base. The database revealed 211 putative mRNA targets of
miR-129-3p, 243 mRNA targets of miR146b-5p, 129 mRNA targets of miR-550a, and 921
targets for miR-543 (Supplemental Material 5). Of the combined 1504 potential targets 140
mRNAs showed significant change at gene expression level (Table 3A-C). It is noteworthy
that multiple target genes showed significantly altered transcription levels in both the GAL-
and RL-treated human fibroblast cultures, further arguing for a consistent effect of the two
different metabolic stressors.
Finally, we attempted to establish if any of these putative mRNA targets of miR-129-3p,
miR-146b-5p, miR-543 and miR-550a showed spatio-temporal regulation in the developing
human brain [31]. Fourteen such transcripts were identified (rfx7, syt14, nova1, kiaa1199,
spata13, osbpl8, exph5, ngef, pag1, acyp1, pde5a, adamtsl1, cyp26b1 and pag1)
(Supplemental Material 6), suggesting that these targets should be the primary focus of
further follow-up examinations in the brain tissue of neurodevelopmental disorders.
CONCLUSIONS
This study established the mRNA and miRNA expression changes in human fibroblast cell
cultures in response to two nutrition-based metabolic stress paradigms. We found that 1)
glucose depleted, galactose supplemented and a lipid reduced, cholesterol depleted medium
produced widespread mRNA and miRNA changes in human fibroblasts; 2) while the most
significantly changed miRNAs showed variation, the overall miRNA changes across the two
metabolic stress conditions showed considerable similarity; 3) it appears that changes in
miRNA expression contributed considerably to altered mRNA expression profile in both the
GAL and RL conditions and 4) we identified 4 significantly changed miRNAs (miR-129-3p,
miR-146b-5p, miR-543 and miR-550a) that are likely to be important mediators of multiple
types of metabolic stress.
Using the individual transcript assessment approach, we identified only four significantly
changed miRNAs (miR-129-3p, miR-146b-5p, miR-543 and miR-550a) across the two
metabolic stressors. Yet, this is not surprising, as transcripts work in networks: while we
observed considerable differences in the most changed miRNAs of the GAL- and RL-treated
fibroblasts, the overall miRNA profile of the two stressors was strikingly similar.
Furthermore, 4 metabolic stress-related transcript pathways (PPARA, CHREBP2,
RACCYCD, and HSP27) were upregulated in both GAL and RL-exposed cultures,
suggesting that this common signature is present both at the miRNA and mRNA level. This
came as a surprise, as the two stressors acts through distinct mechanisms: the GAL condition
primarily creates oxidative radicals through starvation [7], while the RL conditions forces
the cells into a metabolic overdrive [10]. Based on these findings we propose that metabolic
stress, regardless of the type of the insult, might have a common miRNome and mRNA
signature, and this common signature perhaps represents a non-specific resilience response,
helping the cells to adapt and survive.
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Our results also suggest that the four changed miRNAs alone appeared to be able to regulate
the mRNA expression of 52 target genes, arguing that miRNA regulation of the
transcriptome might be a significant contributor to metabolic stress-induced cellular
responses. Unfortunately, miR-543 and miR-550a has not been well studied experimentally,
and their effects remain mostly unknown. However, mir-129-2 and miR-146b-5p have been
a focus of multiple investigations to date: mir-129-2 is located next to a CpG island and is
methylation-associated, and the expression of this miRNA can be epigenetically restored by
de-methylating drugs [22]. Furthermore, mir-129-2 is conserved in vertebrates and regulates
the expression of CP110, ARP2, TOCA1, ABLIM1 and ABLIM3, thus effectively
controlling actin dynamics in the cell [21]. Still, miR-146b-5p might be the most important
finding of our studies: its expression is highly induced by proinflammatory cytokines, with a
clear dependency on IFN-γ, potentially via the JAK/STAT pathway [24,25]. Furthermore, a
decrease of miR-146b-5p has been observed in monocytes during obesity, and it was
associated with loss of the anti-inflammatory signaling action [26]. miR-146b-5p also
regulates signal transduction of TGF-β [27], and appears to play a critical role in the
pathophysiology of various cancers [28,29]. These data suggest that metabolic stress might
regulate miRNA expression through epigenetic modification, and that the two metabolic
stressors trigger an inflammation-like response in the stressed cells. However, this
hypothesis has to be tested more comprehensively in follow-up experiments.
Finally, we need to emphasize that peripheral biomarkers studies are essential to understand
the pathophysiology of human brain disorders. Recent studies indicate that peripheral
biomarkers may aid the diagnosis of psychiatric disorders and help assess treatment efficacy
[30]. However, obtaining peripheral patient tissues and analyzing them at resting state might
not be sufficient to reveal the critical deficits, and they must be challenged to reveal the full
signature of the disease [7,31]. Human dermal fibroblasts as a model system are ideally
suited for such studies [32], as they have several advantages over the functional assays
performed on peripheral blood cells: 1) they can be readily propagated without
immortalization, 2) have a more similar expression profile to brain cells than peripheral
blood cells; 3) are homogenous and very responsive to a variety of stimuli, and 4) they are
minimally affected by epigenetic changes, which usually disappear after the 5th culture
passage.
Our results also suggest that metabolic stress in dermal fibroblasts affects genes that are
important for brain development and homeostasis. The 4 miRNAs with differential
expression in both the RL and GAL condition (miR-129-3p, miR-146b-5p, miR-543 and
miR-550a) regulated multiple genes (e.g. NGEF, NOVA1, PDE5A) that show region- and
age-specific transcription in the human brain [33], suggesting that deregulation of these
transcripts might have significant consequences on brain function, and should be examined
in the context of neurodevelopmental disorders. Thus, dermal fibroblasts are appealing,
readily available human biomaterials, allowing to perform controlled, functional and
reproducible experiments on human tissue. This is especially important for studying major,
polygenic psychiatric disorders, where postmortem tissue availability is limited and the
genetic animal models do not fully recapitulate the human disease. This study defined the
miRNA/mRNA transcriptome responses of fibroblasts to metabolic stress in healthy
individuals, and similar studies should be performed in diseased patient material – the
response of their transcriptome to the metabolic stress will be more revealing of
pathophysiology than the case-control differences under resting, unchallenged conditions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Research highlights
• metabolic stress produced strong mRNA and miRNA changes in human
fibroblasts
• miRNA changes across two metabolic stress conditions showed substantial
similarity
• miRNA expression contributed to altered mRNA expression
• miRNA and mRNA changes were correlated
• miR 129 3p, miR 146b 5p, miR 543 and miR 550a are mediators of metabolic
stress
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Figure 1. Experimental design.
Flowchart representing the sample collection and grouping, the experiments and analyses
performed. In summary, skin biopsies were collected from 17 male and female individuals,
and used to establish in vitro fibroblast cultures. Each fibroblast culture was then cultured in
standard (STD), galactose containing (GAL) or reduced lipid (RL) media. DNA microarrays
were used to detect the mRNA profile of each individual sample in each culture condition.
4-5 samples of similar age and gender were grouped before performing miRNA expression
profiling with miRNome qPCR arrays. Grouping-sample effects were examined in
individual samples with custom qPCR arrays containing selected miRNA assays. Finally, we
preformed correlation analyses between the commonly changed miRNAs and their putative
mRNA targets.
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Figure 2. qPCR validation of selected mRNA expression changes.
10 transcripts were validated using qPCR (SCD, FABP3, DHCR7, INSIG1, QPRT,
HMGCR, HMGCS1, LDLR, FADS1, FADS2). X- axis denotes microarray-obtained
average log2 ratios (ALR), while Y-axis denotes actin-normalized -ΔΔCt values obtained by
qPCR. Note that the microarray and qPCR data were highly correlated (GAL: r=0.92
p<0.001; RL: r=0.72, p<0.001). For further details, see Supplemental Material 4.
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Figure 3. Commonly changed miRNAs in GAL and RL culture conditions.
45 and 34 miRNAs showed significant change in GAL and RL conditions, respectively (red-
decreased; blue – increased). Note that the 4 commonly changed miRNAs had the same
directionality in both GAL and RL conditions, and they were significantly altered in both
pairwise (ppval) and groupwise (gpval) testing.
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Figure 4. Overall miRNA pattern changes in GAL and RL conditions are highly correlated.
The 45 miRNAs with significantly changed expression pattern in GAL conditions were
assessed in the RL samples (A) and the 34 miRNAs with significantly changed expression
pattern in RL conditions were assessed in the GAL samples (B). Note that the miRNA
pattern observed in either metabolic stressor also showed a similar, highly correlated
expression pattern in the other condition.
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Figure 5. miRNA expression pattern separates the STD, GAL and RL lipid conditions.
Two-way unsupervised hierarchical clustering was performed on the expression level (ΔCt)
of 75 differentially expressed miRNAs. Samples were clustered vertically, miRNAs were
clustered horizontally. Each colored square represents a normalized gene expression level,
color coded for increase (red) or decrease (blue) from the mean. Color intensity is
proportional to magnitude of change. The clustering resulted in a perfect separation of
samples into three discrete groups corresponding to culture conditions (vertical dendrogram,
green STD, yellow GAL, and orange RL).
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Figure 6. Correlation of miRNA changes between individual and pooled fibroblast samples
cultured in GAL (A) and RL (B) conditions.
22 miRNAs were assessed in the validation study, with the pooled ΔΔCTs plotted on X axis
and the ΔΔCTs from individual samples plotted on the Y axis. Each miRNA represents a
single data point. The correlation coefficient indicates that pooling of the samples did not
skew artificially the miRNA pattern observed in GAL and RL.
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Table 1
mRNA transcriptome changes. Microarray gene expression data, subjected to BioCarta pathway analysis
with GSEA, identified 19 pathways enriched in fibroblasts cultured in GAL (A) and 15 in RL (B). The
significantly changed BioCarta pathways are ranked by a net enrichment score (NES). The number of genes in
each pathway is depicted in the Size column. Note that there are 4 differentially expressed pathways common
for GAL and RL treatment (*).
A. Galactose (GAL) media
NAME SIZE NES p-value
RACCYCD* 26 1.93 0.000000
CELLCYCLE 23 1.83 0.000000
SRCRPTP 11 1.70 0.000000
P53 16 1.70 0.002045
TEL 18 1.73 0.010730
STATHMIN 19 1.57 0.011516
CFTR 12 1.65 0.012000
CERAMIDE 22 1.67 0.012448
ATRBRCA 21 1.60 0.016129
G2 24 1.59 0.026157
HSP27* 15 1.47 0.026639
CARM_ER 34 1.61 0.027451
PLCE 12 1.47 0.030864
CHREBP2* 42 1.61 0.031373
AKAPCENTROSOME 15 1.53 0.031809
CHEMICAL 22 1.56 0.032520
RB 13 1.53 0.034137
PPARA* 56 1.43 0.036000
ATM 20 1.58 0.044807
B. Reduced lipid (RL) media
NAME SIZE NES p-value
PPARA* 56 1.80 0.000000
P38MAPK 39 1.56 0.009579
VIP 26 1.60 0.009709
BAD 26 1.48 0.015936
CHREBP2* 42 1.64 0.022945
RACCYCD* 26 1.65 0.027559
GCR 19 1.46 0.038000
HSP27* 15 1.49 0.040541
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NAME SIZE NES p-value
CD40 15 1.58 0.044000
LYM 11 1.37 0.047714
TNFR2 18 1.53 0.048583
TALL1 15 1.52 0.048638
IL22BP 16 −1.56 0.020638
DNAFRAGMENT 10 −1.51 0.030488
AHSP 11 −1.59 0.043222
*Commonly upregulated in NL and GAL treatment
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Table 2
miRNA expression profile changes in GAL (A) and RL (B) treatment in human fibroblasts. Blue -
increased expression; Red – reduced expression; ΔΔCt - normalized threshold cycle difference between
experimental and control samples; gt - groupwise t-test; pt – pairwise t-test. The correlations of these data are
graphically represented in Figure 3.
GAL-induced miRNA expression changes and their expression in RL
miRNA ID ddCt (GAL-STD) gt-test (GAL-STD) pt-test (GAL-STD) ddCt (RL-STD) gt-test (RL-STD) pt-test (RL-STD)
hsa-miR-378b −2.065 0.006 0.003 −0.512 0.548 0.614
hsa-miR-1183 −1.875 0.023 0.064 −0.485 0.557 N/A
hsa-miR-429 −1.801 0.019 0.154 −2.877 N/A N/A
hsa-miR-3682-3p −1.704 0.031 0.178 −0.212 0.659 0.936
hsa-miR-187* −1.683 0.034 0.074 −1.270 N/A N/A
hsa-miR-4302 −1.604 0.019 0.036 1.038 0.143 0.067
hsa-miR-375 −1.522 0.149 0.041 −0.417 0.535 0.862
hsa-miR-3200-5p −1.283 0.041 0.128 0.338 0.489 0.509
hsa-miR-3161 −1.269 0.017 0.002 −0.015 0.982 0.865
hsa-miR-4267 −1.154 0.006 0.015 −0.915 0.105 0.085
hsa-miR-378 −1.115 0.057 0.040 0.935 0.169 0.183
hsa-miR-3156-5p −1.055 0.022 0.034 −0.148 0.723 0.870
hsa-miR-550a −1.054 0.031 0.025 −1.236 0.025 0.039
hsa-miR-4257 −1.044 0.020 0.327 −0.972 0.227 0.436
hsa-miR-3159 −0.943 0.142 0.037 −3.222 0.299 0.325
hsa-miR-550a* −0.941 0.042 0.133 −1.192 0.130 0.072
hsa-miR-720 −0.903 0.090 0.023 −0.236 0.588 0.335
hsa-miR-2278 −0.839 0.287 0.035 −1.490 0.155 0.169
hsa-miR-3907 −0.827 0.070 0.013 0.291 0.436 0.343
hsa-miR-3687 −0.717 0.042 0.011 −0.370 0.567 0.648
hsa-miR-532-3p −0.709 0.062 0.029 −0.069 0.820 0.757
hsa-miR-3190 −0.658 0.430 0.050 −0.930 0.242 0.572
hsa-miR-1247 −0.645 0.450 0.022 0.177 0.803 0.800
hsa-miR-3647-3p −0.590 0.011 0.048 −0.017 0.949 0.960
hsa-miR-301a 0.602 0.038 0.025 0.802 0.070 0.060
hsa-miR-369-3p 0.612 0.029 0.030 0.575 0.052 0.025
hsa-miR-874 0.616 0.313 0.002 0.632 0.398 0.277
hsa-miR-486-5p 0.626 0.279 0.029 −0.196 0.754 0.680
hsa-miR-543 0.659 0.025 0.020 0.610 0.021 0.035
hsa-miR-1260b 0.660 0.077 0.049 0.290 0.459 0.431
hsa-miR-424 0.698 0.061 0.011 0.919 0.104 0.052
hsa-miR-127-5p 0.713 0.069 0.045 0.696 0.120 0.114
hsa-miR-3913-5p 0.757 0.343 0.031 N/A N/A N/A
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miRNA ID ddCt (GAL-STD) gt-test (GAL-STD) pt-test (GAL-STD) ddCt (RL-STD) gt-test (RL-STD) pt-test (RL-STD)
hsa-miR-628-5p 0.871 0.020 0.067 0.355 0.440 0.552
hsa-miR-181a* 0.876 0.039 0.014 0.759 0.213 0.146
hsa-miR-129-3p 0.949 0.011 0.053 1.108 0.020 0.051
hsa-miR-146b-5p 1.058 0.007 0.011 1.487 0.015 0.005
hsa-miR-1271 1.227 0.032 0.113 1.338 0.171 0.339
hsa-miR-1285 1.386 0.010 0.037 0.667 0.407 0.517
hsa-miR-337-5p 1.550 0.017 0.103 1.200 0.060 0.061
hsa-miR-217 2.018 0.112 0.013 1.323 0.097 0.223
hsa-miR-3176 2.041 0.018 0.009 0.635 0.373 0.515
hsa-miR-497* 2.313 0.040 0.079 1.803 0.098 0.204
hsa-miR-1227 2.462 0.014 0.113 0.488 0.343 0.172
hsa-miR-146b-3p 3.795 0.046 0.123 3.291 0.216 0.205
RL-induced miRNA expression changes and their expression in GAL
miRNA ID ddCt (RL-STD) gt-test (RL-STD) pt-test (RL-STD) ddCt (GAL-STD) gt-test (GAL-STD) pt-test (GAL-STD)
hsa-miR-3154 −1.342 0.039 0.047 −2.425 0.161 0.267
hsa-miR-550a −1.236 0.025 0.039 −1.054 0.031 0.025
hsa-miR-16-1* −1.181 0.014 0.063 −0.437 0.347 0.311
hsa-miR-138-1* −0.924 0.326 0.021 0.219 0.775 0.712
hsa-miR-641 −0.887 0.042 0.253 −0.059 0.875 0.726
hsa-miR-2110 −0.805 0.043 0.031 0.017 0.953 0.965
hsa-miR-320e −0.618 0.032 0.118 0.162 0.384 0.513
hsa-miR-376c 0.493 0.039 0.027 0.490 0.114 0.050
hsa-miR-296-5p 0.561 0.011 0.018 0.085 0.736 0.623
hsa-miR-517* 0.595 0.099 0.013 0.245 0.475 0.375
hsa-miR-543 0.610 0.021 0.035 0.659 0.025 0.020
hsa-miR-214 0.636 0.006 0.032 0.703 0.088 0.075
hsa-miR-195 0.689 0.011 0.061 0.163 0.600 0.586
hsa-miR-18a* 0.692 0.057 0.014 −0.504 0.238 0.141
hsa-miR-19a 0.710 0.103 0.035 0.168 0.660 0.323
hsa-miR-212 0.742 0.031 0.032 0.404 0.155 0.078
hsa-miR-132* 0.753 0.120 0.002 0.766 0.122 0.292
hsa-miR-411 0.779 0.016 0.066 0.331 0.391 0.410
hsa-miR-330-5p 0.854 0.117 0.007 0.797 0.261 0.347
hsa-miR-431 0.864 0.023 0.004 0.579 0.063 0.016
hsa-miR-154* 0.891 0.008 0.115 1.052 0.087 0.110
hsa-miR-18a 0.900 0.039 0.029 0.198 0.597 0.375
hsa-miR-29a* 0.912 0.041 0.116 0.801 0.085 0.220
hsa-miR-135b 0.927 0.148 0.037 0.698 0.395 0.249
hsa-miR-22* 1.033 0.049 0.194 0.966 0.083 0.339
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miRNA ID ddCt (RL-STD) gt-test (RL-STD) pt-test (RL-STD) ddCt (GAL-STD) gt-test (GAL-STD) pt-test (GAL-STD)
hsa-miR-31 1.105 0.004 0.012 0.750 0.065 0.079
hsa-miR-129-3p 1.108 0.020 0.051 0.949 0.011 0.053
hsa-miR-758 1.188 0.042 0.042 0.199 0.672 0.608
hsa-miR-106b* 1.193 0.035 0.229 0.188 0.795 0.918
hsa-miR-299-3p 1.414 0.048 0.109 0.612 0.159 0.243
hsa-miR-146b-5p 1.487 0.015 0.005 1.058 0.007 0.011
hsa-miR-196b* 1.599 0.025 0.034 1.226 0.114 0.289
hsa-miR-21* 1.647 0.003 0.019 1.102 0.093 0.052
hsa-miR-331-5p 2.660 0.010 0.041 0.058 0.915 0.932
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Table 3
miRNA and mRNA expression changes are correlated in human fibroblasts. The three commonly
changed miRNAs in both GAL and RL conditions were correlated with expression changes of 52 putative
target mRNAs. A. miR-129-3p target changes, B. miR-550a target changes, C. miR-146b-5p target changes.
The commonly changed mRNAs in both GAL- and RL-medium exposed human fibroblasts are marked with
an asterisk.
A. miR-129-3p
Gene ALR GAL pval GAL Gene ALR RL pval RL
FADS1* 1.08 0.000001 FADS1* 1.22 0.000000
FADS1* 1.08 0.000001 FADS1* 1.22 0.000000
FADS1* 1.06 0.000001 FADS1* 1.11 0.000000
DGKI 0.68 0.000073 STARD4 0.94 0.000000
LHFPL2 0.63 0.000000 TMTC1* 0.57 0.000173
PTGER4* 0.51 0.000302 PTGER4* 0.57 0.000329
TMTC1* 0.50 0.000007 CCDC102B 0.51 0.006941
CDK1 0.49 0.007441 RCAN2 0.45 0.000727
CDCA7L 0.47 0.000002 CHML 0.43 0.000010
PKIA 0.43 0.000075 RFX7 0.41 0.000179
C2orf88 0.41 0.000036 RIMS1 0.38 0.004726
RDH10 −0.42 0.000011 CYP27C1 0.38 0.000169
ZNF436 −0.42 0.000329
BAALC −0.60 0.000524
B. miR-550a
Gene ALR GAL pval GAL Gene ALR RL pval RL
CLIC2 1.18 0.000000 DSTN 0.44 0.000322
SPATA13 0.50 0.000059 EXPH5* 0.41 0.008081
C1QTNF2 0.48 0.002883 NGEF 0.40 0.005541
OSBPL8 0.48 0.000000 APOL6 −0.93 0.000000
PLD1 0.45 0.000245
SCARA3 0.39 0.000014
ADAMTS6 −0.38 0.005308
EXPH5* −0.51 0.001573
MYH2 −0.80 0.000192
C. miR-146b-5p
Gene ALR GAL pval GAL Gene ALR RL pval RL
IFIT3 0.65 0.000003 SVIL* 0.58 0.000000
IQGAP3 0.64 0.000058 KRTAP1-5* 0.56 0.000110
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Gene ALR GAL pval GAL Gene ALR RL pval RL
IRAK1 0.61 0.000001 SVIL* 0.50 0.000009
SYT14 0.61 0.000101 CLCN6* 0.46 0.000000
RAB7L1 0.58 0.000000 PID1 0.42 0.000173
RAB7L1 0.55 0.000000 NOVA1 0.41 0.000848
CLCN6* 0.52 0.000001 SLC1A1* −0.45 0.000093
SVIL* 0.44 0.000079 LRRC15 −0.45 0.000372
STRBP 0.43 0.000607 KIAA1199 −0.47 0.001176
TIMELESS 0.42 0.000047
RACGAP1 0.41 0.000632
STIL 0.40 0.002208
WISP1 −0.38 0.002183
DNAL1 −0.39 0.000081
DNAL1 −0.40 0.002178
SLC1A1* −0.49 0.000259
KRTAP1-5* −0.53 0.003753
RASGRP1 −0.67 0.000057
D. miR-543
Gene ALR GAL pval GAL Gene ALR RL pval RL
RRAGD* 2.36 0.000000 NRXN3 1.98 0.009901
RRAGD 1.48 0.000000 ABCA1* 1.60 0.000000
PAG1 0.98 0.000000 ABCA1* 0.92 0.000000
PAG1 0.91 0.000000 PLA2G4A 0.86 0.002028
LAMA1 0.83 0.000029 GALNT1 0.84 0.003950
C3orf55 0.82 0.000002 RRAGD* 0.79 0.009357
PAG1* 0.80 0.000000 PPP1R12B* 0.76 0.003190
PRKAR2B* 0.76 0.000002 GALNT1 0.70 0.005351
TOX 0.68 0.000073 GALNT1 0.63 0.002321
ZNF367 0.64 0.000001 COL16A1 0.61 0.000219
CDK1 0.63 0.000099 ZNF436 0.56 0.000329
PBX3 0.62 0.000000 TRIM13 0.50 0.000035
DCLK1 0.61 0.000864 ZNF436 0.49 0.001606
FNIP2* 0.58 0.000013 DUSP3* 0.46 0.000321
ZCCHC14 0.58 0.000000 EVI5 0.39 0.000685
CDK1 0.58 0.000135 TGFB1 0.39 0.000077
GTSE1 0.56 0.001911 DDX3X 0.38 0.005765
CDK1 0.56 0.000136 PAG1* 0.38 0.000839
BEX2 0.55 0.000005 FNIP2* 0.38 0.000458
GTSE1 0.54 0.001029 CCDC117 −0.38 0.000395
DUSP3* 0.54 0.000000 ADAMTSL1 −0.41 0.000269
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Gene ALR GAL pval GAL Gene ALR RL pval RL
FNIP2 0.52 0.000006 EEF1A1 −0.42 0.003515
ESCO2 0.51 0.000066 SMAD5 −0.42 0.008163
E2F7 0.51 0.000144 ADAMTSL1* −0.43 0.002492
FMNL2 0.49 0.000014 TMEM133 −0.43 0.003737
B3GNT5 0.49 0.000143 ADAMTSL1* −0.44 0.004797
ABCA1* 0.49 0.000012 PDP1 −0.44 0.000010
CDK1 0.49 0.007441 ADAMTSL1 −0.53 0.000006
OSBPL8 0.48 0.000000 CHML −0.53 0.000279
DCLK1 0.48 0.003116 PDE5A* −0.56 0.002906
DCLK1 0.48 0.003116 GBP1 −0.60 0.003012
SLC2A13 0.47 0.000000 RAPH1* −0.68 0.000064
OSBPL1A 0.47 0.000000 HIPK2 −0.71 0.000009
ABCA1* 0.47 0.000006 PRKAR2B* −0.75 0.000159
RAD51AP1 0.46 0.000394 CREB5* −1.49 0.000041
DUSP3 0.46 0.000000 CREB5* −1.58 0.000760
LAMP2 0.45 0.000000
GTSE1 0.45 0.003273
FMNL2 0.45 0.000000
WHSC1 0.44 0.000477
STRBP 0.43 0.000607
CCNF 0.43 0.000305
SMC4 0.42 0.000009
DUSP3 0.42 0.000000
C3orf55 0.41 0.000024
SLC2A13 0.40 0.000035
ATP6V1A 0.40 0.000000
OSBPL8 0.40 0.000000
HMGB2 0.40 0.000029
ACYP1 0.40 0.000001
RBM47 0.40 0.000154
MEGF9 0.40 0.000002
ZCCHC14 0.40 0.000657
OSBPL1A 0.40 0.000003
CD163 0.39 0.005055
ATP6V1A 0.39 0.000022
WHSC1 0.38 0.000535
TMEM135 0.38 0.000045
SC5DL 0.38 0.000265
NRXN3 −0.38 0.002052
USP53 −0.38 0.002009
NRCAM −0.38 0.000730
PDE5A* −0.39 0.000332
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Gene ALR GAL pval GAL Gene ALR RL pval RL
MDM4 −0.40 0.000436
COL1A2 −0.41 0.000018
TRIM13 −0.41 0.001256
SNAPC3 −0.43 0.000598
ADAMTSL1* −0.43 0.000002
ARHGAP29 −0.45 0.000223
RAPH1 −0.45 0.000001
SYNE1 −0.47 0.000020
GATS −0.47 0.000009
RAPH1* −0.49 0.000071
CREB5* −0.50 0.000029
RAPH1 −0.52 0.000001
RAPH1 −0.52 0.000007
ACVR2A −0.52 0.000006
CHN1 −0.53 0.000002
FNDC3B −0.54 0.000034
CACNB4 −0.56 0.000001
SYTL4 −0.56 0.000113
ADAMTSL1* −0.57 0.000000
CREB5* −0.59 0.000234
ADAMTSL1 −0.60 0.000003
PPP1R12B* −0.63 0.000179
PAWR −0.64 0.000017
ID4 −0.74 0.000000
ID4 −0.80 0.000000
ID4 −0.83 0.000002
ARRDC4 −0.85 0.000002
CYP26B1 −1.16 0.000000
ALR- average log2 ratio; RL- reduced lipid media; GAL- galactose media
*
commonly changed mRNAs in GAL and NL treatment
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Abstract
Background—Peripheral biomarkers for major psychiatric disorders have been an elusive target 
for the last half a century. Dermal fibroblasts are a simple, relevant, and much underutilized model 
for studying molecular processes of patients with affective disorders as they share considerable 
similarity of signal transduction with neuronal tissue.
Methods—Cultured dermal fibroblast samples from patients with Major Depressive Disorder 
(MDD) and matched controls (CNTR) (n=16 pairs, 32 samples) were assayed for genome wide 
mRNA expression using microarrays. In addition, a simultaneous qPCR-based assessment of 
>1,000 miRNA species was performed. Finally, to test the relationship between the mRNA-
miRNA expression changes, the two datasets were correlated with each other.
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Results—Our data revealed that MDD fibroblasts, when compared to matched controls, showed 
a strong mRNA gene expression pattern change in multiple molecular pathways, including cell-to-
cell communication, innate/adaptive immunity and cell proliferation. Furthermore, the same 
patient fibroblasts showed altered expression of a distinct panel of 38 miRNAs, which putatively 
targeted many of the differentially expressed mRNAs. The miRNA-mRNA expression changes 
appeared to be functionally connected, as the majority of the miRNA and mRNA changes were in 
the opposite direction.
Conclusions—Our data suggest that a combined miRNA-mRNA assessments are informative 
about the disease process, and that analyses of dermal fibroblasts might lead to the discovery of 
promising peripheral biomarkers of MDD, which could be potentially used to aid the diagnosis 
and allow mechanistic testing of disturbed molecular pathways.
Keywords
human fibroblasts; major depression; miRNA; gene expression; DNA microarray; biomarker
INTRODUCTION
There has been an intensive search for peripheral biomarkers of major psychiatric disorders 
for the last half a century. These efforts encompassed gene expression profiling of peripheral 
mononuclear cells (1, 2), biochemical evaluations of serum (3), urine (4), saliva (5), and 
cerebrospinal fluid (6), gene association studies of DNA markers (7) and many other 
approaches. More recently, inducible pluripotent stem cells (IPSCs) emerged as a very 
promising model for studying neuronal lineage disturbances across various disorders (8–10). 
Unfortunately, the complex diagnostic-phenotypic-genetic-etiologic heterogeneity continues 
(11) to provide significant obstacles for identifying highly specific and sensitive peripheral 
biomarkers of mental disorders.
Transcriptome profiling experiments of postmortem human brain tissue from subjects with 
major depressive disorder (MDD) suggest evidence of local inflammatory, apoptotic, 
oxidative stress and multiple other, non-brain specific molecular processes (12–17). 
Emerging evidence argues that many of these changes might be, at least partially, driven by 
altered expression of microRNAs (miRNAs): miRNA levels change during stress, in the 
brain of animal models of depression, and in human postmortem brain of MDD subjects(18) 
and depressed suicide subjects (19).
Importantly, peripheral biomarker studies of MDD over the last several decades revealed 
that peripheral growth factors, pro-inflammatory cytokines, endocrine factors, and metabolic 
markers all contribute to the disease pathophysiology (20). These combined data suggest 
that MDD is not only a disease of the CNS, but affects the whole body (21, 22), and that 
peripheral cellular-molecular events are strongly correlated with the disease pathology in the 
CNS (23). Experimental data suggest that analyzing patient dermal fibroblasts is a simple, 
relevant, and much underutilized model for studying processes of signal transduction in 
patients with affective disorders (24–26). Dermal fibroblasts are easy to establish and 
maintain in culture without transformation, and the majority of confounding factors (e.g. life 
style or medication use) are virtually eliminated after several rounds of cell division. 
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Furthermore, a recent study of fibroblasts obtained from MDD patients highlights the role 
that oxidative stress might play in the pathophysiology of MDD (25), which has been 
already well-established across multiple other research models and patient populations (27, 
28). Thus, analyzing dermal fibroblast cultures from patients can give us meaningful 
insights into the molecular effects of the combined genetic predisposition to the disorder.
It appears that biomarker panels hold a greater promise than single analyte molecules in 
aiding the diagnosis, monitoring disease progression or therapeutic response in MDD (20). 
As understanding non-neuronal changes in MDD can be informative of the overall disease 
pathophysiology (23), we performed a combined mRNA-miRNA profiling of dermal 
fibroblasts from patients with MDD and matched controls.
METHODS AND MATERIALS
Participants in the study
The Study was approved by the Vanderbilt University Institutional Review Board (IRB). 
Procedures for recruitment and diagnosis have been described previously (24, 25). All 
participants were diagnosed with a current Major Depressive Episode according to the 
Structured Clinical Interview for DSM-IV-TR (29) with an exclusion criteria of other 
primary axis I DSM-IV diagnosis. A written informed consent was obtained from all 
participants before collecting skin biopsy samples. Sixteen pairs of subjects with Major 
Depressive Disorder (MDD) and healthy controls (CNTR) were matched by age, race and 
sex. The average age of the MDD patients and CNTR were comparable (MDD=34.9, 
CNTR=35.2), as were the sex (12F/4M in both groups) and race (12W/4AA), but there was 
a significant difference in body mass index at the time of skin biopsy (25.4 in CNTR and 
32.3 in MDD, p=0.03) (Supplemental Table S1).
Human dermal fibroblasts
The skin biopsy was obtained from the lateral side of the upper arm (1 × 2 mm) according to 
a protocol previously described in details (24, 25). The sample was put into regular 
Dulbecco’s Modified Eagle’s Medium (DMEM, MediaTech, Manassas, VA, USA) without 
serum and processed the same day. Briefly, biopsy sample was cut into several smaller 
pieces with scissors and incubated in trypsin and collagenase mix at 37°C for 1 hr. Regular 
medium was added [DMEM containing high glucose, L-glutamine, 10% fetal bovine serum 
(FBS, ThermoScientific HyClone, Logan, UT, USA), and Penicillin/Streptomycin solution 
(MediaTech)] and biopsy pieces with dissociated cells were pelleted by centrifugation. The 
supernatant was discarded. Biopsy pieces with cells were resuspended in fresh regular 
medium and transferred to 60 mm tissue culture plates. Cells were cultured in incubator at 
37°C and 5% CO2 concentration. Medium was changed 3 times a week. In about 2–3 weeks 
the fibroblasts divided and became confluent. The fibroblasts were subcultured using 0.5% 
Trypsin-EDTA (Invitrogen) as described elsewhere (30) and expanded for freezing in a 
liquid nitrogen cell repository or expanded for experiments. Selected fibroblasts from 
matching patient/control pairs were cultured simultaneously to ensure they grow under the 
same conditions. Cell growth and proliferation were checked regularly during the whole 
experiment. All cultured fibroblasts were less than passage 15. At the end of experiment, the 
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fibroblasts were washed 2X with ice-cold PBS, collected with cell scraper, pelleted by 
centrifugation and frozen on dry ice and stored at -80°C.
mRNA expression analysis by microarrays
Total RNA was isolated using the mirVana™ miRNA Isolation Kit (Ambion, Foster City, 
CA, USA) and RNA quality assessed by an Agilent 2100 Bioanalyzer (Agilent, Palo Alto, 
California, USA). cDNA was generated using 2 μg of total RNA. cDNA synthesis, 
amplification and labeling were performed using The Enzo Life Sciences Single-Round 
RNA Amplification and Biotin Labeling System (Enzo Life Sciences, Famingdale, NY, 
USA). 5 μg of the biotin labeled, fragmented aRNA were hybridized to a GeneChip HT HG-
U133+ PM Array Plate (Affymetrix Inc, Santa Clara, CA, USA) at the Vanderbilt 
Microarray Shared Resource core facility.
Segmented images from each mircoarray were normalized and log2 transformed using GC-
robust multi-array analysis (GC-RMA) (31). The normalized expression values were used in 
all analyses. Average expression values for each group (MDD and CNTR) were calculated 
for each gene probe. The magnitude of expression change was determined by the Average 
Logarithmic Ratio (ALR=meanMDD - meanCNTR). Student’s paired and grouped two-tailed 
t-tests were used to test the significance of the difference in gene expression (32–36). A 
gene was considered to be differentially expressed between MDD and CNTR when it met 
the dual criteria of |ALR|>0.585 (50%) and both pairwise and groupwise p-values<0.05.
The differentially expressed genes were subjected to a two-way hierarchical clustering 
analysis based on Pearson correlation using GenePattern software (37). Gene set enrichment 
analysis (GSEA) based on pre-defined gene classes were carried out with the GenePattern 
software (38). GSEA determines whether an a priori defined set of genes shows statistically 
significant, concordant differences between our subject groups based on the BioCarta 
defined molecular pathways. GSEA calculates a normalized enrichment score (NES), which 
reflects the degree to which a gene set is overrepresented in the ranked list of genes and a 
nominal p-value which estimates the statistical significance of the enrichment score for a 
single gene set. BioCarta gene sets were considered differentially expressed at nominal p-
value <0.05.
mRNA data validation by qPCR
cDNA was generated with random primers using High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA). Primers for 13 genes (heparin-
binding EGF-like growth factor - HBEGF, major histocompatibility complex, class II 
invariant chain - CD74, major histocompatibility complex, class II, DP alpha 1 – HLA-
DPA1, glutathione S-transferase theta 1 - GSTT1, major histocompatibility complex, class 
II, DR alpha - HLA-DRA, major histocompatibility complex, class II, DQ beta 1 - HLA-
DQB1, major histocompatibility complex, class II, DP beta 1 - HLA-DPB1, major 
histocompatibility complex, class II, DQ alpha 1 - HLA-DQA1, interleukin 11 - IL11, Met 
proto-oncogene - MET, protocadherin 10 - PCDH10, S100 calcium binding protein B - 
S100B, tumor necrosis factor receptor superfamily, member 19 – TNF19) with efficiency 
>85% were used in SYBR Green based PCR reactions. Each sample was tested in 4 
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technical replicates on an ABI Prism 7300 thermal cycler (Applied Biosystems, Foster City, 
CA). The cycle threshold (Ct) of the housekeeping gene Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH) was used for normalization of all samples.
miRNome Arrays and qPCR validation
Small RNAs were isolated using the mirVana™ miRNA Isolation Kit (Ambion, Foster City, 
CA, USA), and cDNA was prepared from it with miScript II RT Kit (Qiagen, Valencia, CA, 
USA) using miScript HiSpec Buffer. The individual sample cDNAs were pooled in equal 
proportions into four groups based on gender and age (Supplemental Table S1). The levels 
of 1008 miRNAs were assessed with Human miRNome miScript miRNA PCR Array 
(Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions and as previously 
described (26). A 30% difference between the average ΔCt for MDD and CNTR (|ΔΔCt|
>0.3785) and a group-wise p-value generated by a ttest (p<0.05) were used to determine 
differential expression for each miRNA.
Custom generated miScript miRNA PCR Arrays (Qiagen, Valencia, CA, USA) were used to 
assay the level of seven miRNAs: hsa-miR-21, hsa-miR-377, hsa-miR-193a-3p, hsa-
miR-542-3p, hsa-miR-22, hsa-miR-103a, hsa-miR-185. This assessment was performed on 
all individual samples (MDD n=16; CNTR n=16).
RESULTS
mRNA signature in MDD fibroblasts
The experimental design for our study is presented in Supplemental Figure S1. In the first 
part of the study, cultured fibroblast samples from patients with Major Depressive Disorder 
(MDD) and matched control (CNTR) subjects (n=16 pairs, 32 individuals) (Supplemental 
Table S1) were assayed for differential gene expression using GeneChip HT HG-U133 Plus 
PM 96 Array Plate (Affymetrix Inc, Santa Clara, CA). We identified 162 differentially 
expressed gene probes (Supplemental Table S2) that reported > 50% change, and p<0.05 in 
both pairwise and groupwise assessment. Of the 162 changed gene probes, representing 139 
unique known genes, 25 showed increased expression and 114 had decreased levels in 
MDD, suggesting a predominant loss of function, rather than induction of gene expression in 
the diseased subjects. A two-way hierarchical clustering (genes × samples) of the expression 
levels of these gene probes resulted in separation the majority of MDD samples to a distinct 
class (Supplemental Figure S2).
Among the individual genes with the most prominent decrease were protocadherin 10 
(PCDH10) (ALR= -1.73, ppval=0.00154, gpval=0.00057), tenascin XB (TNXB) 
(ALR=-1.30, ppval=0.04545, gpval=0.02515), periplakin (PPL) (ALR=-1.34, 
ppval=0.00556, gpval=0.02714), and hepatocyte growth factor receptor met (MET) 
(ALR=-1.21, ppval=0.04474, gpval=0.0012), which are involved in cell-cell 
communication/adhesion. Of these, due to its known effects on brain development and 
function, MET attracted particular attention and we decided to assess the expression of 
genes belonging to the MET intracellular cascade defined by Biocarta in a targeted fashion. 
Overall, from the 37 genes 16 showed a significant difference (Figure 1) including 
Garbett et al. Page 5
Biol Psychiatry. Author manuscript; available in PMC 2016 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
phosphoinositide-3-kinase, regulatory subunit 1 (PIK3R1), hepatocyte growth factor (HGF), 
GRB2-associated binding protein 1(GAB1), son of sevenless homolog 1 (SOS1), Rap 
guanine nucleotide exchange factor 1 (RAPGEF1), signal transducer and activator of 
transcription 3 (STAT3) protein tyrosine phosphatase, non-receptor type 11 (PTPN11), p21/
Cdc42/Rac1-activated kinase 1 (PAK1), mitogen-activated protein kinase 1 (MAPK1), v-crk 
sarcoma virus CT10 oncogene homolog like (CRKL), jun oncogene (JUN), 
phosphoinositide-3-kinase, catalytic, alpha polypeptide (PTEN), member of RAS oncogene 
family (RAP1A) mitogen-activated protein kinase kinase 1 (MAP2K1), and v-Ha-ras 
Harvey rat sarcoma viral oncogene homolog (HRAS). Furthermore, HGF/MET 
morphogenic signaling synergizes with v-erb-b2 erythroblastic leukemia viral oncogene 
homolog 2 (ErbB2) to enhance cell motility (39), and our data also revealed a significant 
downregulation of ErbB2, further supporting the notion for a deficit in HGF/MET-mediated 
signaling in MDD fibroblasts.
In addition to a targeted MET pathway analysis, we also performed an unbiased pathway 
enrichment analysis using Gene Set Enrichment Analyses (38). Using this approach, we 
identified 10 differentially expressed BioCarta gene sets, six of which were upregulated and 
4 were downregulated in MDD samples (Table 1). Interestingly, most of these molecular 
pathways were related to cell-to-cell communication and are known for their role in the 
adaptive and innate immune system. These pathway analyses argue that the primary gene 
expression disturbance in the fibroblasts of MDD patients is in the expression of immune 
response genes, which has been also reported in the postmortem brain tissue of patients with 
MDD (12).
qPCR validation of mRNA signature
Fourteen of the differentially expressed mRNA species were selected for further validation 
by qPCR. The genes for validation were primarily chosen because of their involvement in 
the immune system response, a process that has been previously implicated in the 
pathophysiology of the disease. Twelve of fourteen selected transcripts showed similar, 
significant expression differences between the control and MDD samples by the two 
methods, with a high degree of correlation between the microarray-reported ALRs and 
qPCR-obtained ΔΔCts (r=0.84) (Supplemental Figure S3), but did not show correlation with 
body mass index in either dataset. qPCR-reported expression differences between the 
control and MDD samples were as follows: CD74: ΔΔCt=2.29, p=0.012; HLA-DRA: ΔΔCt 
=1.61, p=0.017; HLA-DQB1: ΔΔCt=1.31, p=0.018; IL11: ΔΔCt=1.13, p=0.017; HLA-
DPA1: ΔΔCt=1.08, p=0.011; S100B: ΔΔCt=1.05, p=0.031; HBEGF: ΔΔCt= 1.00, p=0.010; 
HLA-DPB1: ΔΔCt=0.43, p=0.156; HLA-DQA1: ΔΔCt=0.29, p=0.285; MET: ΔΔCt=-0.42, 
p=0.043; PCDH10: ΔΔCt=-0.91, p=0.036; TNF19: ΔΔCt=-1.11, p=0.007 and GSTT1: 
ΔΔCt=-3.77, p=0.007.
miRNA signature in MDD fibroblasts
miRNAs are important control elements in the fine-tuning of gene expression, and are 
capable of regulating extensive transcriptional networks (26, 40). Therefore, we further 
sought to determine if there was a disturbance of miRNA expression profile in MDD 
fibroblasts. Small RNA species were isolated from each fibroblast culture, cDNA was 
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generated, pooled in 4 groups according to gender and age, and then used to probe Human 
MirNome arrays, containing assays for 1008 known human miRNAs (26). We observed that 
approximately 50% (561) of the tested miRNAs were expressed in cultured dermal 
fibroblasts. We used a dual expression-significance criteria (26) for determining differential 
miRNA expression (>30% change, p<0.05). We detected 38 miRNAs with distinctly 
different expression in MDD fibroblasts compared to healthy controls (Supplemental Table 
S3). Of these, 17 miRNAs reported lower and 21 higher levels in MDD fibroblasts. Using 
unsupervised two-way hierarchical clustering of expression levels, these 38 miRNAs 
provided a clear separation basis of the MDD and CNTR samples (Figure 2).
Since the miRNA levels were assayed on 4 pooled sets of samples, we sought to validate the 
observed differences in individual samples. For this purpose, we created custom qPCR 
arrays containing assays for 7 differentially expressed miRNAs; hsa-miR-21*, hsa-miR-377, 
hsa-miR-193a-3p, hsa-miR-542-3p, hsa-miR-22, hsa-miR-103a, hsa-miR-185. miRNA 
expression levels for these 7 miRNA species showed an extremely high correlation (R2 = 
0.93, p<0.001) between the pooled sample and individual sample assessments, suggesting 
that the observations made using the combined samples were not an artifact generated by the 
pooling (Figure 3).
Cross-talk between miRNA and mRNA expression in MDD fibroblasts
Next, we tested if the miRNA signature can explain some of the mRNA signature in MDD 
fibroblasts. To achieve this, we identified all predicted target genes/mRNAs for each of the 
38 miRNAs using miRDB online database for miRNA target prediction and functional 
annotations (41),(42) and tested if the targeted mRNAs were enriched in the transcriptome 
profile of MDD fibroblasts (Table 2). 32 out of 38 miRNAs (89%) had at least one target 
mRNA that was differentially expressed between the MDD and control samples. 
Furthermore, 51% of the differentially expressed mRNAs were targets of at least one of the 
38 miRNAs that were differentially expressed in the MDD fibroblasts. These findings 
suggest that the miRNA-mRNA expression signatures of MDD fibroblasts are strongly 
interconnected.
miRNAs are most commonly considered negative regulators of mRNA expression (44, 45), 
so we hypothesized that the miRNA and their mRNA targets will show expression changes 
in the opposite direction. Indeed, we found that 28 (76%) of the miRNAs with altered 
expression had mRNA targets changed in the opposite direction. Acknowledging the fact 
that different prediction algorithms produce different sets of target genes, we also performed 
a secondary identification of miRNA targets using TargetScan Release 6.2 (http://
www.targetscan.org/) (43). TargetScan identified miRNA targets (Supplemental Table S4) 
that were somewhat different from the ones identified by miRDB, but strikingly similar in 
terms of relating the miRNA and the mRNA changes in MDD; 65% (TargetScan) and 76% 
(MiRDB) of the differentially changed miRNAs had mRNA targets that were changed in the 
opposite direction. Regardless of these differences, the findings across the two databases 
suggest a functionally interconnected miRNA-mRNA network disturbance in MDD 
fibroblasts, where many (if not the majority) of the mRNA changes are miRNA driven. 
Nevertheless, it remains challenging to establish which specific miRNA species control 
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what individual mRNA transcripts, as 64% of the differentially expressed mRNAs in MDD 
fibroblasts were hypothetically controlled by more than one miRNA.
DISCUSSION
Our data revealed that 1) MDD fibroblasts, when compared to matched controls, show a 
strong mRNA gene expression difference in molecular networks known to engage in cell-to-
cell communication and innate/adaptive immunity; 2) the same patient fibroblasts showed 
altered expression in a distinct panel of 38 miRNAs, which appeared to target many of the 
differentially expressed mRNAs; 3) the miRNA-mRNA expression changes appeared to be 
functionally connected, as the majority of the miRNA and mRNA changes were in the 
opposite direction.
These findings have conceptual implications for our understanding of MDD 
pathophysiology. Our findings reinforce the notion that MDD is not only a disease of the 
brain, but molecular deficiencies in MDD patients are detectable in other peripheral organs 
(28, 46), including dermal fibroblasts. In addition, it is important to note that the observed 
mRNA and miRNA changes in the patient fibroblasts are most likely driven by genetic 
susceptibility to the disease, rather than effects of the environment and lifestyle: most of the 
epigenetic changes, environmental influences and drug effects are likely to disappear over 
time, as the fibroblasts continuously divide in the culture (25, 26). However, our 
experiments cannot exclude the possibility that some of the extremely stable, cell-division-
resistant epigenetic factors might also contribute to the observed changes (47, 48). In 
summary, the molecular changes observed in cultured fibroblasts of MDD patients can 
provide us clues about lifestyle- and medication-independent, conserved disturbances in 
MDD across the various tissue types.
An unexpected and interesting finding of this study is the strikingly different level of 
expression of approximately half of the Biocarta defined hepatocyte growth factor receptor 
met (MET) pathway genes. MET is a receptor tyrosine kinase activated by the hepatocyte 
growth factor (HGF) and affecting cellular signaling pathways involved in control of 
proliferation, motility, migration and invasion. Although the functions of MET have been 
primarily studied in the context of cancer (49), MET signaling is also known to be important 
in brain development (50) and the regulation of immune cells (51). Importantly, in a recent 
study HGF was the most highly associated plasma analyte with depressive symptoms (52). 
Furthermore, the met pathway facilitates adult neurogenesis (53), a process that is 
significantly impaired in major depression (54).
Immune system disturbances in MDD appear to be an integral part of the disease process 
(22, 55, 56). The overlap between symptoms of infectious diseases and common affective 
manifestations (57) suggested a shared pathophysiology between these two systems, which 
was investigated in a host of follow-up studies. Ultimately, the combined findings lead to 
the formulation of the inflammatory and neurodegenerative (I&ND) hypothesis of MDD 
(46), which states that MDD is a consequence of neurodegeneration and reduced 
neurogenesis that arise from inflammation and cell-mediated immune activation. Today, this 
view is supported by converging data obtained across different methods and systems. First, 
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postmortem findings identified that MDD patients show a strong dysregulation of immune 
system pathways in the brain, encompassing altered levels of pro- and anti-inflammatory 
cytokine expression of IL-1α, IL-2, IL-3, IL-5, IL-8, IL-9, IL-10, IL-12A, IL-13, IL-15, 
IL-18, IFN-γ and lymphotoxin-α (12). Similarly, altered mRNA levels of immune system 
genes were found in the neocortex of subjects who committed suicide (58, 59). Second, the 
immune deficits appear to be systemic in patients with MDD, and that they are readily 
detectable in the peripheral tissues (2). Inflammation and immune system biomarkers of 
MDD might include C-reactive protein (CRP), cytokines (in particular tumor necrosis 
factor-α (TNF-α) and interleukin-6 (IL-6)), neopterin and tryptophan catabolites (reviewed 
by (28)). Third, while in the most recent genome-wide association study of MDD no SNPs 
achieved genome-wide significance in the MDD discovery or replication phase (60), 
candidate gene studies hint that genetic vulnerability in immune system genes might 
predispose to MDD in a complex pattern (61–64). However, it is also clear that the immune 
system genes are only partially responsible for the genetic vulnerability of MDD, as a recent 
pathway analysis found that genetic elements regulating growth and organ development 
might also represent vulnerability factors (65). Our results are also aligned with this overall 
view: the disturbance in classic complement pathway, cell-to-cell communication and 
innate/adaptive immunity suggest an integrated immune system and growth disturbance in 
the patient population.
Several miRNAs have been already associated with treatment response or an increased risk 
for major depression (18, 66–68). Recent reports suggest that polymorphism in the miR-30e 
precursor is associated with major depressive disorder risk (69), and that miRNA expression 
was significantly and globally down-regulated in prefrontal cortex of depressed suicide 
subjects (19). In addition, abnormal processing of pre-miR-182 (a circadian clock 
modulator) was found in major depression patients with insomnia (70). Unfortunately, due 
to lack of replication, specific experimental design, differences in analyzed tissue and 
variety of cohorts the data are challenging to interpret and combine into a comprehensive 
view in a context of MDD. However, it is clear that miRNAs play a pivotal role in a vast 
variety of MDD-relevant biological processes, including synaptic plasticity, neurogenesis, 
and stress response (for a review, see (18)). Thus, it is worth pointing out that at least 8 of 
the 38 differentially expressed miRNAs that we identified in our MDD-fibroblast screen 
have been previously implicated in either pathophysiology of psychiatric disorders or 
pathophysiological processes relevant to MDD: 1) miR-32 and miR-22 levels were altered 
in both our and in a bipolar postmortem dataset (71), 2) miR-22 represses BDNF, serotonin 
receptor 2C (HTR2C), monoamine oxidase A (MAO-A), and the regulator of G protein 
signaling (RGS2) (72), 3) miR-196 plays an important regulatory role in schizophrenia (73), 
4) miR-132 regulates neurite outgrowth and dendritic morphogenesis (74–76), 5) miR-16 
acts as a central effector in 5-HT transporter regulation, mediating the adaptive response of 
serotonergic and noradrenergic neurons to SSRI antidepressant treatment (77), 6) miR-7 
expression is altered in the prefrontal cortex of schizophrenia patients (71), 7) miR-429 is 
downregulated in response to repeated shocks in a rodent model (78), and 8) miR-107 
associated with accelerated disease progression in Alzheimer’s disease through regulation of 
BACE1 (β-site amyloid precursor protein-cleaving enzyme 1) (79).
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Still, in our study, the most promising miRNA candidate for diagnostic biomarker was hsa-
miR-122, with a 350% decrease in MDD cases at p<0.00004. Hsa-miR-122 is highly 
expressed in the hippocampus (80) and has been implicated in regulation of fatty acid 
metabolism (81, 82) and circadian rhythm (83). Unfortunately, its role in the central nervous 
system has not been well established, and understanding its function in the brain requires 
further studies.
In summary, we believe that a combined miRNA-mRNA analysis approach has a potential 
to uncover reliable, disease-related panels of biomarkers. The mRNA/miRNA panel 
identified in this study represents a promising lead, but it will have to be further validated on 
a different cohort of patients and across different experimental manipulations. Even through 
in our data sets we did not observe an association between expression and body mass index 
recorded at the time of the material harvest, we cannot exclude the possibility that some of 
the observed mRNA/miRNA changes might be related to confounding factors such as life 
style.
We wish to emphasize that dermal fibroblasts are an appealing experimental model. First, 
they are easy to obtain and propagate. Second, they are not genetically modified and/or 
immortalized, yet, the resource is not easily depleted. Third, due to their division in the cell 
culture, many confounds and epigenetic changes disappear over time. Fourth, our current 
and previous data suggests that the miRNA and mRNA expression profiles of the fibroblasts 
from MDD patients are likely to be related to the changes that occur in the brain (25, 30, 84, 
85). Fifth, this model is potentially well-suited for in vitro drug screening. Finally, 
establishing this patient-derived model requires only minimal technical and financial 
resources, and is ideally suited for smaller laboratories. In addition, should the need arise in 
follow-up experiments, patient fibroblasts can be transformed into IPSCs that can be 
differentiated into neuronal lineages (86).
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Figure 1. mRNA expression of HGF/MET signaling pathway genes is different between the 
fibroblasts originating from MDD and CNTRL subjects
Y-axis depicts differentially expressed HGF/MET pathway transcripts as defined by 
BioCarta/GSEA. X-axis denotes Average Log2 Ratio (ALR) between the MDD and CNTR 
samples. Bars denote magnitude of change. Note that the vast majority of the genes within 
this pathway were underexpressed in the MDD fibroblasts.
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Figure 2. Clustering of miRNAs that are differentially expressed between the MDD and CNTR 
samples
miRNA levels were assessed in 8 pooled samples (4 CNTR + 4 MDD) using miRNome 
PCR Arrays. 38 miRNAs reported differential expression between fibroblasts from MDD 
patients and healthy controls. Unsupervised two-way hierarchical clustering of these miRNA 
expression levels provided a clear separation between the MDD and CNTR samples. 
Samples were clustered vertically, miRNAs were clustered horizontally. Each colored 
square represents a normalized miRNA expression level, color coded for increase (red) or 
decrease (blue) from the mean. Color intensity is proportional to magnitude of change. The 
clustering resulted in a separation of the samples into two groups, perfectly matching the 
two distinct diagnostic categories (vertical dendrogram: green - CNTR samples, purple – 
MDD samples). For more detail, see Supplemental Figure S2.
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Figure 3. Differential miRNA expression in pooled MDD fibroblast samples validated on 
individual samples
The expression levels of 7 miRNAs in pooled samples determined by miRNome arrays were 
validated on individual samples using custom qPCR arrays (n=32, 16 MDD + 16 CNTR). 
ΔΔCt from the pooled samples are plotted on the x-axis, ΔΔCts from individual samples are 
denoted on the y-axis. Individual data points indicate the expression of 7 miRNA species. 
Note that the two datasets were highly correlated (R2=0.93, p<0.001).
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Fibroblasts from patients with major depressive disorder show
distinct transcriptional response to metabolic stressors
KA Garbett1, A Vereczkei1,2, S Kálmán1,3, L Wang4, Ž Korade1,5, RC Shelton6 and K Mirnics1,3,5
Major depressive disorder (MDD) is increasingly viewed as interplay of environmental stressors and genetic predisposition, and
recent data suggest that the disease affects not only the brain, but the entire body. As a result, we aimed at determining whether
patients with major depression have aberrant molecular responses to stress in peripheral tissues. We examined the effects of two
metabolic stressors, galactose (GAL) or reduced lipids (RL), on the transcriptome and miRNome of human ﬁbroblasts from 16 pairs
of patients with MDD and matched healthy controls (CNTR). Our results demonstrate that both MDD and CNTR ﬁbroblasts had a
robust molecular response to GAL and RL challenges. Most importantly, a signiﬁcant part (messenger RNAs (mRNAs): 26–33%;
microRNAs (miRNAs): 81–90%) of the molecular response was only observed in MDD, but not in CNTR ﬁbroblasts. The applied
metabolic challenges uncovered mRNA and miRNA signatures, identifying responses to each stressor characteristic for the MDD
ﬁbroblasts. The distinct responses of MDD ﬁbroblasts to GAL and RL revealed an aberrant engagement of molecular pathways, such
as apoptosis, regulation of cell cycle, cell migration, metabolic control and energy production. In conclusion, the metabolic
challenges evoked by GAL or RL in dermal ﬁbroblasts exposed adaptive dysfunctions on mRNA and miRNA levels that are
characteristic for MDD. This ﬁnding underscores the need to challenge biological systems to bring out disease-speciﬁc deﬁcits,
which otherwise might remain hidden under resting conditions.
Translational Psychiatry (2015) 5, e523; doi:10.1038/tp.2015.14; published online 10 March 2015
INTRODUCTION
Major depressive disorder (MDD) is a mental disorder character-
ized by persistent depressed mood, anhedonia, sleep and appetite
disturbances, and feelings of worthlessness, guilt and hope-
lessness. It is increasingly viewed as an illness of the body as well
as of the mind.1 Both genetic and environmental factors have
been associated with the etiology of the disease,2 but their
interplay remains unexplained to date. Stressful life events are
associated with the onset and severity of major depression;3
therefore, we speculated that aberrant adaptive responses to
stressors would be also detectable at the cellular level.
Coordination of cellular responses to stress is largely accom-
plished by mitochondria.4 Regardless of the type of stress a cell is
experiencing (for example, exposure to harmful chemicals,
changes of nutrient or oxygen supplies, dangerous levels of
reactive oxygen species or even pathogen invasion), mitochondria
utilize a wide array of mechanisms aimed at restoring cellular
homeostasis.5 Therefore, the health of these cellular organelles is
critical not only for the fate of the individual cells, but for the well-
being of the entire organism. Not surprisingly, abnormalities in
mitochondrial functions have been implicated in neurological6
and psychiatric disorders,7–9 and speciﬁcally in MDD.10 In addition,
mitochondria are involved in multiple metabolic pathways and are
the most prominent generators of energy in the cell. Energy is
produced in the cytoplasm through glycolysis, or in the
mitochondria through oxidative phosphorylation, also known as
mitochondrial respiration. The reliance on energy produced by
mitochondrial respiration, rather than glycolysis, can be
experimentally shifted by changing the sugar source in the cell
culture medium from glucose to galactose (GAL).11 The shift to
oxidative phosphorylation can reveal mitochondrial deﬁcits
intersecting control of carbohydrate metabolism and energy
homeostasis. Energy production is also tightly interconnected with
lipid metabolism through the key metabolite acetyl-CoA. Acetyl-
CoA may remain in the mitochondria for energy production or
may be exported for de novo fatty acid synthesis into the
cytoplasm, depending mainly on the availability of fatty acids. This
adaptive shift can be experimentally directed by limiting the fatty
acid supply in the cell culture medium. Therefore, cellular
adaptation to stress can be tested by simple manipulations of
the carbohydrate and fatty acids source in the culture medium.
Molecular adaptation to stress in the context of mental
disorders is difﬁcult to address in the human brain. Alternatively,
we used in vitro propagated peripheral cells to test the effects of
metabolic stress. Dermal ﬁbroblasts are an appealing cell-based
model for studying peripheral events associated with brain
disorders, based on the ease of establishing them from skin
biopsies, and the ability to maintain in culture without additional
reprograming.12 In addition, the confounding variability in human
samples on the basis of patients’ hormones, life style or
medication use, are virtually eliminated after several cell divisions.
To date, skin ﬁbroblast cultures have been used successfully to
elucidate molecular mechanisms associated with
schizophrenia13,14 and developmental disorders,15,16 and for
discerning abnormalities in signal transduction pathways in
MDD.12,17–19 In addition, previous reports for dysregulations in
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lipid metabolism20 and mitochondrial respiration,21 suggest
abnormalities in mitochondrial function in the periphery of MDD
patients. Therefore, we aimed at elucidating whether MDD
ﬁbroblasts would in addition exhibit molecular deﬁcits in response
to metabolic stressors such as GAL and reduced lipids (RL) in the
culture medium. In this manuscript, we present the experimental
data gathered from metabolically challenged human dermal
ﬁbroblasts and discuss their relevance to MDD.
MATERIALS AND METHODS
Human ﬁbroblasts
This study was approved by the Vanderbilt University Institutional Review
Board. Participants were diagnosed with a current major depressive
episode according to the Structured Clinical Interview for DSM-IV-TR22 with
an exclusion criteria of other primary axis I DSM-IV diagnosis. Procedures
for recruitment and diagnosis have been described previously.12,18 A
written informed consent was obtained from all the participants before
any procedures were conducted. Sixteen healthy controls (CNTR) were
matched by age, race and gender to MDD patients (Supplementary
Material 1). The MDD and CNTR subject groups had similar average age
(MDD=34.9, CNTR= 35.2), representation of gender (12 female and four
male) and race (12 white and four African American). Fibroblast cultures
were established from skin biopsies according to a protocol previously
described.12,18
Brieﬂy, ﬁbroblast cultures underwent 5–10 passages with DMEM
(Dulbecco’s Modiﬁed Eagle’s medium; Mediatech, Manassas, VA, USA)
containing 250mM glucose and 1mM sodium pyruvate, supplemented
with 2 mM L-glutamine (Mediatech), 10% fetal bovine serum (Thermo
Scientiﬁc HyClone, Logan, UT, USA) and antibiotic/antimycotic solution
(Invitrogen, Carlsbad, CA, USA). Cultures were maintained at 37 °C and 5%
CO2. A cell line from each patient was divided into three plates (plating
density 1.2 × 106 cells per plate) and after overnight adherence, each plate
received one of the following formulations: (1) standard (STD) medium:
DMEM containing 25mM glucose; (2) galactose-containing (GAL) medium:
DMEM with no glucose, supplemented with 10mM GAL (Sigma-Aldrich, St.
Louis, MO, USA); (3) RL medium: DMEM containing 25mM glucose,
supplemented with lipid-reduced fetal bovine serum (Thermo Scientiﬁc
HyClone). All the cultures were grown for 7 days, refreshing the media
every 2 days. The cells were collected after washing with ice-cold
phosphate-buffered saline twice, and then trypsinized, pelleted (700 g for
8 min at 18 ºC) and stored at −80 °C until RNA isolation. In all the tested cell
lines, neither GAL nor RL exhibited a detectable effect on cell growth and
mortality.
RNA isolation and analyses
Total RNA and small RNA fractions were isolated from frozen ﬁbroblasts
using mirVana microRNA (miRNA) isolation Kit (Ambion, Austin, TX, USA)
according to manufacturer’s instruction. Both total RNA and small RNA
were eluted with 100 μl Elution Solution. Agilent 2100 Bioanalyzer was
used to determine the quality and size of the RNA preps. Total RNA
integrity number for all messenger RNA (mRNA) samples ranged from 9.4
to 10, and was similar between the MDD and CNTR groups and various
conditions. The samples were stored at −80 °C until further use.
The mRNA levels in each ﬁbroblast culture were examined with the
GeneChip HT HG-U133+ PM Array Plate (Affymetrix, Santa Clara, CA, USA).
The complementary DNA synthesis from total RNA, labeling and
hybridization were performed according to manufacturer’s protocol. The
segmented images from each GeneChip were normalized and log2
transformed using GC-robust multi-array analysis.23 The average logarith-
mic ratio (ALR=MeanMDD−MeanCNTR) was calculated for each gene probe,
as an indicator for magnitude of change and Student’s paired and group
two-tailed P-values as indicators for signiﬁcance of change. Signiﬁcance
was established according to the dual criteria of |ALR|40.3785 (30%
change) and both pairwise and groupwise P⩽ 0.01. Quantitaive PCR
validation of the microarray data was performed with RT2 custom Proﬁler
PCR Arrays (Qiagen, Valencia, CA, USA), designed to test the mRNA
expression level of 10 genes involved in the regulation of lipid metabolism:
stearoyl-CoA desaturase (delta-9-desaturase), fatty acid binding protein 3,
7-dehydrocholesterol reductase, insulin induced gene 1, quinolinate
phosphoribosyltransferase, 3-hydroxy-3-methylglutaryl-CoA reductase, 3-
hydroxy-3-methylglutaryl-CoA synthase 1, low-density lipoprotein recep-
tor, fatty acid desaturase 1, fatty acid desaturase 2. The differentially
expressed genes were subjected to a two-way hierarchical clustering
analysis using GenePattern software.24 In addition, for each gene probe,
we applied a linear statistical model with gene expression values as the
outcome variable and group, stressor and group× stressor as ﬁxed effects
(groups: CNTR, MDD; stressors: GAL, RL). Data were analyzed with
procedure MIXED in SAS software (version 9.3, SAS Institute, Cary, NC,
USA). Gene set enrichment analysis (GSEA) based on pre-deﬁned gene
classes were carried out with the GenePattern software.25 BioCarta deﬁned
set of genes were considered signiﬁcantly overrepresented at P⩽ 0.05.
The miRNA levels were interrogated with miRNome miScript miRNA PCR
Arrays (Qiagen). The complementary DNA was prepared from small RNA
preps with miScript HiSpec Buffer according to miScript II RT Kit (Qiagen)
instructions. The complementary DNA from each sample was quantiﬁed
and proportionately combined into four pools of samples according to age
and gender (Supplementary Material 1). Creating multiple sample pools
from closely matched individuals allowed us a reduced work load and cost,
while still retaining the ability to establish statistical signiﬁcance in the
downstream analyses. However, to avoid any pooling biases and outlier
effects, the outcome of these data had to be validated in the individual
samples. As a result, signiﬁcantly changed miRNA levels in each individual
ﬁbroblast sample were examined with custom miScript miRNA PCR Arrays.
(Qiagen), containing assays for the following miRNAs: miR-146b-5p,
miR-550a, miR-214, miR-132*, miR-376c, miR-19a, miR-181a*, miR-486-5p,
miR-424*, miR-542-3p, miR-22, miR-376b, miR-29b, miR-564. The selection
of the 14 miRNA assays was based on a statistically signiﬁcant difference in
response to GAL or RL in the MDD or the CNTR group. The Ct values for
each miRNA from both miRNome and custom qPCR arrays were
normalized to the average Ct from a set of housekeeping genes and thus
ΔCt values were generated. At Ct435, a miRNA level was considered non-
detectable. In cases where the levels of a miRNA were non-detectable in
two or more samples within a group, the miRNA was not used for further
comparisons. The miRNA difference of expression between groups was
measured by ΔΔCtRL =MeanΔCtRL−MeanΔCtSTD and ΔΔCtGAL =MeanΔCt
GAL−MeanΔCtSTD. A miRNA was considered differentially expressed when |
ΔΔCt|40.3785 and pairwise P⩽ 0.05. Group× stressor interaction was
determined by the dual criteria of |ΔΔΔCt|40.3785 (30% difference) and
groupwise P⩽ 0.05. ΔΔΔCtGAL =ΔΔCtMDDGAL−ΔΔCtCNTRGAL; ΔΔΔCtRL
=ΔΔCtMDDRL−ΔΔCtCNTRRL.
RESULTS
MDD ﬁbroblast response to metabolic stress: mRNA changes
Metabolic stress response in MDD and CNTR ﬁbroblasts from 32
subjects (16 MDD and 16 CNTR) was achieved by exposure to
culture media containing GAL or RL (Supplementary Material 2).
Analysis of mRNA species by oligonucleotide microarrays revealed
that GAL substitution of glucose in the growth medium resulted in
robust changes in the transcriptome of both MDD and
CNTR ﬁbroblasts. Using dual criteria for establishing signiﬁcant
expression differences (|ALRGAL− STD| 4 0.3785 (30% change)
and both group- and pairwise P⩽ 0.01), we identiﬁed 1196
transcripts changed in GAL-treated MDD ﬁbroblasts
(Supplementary Material 3A). Of those, 975 were upregulated as
a result of GAL treatment. According to the same criteria, 1111
probes were changed in CNTR ﬁbroblasts, 733 of which were
upregulated. In comparison with the CNTR ﬁbroblasts, MDD
ﬁbroblasts revealed a distinct GAL-induced mRNA pattern; of the
total number of mRNAs, 310 (26%) were only exhibited in MDD
(Supplementary Material 4A).
RL treatment also resulted in pronounced mRNA changes in
both MDD and CNTR cells. Differential expression in RL conditions
(compared with STD media) was noted for 312 transcripts in the
MDD: 262 upregulated and 50 downregulated mRNAs. Similarly, in
CNTR ﬁbroblast, 360 mRNA species (261 upregulated, 99 down-
regulated) were differentially expressed in RL compared with STD
conditions (Supplementary Material 3B). Importantly, the MDD
ﬁbroblasts responded to RL condition differently than CNTR; 103
(33.4%) of all mRNA changes induced by RL were only exhibited in
MDD (Supplementary Material 4B).
It was remarkable that both GAL and RL treatments resulted in
distinct mRNA changes in MDD ﬁbroblasts that were not present
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in CNTR, therefore, we further sought to identify the interaction
effect between disease state and metabolic challenge (group×
stressor) by applying a linear statistical model. We used a dual
signiﬁcance cutoff criterion of |ΔALR|40.3785 (30% change) and
P⩽ 0.01. We found that the characteristic MDD signature in
response to GAL (MDD×GAL) was deﬁned by 28 (Figure 1a), and
in response to RL (MDD×RL) was deﬁned by 20 mRNA species
(Figure 1b). Two of the genes (integrator complex subunit 4; INTS4
and NEDD4 binding protein 2-like 1; N4BP2L1) overlapped in the
MDD×GAL and MDD×RL response-deﬁning pattern.
Custom qPCR arrays were used to validate the microarray-
detected mRNA changes in response to GAL and RL. The arrays
were designed to test the mRNA expression level of 10 genes
involved in lipid metabolism with signiﬁcantly changed expression
in MDD and in CNTR samples in GAL vs STD and in RL vs STD
conditions. The statistical signiﬁcance of the microarray-detected
expression changes for all 10 genes was conﬁrmed by qPCR
(Figure 2). In addition, the microarray’s ALRs had a high correlation
with the qPCR’s −ΔΔCt in both GAL vs STD and RL vs STD
comparisons.
To better understand what molecular pathways are differently
engaged in MDD compared with CNTR in response to metabolic
stress, we performed GSEA with predetermined gene sets by
BioCarta. Signiﬁcantly enriched gene sets, representing molecular
pathways, were identiﬁed for both MDD and CNTR in GAL and RL
environment (Table 1, GSEA). GAL treatment induced enrichment of
21 pathways in MDD and 17 in CNTR. Nine of the 21 gene sets
(43%) were only enriched in MDD and are involved in cell cycle
Figure 1. Disease × stressor interaction mRNA signatures. (a) MDD×GAL and (b) MDD×RL. The ALR (MeanRL−MeanSTD) of the probes with
signiﬁcant disease × challenge interaction were subjected to unsupervised hierarchical clustering. The colored squares represent the increase
(red) or decrease (blue) of each ALR from the mean. Color intensity is proportional to magnitude of change. Clear separation of MDD and
CNTR groups was observed. Furthermore, two genes (INTS4 and N4BP2L1—denoted by arrows) are commonly present in both signatures.
CNTR, control; GAL, galactose; MDD, major depressive disorder; mRNA, messenger RNA; RL, reduced lipid; STD, standard.
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regulation (PTC1, MPR, ACAP95, ARF), apoptosis (HSP27, SET, BAD),
anti-inﬂammation (IL10) and cell survival (IL7). RL resulted in
enrichment of 19 pathways in MDD and 15 in CNTR. Ten of the 19
gene sets (53%) were only enriched in MDD and are involved in cell
repair (TFF), survival (TRKA), migration (ECM) and proliferation
(CDMAC, SPRY), and also in regulation of metabolism (GH) and
energy production (FEEDER, GLYCOLYSIS). Overall, GSEA revealed
that the speciﬁc changes in MDD evoked by both metabolic
stressors are represented by approximately half of all detected
molecular pathways, indicating that MDD ﬁbroblasts utilize different
strategies for adaptation to the metabolic stressors. Moreover,
challenging the MDD ﬁbroblasts with GAL and RL exposed
characteristic molecular signatures undetectable at STD conditions.
MDD ﬁbroblast response to metabolic stress: miRNA changes
The miRNAs are important regulators of mRNA function and they
are heavily involved in control of metabolism and energy
homeostasis.26 Therefore, we sought to identify the miRNA
response to metabolic challenges in the same MDD ﬁbroblasts
in which differential mRNA expression patterns had been
established.
The miRNA samples, isolated individually from the 16 MDD and
16 CNTR ﬁbroblast cultures, were pooled into four sets according
to the patients’ age and gender (Supplementary Material 1).
Human miRNome miScript miRNA PCR Arrays (Qiagen) were used
to proﬁle the expression of the 1008 most abundantly expressed
miRNA species in the human miRNA genome (miRNome).
Figure 2. qPCR validation of the differential mRNA expression detected with microarrays. The differential expression of 10 mRNAs, detected
with microarrays, was validated with custom qPCR arrays (groups: MDD, CNTR; culture conditions: STD, GAL, RL). ALR (ALRGAL=MeanGAL−
MeanSTD, blue, ALRRL=MeanRL− MeanSTD, pink) was used as an estimate for the microarray expression changes and was plotted on the x axis.
ΔΔCt (ΔΔCtGAL=ΔCtGAL−ΔCtSTD, blue; ΔΔCtRL=ΔCtRL−ΔCtSTD, pink) was used for a qPCR expression changes estimate and was plotted as
−ΔΔCt on the y axis. Note that the estimates from both analyses in each comparison were highly correlated. CNTR, control; GAL, galactose;
MDD, major depressive disorder; mRNA, messenger RNA; qPCR, quantitative PCR; RL, reduced lipid; STD, standard.
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Approximately 50% of the assayed miRNAs were detected in
human cultured dermal ﬁbroblasts, regardless of disease status or
culture condition. Signiﬁcant expression differences in metabolic
stress vs STD conditions were deﬁned when change was larger
than 30% (|ΔΔCt|40.3785) and paired t-test P⩽ 0.05. In response
to GAL challenge, MDD ﬁbroblasts revealed expression changes in
63 miRNAs (Supplementary Material 5A). The number of miRNAs
changed by GAL challenge in CNTR samples was substantially
lower, 38 miRNAs. In addition, 81% of the miRNAs changed in GAL
were speciﬁc for MDD ﬁbroblasts.
RL elicited much stronger miRNA response in MDD (147
miRNAs), compared with CNTR (38 miRNA) (Supplementary
Material 5B), leading us to believe that MDD ﬁbroblasts are
experiencing the RL environment as much more stressful than
CNTRs. Furthermore, 90% of the miRNA RL-response pattern was
observed only in MDD, but not in CNTR.
Validation of miRNome analyses on pooled samples was
performed with custom qPCR array of 14 miRNAs (SABiosciences,
Qiagen) on individual samples. The ΔΔCt (ΔΔCtGAL =ΔCtGAL−ΔCt
STD, ΔΔCtRL =ΔCtRL−ΔCtSTD) from the pooled samples for each
miRNA was correlated with the corresponding ΔΔCt from the
individual samples (Figure 3). Both GAL- and RL-induced miRNA
response demonstrated high correlation between pooled and
individual samples with coefﬁcients of rGAL = 0.920 and rRL = 0.785.
In addition, 85% of the miRNA changes in the individual samples
were signiﬁcantly different in the predicted direction (P⩽ 0.05),
providing a strong validation for the miRNome data.
In addition, in an attempt to identify the miRNA changes that
characterize the speciﬁc response of MDD to each metabolic
challenge, we used a group× challenge linear statistical model
and the dual signiﬁcance criterion of |ΔΔΔCt|40.3785 and
P⩽ 0.05. Thus, we derived two miRNA signatures: (1) representing
MDD×GAL interaction (16 miRNAs) and (2) representing MDD×
RL interaction (36 miRNAs, Figure 4). It is noteworthy that miR-7,
miR-382, miR-296-5p and miR-3176 were common for both
signatures.
Literature search in PubMed for the roles of the MDD×GAL and
MDD×RL signature miRNAs revealed an interesting trend toward
extensive miRNA involvement in the regulation of metabolism, cell
proliferation, survival and migration (Table 2). In relation to control
of metabolism, we found miRNAs regulating insulin levels and
secretion, obesity and starvation in both MDD×GAL (38%) and
MDD×RL (37%) panels. In addition, eight miRNAs from the
MDD×RL panel: miR-3613-3p, miR-33a, miR-192, miR-26a, miR-
-34a, miR-370, miR-15b and miR-296-5p, have been described in
the literature as regulators of lipid metabolism. With regard to cell
proliferation and apoptosis, 56% of the MDD×GAL and 61% of
the MDD×RL miRNAs are known controllers of various signaling
Table 1. BioCarta GSEA enrichment of mRNA expression in response
to GAL and RL challenges
Pathway Size NES P-value
Enriched in CNTR GAL
RACCYCD 26 1.89 0.0076
CELLCYCLE 23 1.81 0.0000
TEL 18 1.74 0.0040
SRCRPTP 11 1.72 0.0000
P53 16 1.66 0.0078
CERAMIDE 22 1.65 0.0115
CFTR 12 1.62 0.0000
CHREBP2 42 1.61 0.0275
G2 24 1.61 0.0199
ATRBRCA 21 1.58 0.0159
CARM_ER 34 1.58 0.0373
STATHMIN 19 1.56 0.0233
ATM 20 1.55 0.0492
CHEMICAL 22 1.53 0.0497
RB 13 1.53 0.0346
AKAPCENTROSOME 15 1.52 0.0471
PLCE 12 1.51 0.0299
Enriched in CNTR RL
PPARA 56 1.83 0.0000
RACCYCD 26 1.71 0.0229
CHREBP2 42 1.65 0.0136
CD40 15 1.59 0.0301
ARF 17 1.57 0.0359
VIP 26 1.57 0.0169
P38MAPK 39 1.53 0.0076
HSP27 15 1.50 0.0389
BAD 26 1.50 0.0217
GCR 19 1.47 0.0360
LYM 11 1.43 0.0368
PLCE 12 1.43 0.0443
IL22BP 16 − 1.53 0.0300
DNAFRAGMENT 10 − 1.54 0.0237
AHSP 11 − 1.56 0.0412
Enriched in MDD GAL
TEL 18 1.98 0.0000
SRCRPTP 11 1.73 0.0020
PTC1 11 1.73 0.0000
G2 24 1.66 0.0021
CARM_ER 34 1.66 0.0056
HSP27 15 1.65 0.0116
RB 13 1.62 0.0062
CERAMIDE 22 1.60 0.0212
P53 16 1.58 0.0220
SET 11 1.58 0.0328
CHEMICAL 22 1.58 0.0243
ATRBRCA 21 1.57 0.0080
MPR 34 1.56 0.0413
CELLCYCLE 23 1.56 0.0305
AKAP95 12 1.56 0.0469
CHREBP2 42 1.56 0.0222
IL10 17 1.53 0.0320
ARF 17 1.50 0.0382
PLCE 12 1.47 0.0301
IL7 17 1.46 0.0258
BAD 26 1.43 0.0138
Enriched in MDD RL
RACCYCD 26 1.90 0.0040
TFF 21 1.88 0.0064
CD40 15 1.78 0.0102
TRKA 12 1.74 0.0084
ECM 24 1.67 0.0234
PPARA 56 1.63 0.0066
HSP27 15 1.62 0.0176
GH 28 1.60 0.0204
GLEEVEC 23 1.58 0.0361
Table. 1. (Continued )
Pathway Size NES P-value
ARF 17 1.54 0.0463
EXTRINSIC 13 1.53 0.0140
CHREBP2 42 1.53 0.0246
CDMAC 16 1.52 0.0355
BAD 26 1.48 0.0118
SPRY 18 1.45 0.0417
FEEDER 9 − 1.53 0.0236
DNAFRAGMENT 10 − 1.54 0.0488
AHSP 11 − 1.56 0.0354
GLYCOLYSIS 10 −1.63 0.0040
Abbreviations: CNTR, control; GAL, galactose; GSEA, gene set enrichment
analysis; MDD, major depressive disorder; mRNA, messenger RNA; RL,
reduced lipid. Molecular pathway enrichment of mRNA in MDD and CNTR.
Pathways enriched only in one group (MDD or CNTR) are in bold.
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cascades, out of which 13% (GAL) and 33% (RL) affect or are
affected by the tumor suppressor protein p53. As p53 is not only a
modulator of apoptosis, but is also involved in regulation of
metabolism,27 some overlap between these categories is
expected. Furthermore, 25% (MDD×GAL) and 39% (MDD×RL)
of the signature miRNAs are known to regulate cell motility.
Interestingly, three of them: miR-34a, miR-34b and miR-199a-3p,
are recognized as regulators of the hepatocyte growth factor
receptor, c-Met,28,29 a key controller of cell migration.
DISCUSSION
Our results demonstrate that the metabolic challenges evoked by
substitution of glucose with GAL or reducing the abundance of
lipids in the growth media of ﬁbroblast cultures result in robust
changes of mRNA and miRNA expression. MDD ﬁbroblasts
responded to the metabolic stress with alternate expression of
1196 (GAL) and 312 (RL) transcripts. A substantial fraction of these
mRNA changes, 26% (GAL) and 33% (RL) were only observed in
MDD, but not in CNTR. The speciﬁc response of MDD ﬁbroblasts to
each challenge was represented by 20 (MDD×GAL) and 28
(MDD×RL) mRNAs with signiﬁcant group by challenge interaction.
The characteristic response of MDD ﬁbroblasts to the metabolic
stressors was even more pronounced on the miRNA level; 81%
(GAL) and 90% (RL) of the total miRNA changes were only
observed in MDD, but not in CNTR. The miRNA signature response
of MDD ﬁbroblasts was deﬁned by 16 (MDD×GAL) and 36
(MDD×RL) miRNAs. The stress-induced changes, observed on
both mRNA and miRNA level, revealed MDD-associated impair-
ments in molecular pathways involved in the control of
metabolism and energy production, cell survival, proliferation
and migration. These impairments are likely to be present in all
the somatic cells, and therefore are informative of the disease
process. In fact, the results are consistent with our previous
ﬁndings in human postmortem brain tissue, as both studies
implicated disturbances in apoptotic molecular pathways.30
Impairments in any of the detected molecular pathways could
be critical for the development and plasticity of the brain and can
result in the disease state of MDD.31 In a previous study, MDD
ﬁbroblasts cultured in STD condition revealed deﬁcits in cell
proliferation and cell motility.32 In this study, we demonstrated
that molecular pathways involved in the same processes were also
impaired in response to metabolic challenges with GAL and RL,
and revealed previously unknown disruption of pathways
regulating metabolism and energy production. Presenting meta-
bolic challenges was instrumental for deﬁning distinct MDD mRNA
and miRNA response signatures that might also contribute to
patients’ aberrant responses to life stressors.
GAL and RL treatments elicited common responses in MDD
ﬁbroblasts. The commonality was demonstrated on both mRNA
and miRNA level. On mRNA level, the overlap between MDD×GAL
and MDD×RL signatures was deﬁned by the integrator complex
subunit 4 (INTS4), and the NEDD4 binding protein 2-like 1
(N4BP2L1). The INTS4 associates with RNA polymerase II, and
therefore potentially has a general effect on regulation of gene
transcription and RNA processing.33 The N4BP2L1 is a paralog of
N4BP2 and is likely involved in cell survival.34 Evidence for MDD
impairment in the regulation of cell survival and proliferation
streamed from the molecular pathway analyses as well. The
HSP27, BAD and ARF molecular pathways were the commonly
enriched pathways in MDD during GAL and RL challenges; all of
which affect cell survival and proliferation. Furthermore, 38%
(GAL) and 17% (RL) of the MDD-enriched gene sets (PTC1, MPR,
ACAP95, ARF, HSP27, SET, BAD, IL7, TRKA, CDMAC, SPRY),
contribute to the regulation of cell survival and proliferation. On
the miRNA level, three of the commonly changed miRNAs are
regulators of cell proliferation and apoptosis.35–37 In addition, a
striking 56–61% of the miRNAs from the MDD×GAL and
MDD×RL signatures have roles in cell cycle and survival
regulation. Overall, these data provide an overwhelming support
for the aberrant engagement of mechanisms regulating cell
proliferation and survival by MDD ﬁbroblasts when exposed to
two distinct metabolic challenges. Commonality between GAL-
and RL-induced responses in MDD was also detected in their
respective miRNA signatures, where at least 38% (GAL) and 37%
(RL) of the miRNAs were regulators of metabolism or energy
homeostasis, indicating deﬁciencies in those signaling cascades in
MDD as well. In summary, the challenges presented by GAL and RL
in MDD ﬁbroblasts affected cellular processes, such as control of
cell proliferation and survival, regulation of metabolism and
energy production. The molecular machinery for regulation of
these processes is located mainly in the mitochondria. Therefore,
our data strongly support the disruption of mitochondrial
functions in patients with MDD, as previously suggested.10
The GAL and RL treatment also evoked different responses in
MDD ﬁbroblasts. The number of mRNAs with changed expression
in GAL was four times the number of mRNAs changed in RL. In
contrast, the mRNA signatures characterizing the speciﬁc response
of MDD to each stress, have similar number of mRNAs (MDD×
GAL= 28, MDD×RL= 20). Therefore, the proportion of the speciﬁc
mRNAs from the total mRNA changes (GAL= 1196, RL = 360) is in
favor of RL (5.6 vs 2.3%). Consequently, we concluded that RL vs
GAL environment more strongly illuminates the molecular deﬁcits
of MDD. Furthermore, additional data, obtained from RL
treatment, reveal abnormalities in MDD, which were not apparent
in GAL. These are the eight miRNAs in the MDD×RL miRNA
signature known to control lipid metabolism, pointing toward the
possibility of fatty acid metabolism dysregulation in patients with
MDD, a phenomenon studied in many different ways during the
last couple of decades.38–42 Another interesting fact revealed only
in RL environment is the presence of six hypoxamirs in the
MDD×RL miRNA signature. Hypoxamirs have been identiﬁed as
miRNAs contributing to mitochondrial respiration arrest in a low
oxygen environment.43 In our study, CNTR ﬁbroblasts upregulated
six hypoxamirs (let-7b*, miR-192, miR-26a, miR-98, miR-23a and
Figure 3. Differential miRNA expression in pooled samples is
validated in individual samples. The expression level of 14 miRNAs,
detected in miRNome analyses of pooled samples, was validated
with independent qPCR arrays of individual samples (groups: MDD,
CNTR; culture conditions: STD, GAL, RL). The expression changes,
estimated with ΔΔCt (ΔΔCtGAL=ΔCtGAL−ΔCtSTD, blue; ΔΔCtRL
=ΔCtRL−ΔCtSTD, pink), from the pooled samples are plotted on the
x axis, and from the individual samples on the y axis. Note that the
values from each comparison were highly correlated. CNTR, control;
GAL, galactose; MDD, major depressive disorder; miRNA, microRNA;
qPCR, quantitative PCR; RL, reduced lipid; STD, standard.
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miR-7)44 in response to RL, whereas MDD ﬁbroblasts down-
regulated them. This particular difference in the MDD response
compared with CNTR further supports the notion of mitochondrial
dysfunction in MDD. The RL challenge was also very informative in
uncovering abnormalities in the process of cell migration; 39% of
the miRNAs in the MDD×RL miRNA signature were regulators of
metastasis. Also, MDD responded to RL with enrichment of ECM
(extracellular matrix) pathway and TFF (Trefoil factors initiate
mucosal healing) pathway; both important players in the
processes of cell migration. The deﬁcit of MDD in cell migration
was not as apparent during adaptation to GAL, but was observed
in a previous study in STD conditions.32
An important question is whether the changes we detect in
peripheral tissues are relevant to a disease process that takes
place primarily in the brain. Genetic factors associated with MDD
are likely to be present throughout the entire body and not just be
speciﬁc to the brain. The adaptive deﬁcits detected in ﬁbroblast
cell lines can be linked back to the function of neurons and the
brain, with multiple examples found in the mRNA and miRNA
challenge-response signatures and in the altered molecular
pathways. On mRNA level, such examples are presented by genes
important for neurite outgrowth, neurodevelopment and synaptic
plasticity: Actin-related protein 2/3 complex, subunit 5 (ARPC5),45
ArfGAP with coiled-coil, ankyrin repeat and PH domains 2
(ACAP2)46 and Beta-1,3-glucuronyltransferase 2 (glucuronosyl-
transferase S, B3GAT2).47 Multiple important roles in the nervous
system are associated with miRNA challenge-response signatures
as well. Generally, 31% (GAL) and 47% (RL) of the miRNAs from the
miRNA signatures are either regulators of molecular events in the
brain or biological markers associated with psychiatric disorders in
the periphery. In particular, we identiﬁed miRNAs with roles in
neurite outgrowth and synapse formation: miR-7,48 miR-26a,49
miR-34a,50 miR-134 (ref. 51) and miR-132;52,53 cell cycle progres-
sion, apoptosis and speciﬁcation of neurons: miR-25,54 miR-34a,55
miR-497 (ref. 56) and miR-376a;57 brain morphogenesis: miR-7,58
miR-370 (ref. 59) and myelination in the central nervous system:
miR-23a.60 Furthermore, our study identiﬁed miRNAs implicated in
the pathological development of schizophrenia, such as miR-132
(ref. 61) and miR-382;62 and of Alzheimer’s, such as miR-98.63 In
addition, several of the miRNAs with aberrant challenge-response
in MDD have been described as potential peripheral biomarkers
for psychiatric or neurological diseases: miR-564 (ref. 64) and
miR-132 for schizophrenia;65 hsa-let-7g and miR-15b for Alzhei-
mer's;66 and miR-1285, miR-34a and miR-34b for Huntington’s
Figure 4. Disease × stressor interaction miRNA signatures. (a) MDD×GAL and (b) MDD×RL. The ΔΔCts (ΔΔCtGAL=ΔCtGAL−ΔCtSTD; ΔΔCtRL
=ΔCtRL−ΔCtSTD) of the miRNAs with signiﬁcant disease × challenge interaction were subjected to unsupervised hierarchical clustering. The
colored squares represent the increase (red) or decrease (blue) of each ΔΔCt from the mean. Increased ΔΔCt represents reduced level of
miRNA in metabolic stress compared with STD conditions. Clear separation of MDD and CNTR groups was observed. Four miRNAs (that is,
miR-7, miR-382, miR-296-5p and miR-3176), denoted by arrows, are commonly present in both signatures. CNTR, control; GAL, galactose; MDD,
major depressive disorder; miRNA, microRNA; RL, reduced lipid; STD, standard.
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disease.67 This study also identiﬁed a number of miRNAs that
respond to different stressors in the nervous system: miR-34b,
which affects the degree of oxidative stress and survival of
dopaminergic neurons;68 miR-296-5p, which responds to oxidative
stress in mouse hippocampal neuronal cultures;69 miR-199a, which
reacts to hypoxia in rat cortical pericytes;70 and miR-98, which is
elevated in the brains of newborn rats experiencing prenatal
stress.71 And last, miR-296-5p, which showed aberrant response to
both RL and GAL in MDD ﬁbroblasts, presents a strong connection
to MDD; miR-296-5p has been identiﬁed as a regulator of
inducible I kappa-B kinase,72 a gene with genetic association
with MDD.73
Taken together, this information gives conﬁdence to the
relevance of our observations in ﬁbroblasts to the MDD disease
state. This study provides a solid foundation for future experi-
ments with human ﬁbroblasts aimed at deciphering the systemic
immune disturbances in MDD. Moreover, our results demonstrate
that aberrant responses to stressors are indeed present in the
peripheral tissues from MDD patients. These responses intersect
multiple cellular processes associated with mitochondria, such as
regulation of metabolism and energy production, cell prolifera-
tion, survival and motility; therefore, they strongly suggest that the
stress-response impairments of MDD patients are most likely
based on impaired mitochondrial functions.
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HUMAN DERMAL FIBROBLASTS IN PSYCHIATRY RESEARCH
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Abstract—In order to decipher the disease etiology,
progression and treatment of multifactorial human brain
diseases we utilize a host of diﬀerent experimental models.
Recently, patient-derived human dermal ﬁbroblast (HDF)
cultures have re-emerged as promising in vitro functional
system for examining various cellular, molecular, metabolic
and (patho)physiological states and traits of psychiatric dis-
orders. HDF studies serve as a powerful complement to
postmortem and animal studies, and often appear to be
informative about the altered homeostasis in neural tissue.
Studies of HDFs from patients with schizophrenia (SZ),
depression, bipolar disorder (BD), autism, attention deﬁcit
and hyperactivity disorder and other psychiatric disorders
have signiﬁcantly advanced our understanding of these
devastating diseases. These reports unequivocally prove
that signal transduction, redox homeostasis, circadian
rhythms and gene*environment (G*E) interactions are all
amenable for assessment by the HDF model. Furthermore,
the reported ﬁndings suggest that this underutilized patient
biomaterial, combined with modern molecular biology tech-
niques, may have both diagnostic and prognostic value,
including prediction of response to therapeutic agents.
 2016 IBRO. Published by Elsevier Ltd. All rights reserved.
Key words: dermal ﬁbroblasts, schizophrenia, major depres-
sion, bipolar disorder, in vitro model, gene*environment
interaction.
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THE NEED FOR MULTIPLE MODEL SYSTEMS
Models simplify complex processes, isolate critical
pathophysiological components and allow
experimentation. In order to study a system, the model
has to be able to test cause–and–eﬀect relationships.
Yet, compromise is unavoidable: we select a model for
its desired features, and the presumably ‘‘less relevant”
variables are sacriﬁced for the sake of simplicity.
Obviously, the choice of the model should always be
guided by the tested hypothesis, as the combination of
various models should result in conclusive data and
gain of new knowledge.
Considering that the brain pathophysiology of
psychiatric disorders can be only analyzed in humans
by non-invasive methods, animal models are the
preferred choice to examine behavioral disturbances
and associated structural and functional brain alterations
that arise from genetic manipulations (Schmidt and
Mirnics, 2012; Schmidt et al., 2014; Brown et al., 2015).
Although these experiments are essential, psychiatric
disorders are uniquely human conditions, and cannot be
interpreted in the disease context without understanding
the events in the diseased tissue (Nestler and Hyman,
2010).
http://dx.doi.org/10.1016/j.neuroscience.2016.01.067
0306-4522/ 2016 IBRO. Published by Elsevier Ltd. All rights reserved.
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Brain biopsies from psychiatric patients are very rarely
justiﬁed, and even when brain biopsy tissue is obtained,
keeping mature neurons alive is extremely challenging
(Hayashi-Takagi et al., 2014). As a result, postmortem
studies are the preferred choice to study disease-related
transcriptome, proteome and metabolome changes.
However, these tissue samples have limited utility for
the most critical functional assays, such as evaluating
gene*environment (G*E) interactions, stress resilience
or drug eﬀects (Horva´th et al., 2011; Horva´th and
Mirnics, 2015). Additionally, as this is a sample of oppor-
tunity, the interpretation of ﬁndings is greatly complicated
by confounds such as individual lifestyle diﬀerences,
comorbidity, drug abuse, medication use, postmortem
interval, hormonal status, cause of death and many other
factors (Mirnics et al., 2006; Schmitt et al., 2008).
Furthermore, perhaps the greatest intrinsic limitation of
postmortem tissue is its limited utility in establishing
diagnosis and aiding therapeutic approaches.
PATIENT BIOMATERIAL MODELS,
ADVANTAGES AND LIMITATIONS
Psychiatric disorders are multifactorial and
multidimensional diseases: the pathology and
pathophysiology encompass biological events that span
genetic, molecular, cellular, neurochemical, systemic,
psychological and social domains (Schmitt et al., 2014).
As a result, all human-based in vitro experimental systems
have limitations, but also oﬀer signiﬁcant advantages: they
allow mechanistic experimentation on patient biomaterial,
and this is especially important as none of the in vivo
rodent models of psychiatric disorders can fully recapitu-
late human genetic diversity and overall disease pheno-
type (Sarnyai et al., 2011; Kaiser and Feng, 2015).
There is a strong need for patient-derived
biospecimens that can be propagated, preferably without
altering the genetic makeup of the patients. Importantly,
the pathophysiological mechanisms associated with
psychiatric disorders such as schizophrenia (SZ) can be
investigated in cell cultures as (1) they show high
heritability, suggesting a signiﬁcant genetic contribution
to the disease, which would be preserved in an in vitro
model (Brennand et al., 2012); (2) psychiatric disorders
appear to be a disease of the whole body (and not only
the brain), therefore many of the disease-associated
immune, endocrine and metabolic dysregulations should
be detectable in peripheral cells as well (Penninx et al.,
2013; Shivakumar et al., 2014); (3) the molecular anoma-
lies which contribute to the neural dysfunction (e.g. altered
oxidative and energy homeostasis, mitochondrial
changes, metabolic disruptions, signal transduction distur-
bances) are also present in patient-derived peripheral
tissues.
Investigators have been testing meaningful patient-
derived functional experimental models for decades. To
date, the most commonly used patient-derived models
include (1) peripheral blood leukocytes; (2) immortalized
peripheral lymphocytes; (3) olfactory epithelium, (4)
induced pluripotent stem cells (iPCSs), (5) induced
neural progenitor cells (iNPCs) and induced neuronal T
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cells (iNCs) and (6) human dermal ﬁbroblasts (HDFs)
(Hayashi-Takagi et al., 2014). Each of these cellular mod-
els have advantages and shortcomings, described below
and summarized in Table 1.
In addition to the inherent diﬀerences between all
cellular models, they all share a common limitation: the
cells are maintained in an artiﬁcial environment. The
biology of all cells (including, but not limited to
proliferation, migration, and function) is highly
dependent on the microenvironment. Unfortunately, we
have limited understanding of in vivo spatiotemporal
relationships and microenvironments (Lu et al., 2011;
Tatullo et al., 2015). We cannot recreate them in our
in vitro culturing environments, and the physiological
niche of the dissociated cells is certainly far from ideal.
For example, we know that self-maintenance and renewal
of cell cultures is highly dependent on the extracellular
matrix (ECM) remodeling in a cell-type-speciﬁc fashion
(Przybyla et al., 2013): it appears that some cells grown
in vitro are capable of modifying their microenvironment
by producing ECM-proteins, glycopeptides and proteases
(e.g. cultured astroglia or HDFs) (Biran et al., 1999; Fulla´r
et al., 2015), while other cell types (e.g. pluripotent stem
cells and neurons) require support in niche-modulation
from feeder cells such as mouse embryonic ﬁbroblasts
or astroglia (Moore et al., 2009; Przybyla et al., 2013).
Peripheral leukocytes
Peripheral leukocytes, and particularly peripheral blood-
derived mononuclear cells have a long history of use in
psychiatric research, assuming a bidirectional
communication between the immune and nervous
systems (Naydenov et al., 2007; Khandaker and
Dantzer, 2015). It has been argued that peripheral leuko-
cytes and brain cells share considerable similarities in
their proteome, signaling signature, and hormone and
drug response (Gladkevich et al., 2004; Iga et al.,
2008). Several studies revealed peripheral leukocyte
number and functional alterations in psychiatric diseases,
establishing it as a useful ex vivo model (reviewed in
Gladkevich et al., 2004; Iga et al., 2008). The main advan-
tages of the peripheral leukocyte/mononuclear cell model
are that (1) they can be easily and repeatedly harvested
during the course of the illness, and (2) they are reactive
to external and internal stimuli, allowing monitoring of
the disease state. In contrast, the main drawbacks of
the peripheral blood cell models are the considerable
individual variability and sensitivity to factors that are inde-
pendent of the course of the neuropsychiatric disorders
(e.g. lifestyle, hormonal status, circadian rhythm, expo-
sure to pathogens) (Gladkevich et al., 2004; Druzd
et al., 2014). In addition, the number and function of circu-
lating leukocytes are aﬀected by the psychopharmacolog-
ical treatment (Munzer et al., 2013; Tourjman et al.,
2013). All these factors are a considerable source of
‘‘biological noise” that results in a considerable variability
among subjects, often preventing discovery of small eﬀect
sizes or discerning clear causality (Krieger et al., 1998).
However, peripheral blood cells are still quite useful for
performing one-generation-long ex vivo functional assays
(Naydenov et al., 2007).
Immortalized lymphocytes
In contrast to natively harvested, unmodiﬁed leukocytes,
immortalized lymphocytes have self-renewal capacity
and represent a virtually unlimited source of
experimental material. However, immortalization (which
introduces foreign genetic material into the cells) is a
time- and resource-consuming process which might
erase the majority of epigenetic modiﬁcations, and alter
the DNA makeup of the cell lines to the degree that the
responses might not properly mimic the cellular
response found in unmodiﬁed cells (Fridman and
Tainsky, 2008). In addition, immortalized cell lines exhibit
signiﬁcant karyotypic instability and disturbed DNA dam-
age response (Toouli et al., 2002). Hence, these cells
are more appropriate for addressing narrow focused
questions in the context of the donor’s genetic back-
ground (e.g. the brain-derived neurotrophic factor
(BDNF)-induced serotonin receptor changes) (Mo¨ssner
et al., 2000), but less practical for the investigation of
the broad spectrum of cellular functions (e.g. transcrip-
tome and proteome signatures).
Olfactory epithelium
Olfactory epithelium-derived cell cultures are promising
models in neuropsychiatric research (Borgmann-Winter
et al., 2015). Biopsies or exfoliated tissue samples yield
a mixture of multipotent stem cells, mature and develop-
ing neurons and glia (Huard et al., 1998). Consequently,
ex vivo and in vitro experiments (reviewed by
Borgmann-Winter et al., 2015) can be performed on cells
which closely reﬂect the donor’s neurobiology without
compromising the self-renewal capacity. Unfortunately,
these cell cultures remain quite diverse even after
culturing (Huard et al., 1998), and represent a mixture
of diﬀerent cell types at various stages of diﬀerentiation,
which can change based on culturing conditions (Fe´ron
et al., 2013), presented co-factors (Greiner et al., 2011),
number of passages and site of the biopsy (Borgmann-
Winter et al., 2015). During culturing some cells maintain
proliferative capacity, others progress to replicative
senescence, while the highly diﬀerentiated cells respond
to odorants in the primary cultures (Gomez et al., 2008).
Thus, these experiments require standardized methodol-
ogy, careful identiﬁcation of the examined cells via
molecular phenotyping, and conservative interpretation
of ﬁndings. In summary, olfactory epithelium cell cultures
present a unique, very valuable experimental system, with
drawbacks related to the complexity of biomaterial
harvest and subsequent culturing challenges.
Induced pluripotent stem cells (iPSC)
In the last decade iPSCs emerged as an exciting,
disease-relevant experimental model (Tang et al.,
2015). iPSCs, re-programed from somatic cells can diﬀer-
entiate into virtually any adult cell type, resulting in an
unlimited source of patient-speciﬁc biomaterial
(Takahashi et al., 2007). The technology is rapidly
developing, and several protocols exist for reprogram-
ming and diﬀerentiation with varying eﬃcacy and results
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(Singh et al., 2015). Disease- and patient-speciﬁc iPSC
lines have been created for several disorders, including
Parkinson’s disease (Park et al., 2008 and Soldner
et al., 2011), amyotrophic lateral sclerosis (Dimos et al.,
2008), spinal muscular atrophy (Ebert et al., 2009), Alz-
heimer’s disease (Israel et al., 2012), Huntington’s dis-
ease (Park et al., 2008), and SZ (Brennand et al.,
2012). Still, it is worth noting that during reprogramming,
unforeseen DNA mutations may occur and signiﬁcant part
of the epigenome becomes rearranged (Martins-Taylor
and Xu, 2012). This (epi)genetic instability of iPSCs could
result in great heterogeneity within cultures, often neces-
sitating performing the experiments on multiple cell lines
from the same individuals (Brennand et al., 2014).
Additionally, creating and maintaining iPSCs is a labor-
intensive, and a time- and resource-consuming endeavor.
iNCs
Currently, neural cells can be derived from somatic cells
via iPSC diﬀerentiation (Hu et al., 2010) or via lineage
conversion (direct transdiﬀerentiation) (Pang et al.,
2011). The reprogramming and diﬀerentiation of iPSCs
into neural progenitor cells (NPCs) and mature neurons
is achieved by forced expression or exogenous addition
of growth factors and small molecules (reviewed by Kim
et al., 2014). The obtained cells are thought to undergo
the neuronal developmental pathways observed in the
brain, and can be easily cultured and stored (Hu et al.,
2010; Song et al., 2013). Technical challenges associated
with iPSC research (i.e. generation time and resource
demands, (epi)genetic changes, population heterogeneity
and oncogenesis) motivated the development of alterna-
tive iNC generation methods, i.e. cell lineage conversion
(Pang et al., 2011). Remarkably, the expression of only
two microRNAs or a single transcription factor might be
suﬃcient to induce neural cell fate in human postmitotic
somatic cells and produce functional neurons (Yoo
et al., 2011; Chanda et al., 2014).
Both iPSC-derived and transdiﬀerentiated iNCs form
functional synapses and resemble the receptor
expression and electrophysiologic proﬁle of neurons in
the brain (Belinsky et al., 2014; Chanda et al., 2014).
Moreover, iNCs with diﬀerent neurotransmitter- and
region-speciﬁc identity can be generated, such as
GABAergic cortical interneurons (Liu et al., 2013),
glutamatergic pyramidal neurons, dopaminergic midbrain
neurons, or spinal motor neurons (Zeng et al., 2010).
However, the iNC models need comprehensive validation
by genetic, electrophysiologic and pharmacologic
approaches due to the following reasons: (1) de novo
copy number variations (CNVs) are likely to happen
through the somatic cell – iPSC – iNC transitions
(Corrales et al., 2012); (2) the maturation of neurons
requires 6–12 weeks. During this time window there are
virtually thousands of gene expression changes (Fathi
et al., 2011; Dage et al., 2014) and the extended culture
period often results in heterogeneous, asynchronic cell
populations consisting of progenitors, glial cells, mature
and immature neurons (Belinsky et al., 2014). (3) iPSCs
‘‘reset” in their epigenetics, telomere processing and
mitochondrial organization (Rohani et al., 2014) while
transdiﬀerentiated neurons retain the donor’s age-
related signature (Mertens et al., 2015).
HDFs
Notably, the HDF model excels in many of the important
experimental considerations listed above: (1) they are
relatively easy to obtain from ambulatory skin biopsies
(Vangipuram et al., 2013, Wang et al., 2004), (2) their
maintenance does not require signiﬁcant equipment,
chemical or human resources; (3) they can be easily prop-
agated for long periods of time without genetic manipula-
tion or external growth factors and stored in liquid nitrogen
for years (Auburger et al., 2012;); and (4) HDF cultures
consist of mitotic and post-mitotic, uniform ﬁbroblast cells
(Bayreuther et al., 1991) and retain genetic stability for
15–20 passages (Ha¨nzelmann et al., 2015), making a
single biopsy suﬃcient for hundreds of experiments. All
these considerations make HDF cultures an appealing,
cost-eﬀective experimental model.
There are several drawbacks that should be
considered when using the HDF experimental model.
First, in vivo and in vitro cellular aging-related changes
in HDFs must be considered, as several experiments
examined the eﬀects of donor’s age on cell viability and
senescence based on multiple parameters (e.g. life
span, replicative life span, growth rate, replicative
potential, proliferation rate). These publications reveal
that mRNA, miRNA and protein levels (Waldera-Lupa
et al., 2014), DNA methylation (Koch et al., 2011), intra-
cellular calcium levels, mitochondrial function and cell
size (Peterson and Goldman, 1986) are all inﬂuenced by
the age of the HDF donor. These ﬁndings necessitate
careful case-control age matching and/or use of senes-
cence markers. Furthermore, to avoid consequences of
in vitro cellular aging, matching of HDF passage is equally
important, as multiple studies reveal that the mitotic rate
(Maier et al., 2007), telomere length, DNA methylation
(Ha¨nzelmann et al., 2015), proteome and protein phos-
phorylation (Sprenger et al., 2010) change after the 15th
passage in HDF cultures and the cells enter replicative
senescence between passage 21 and 40 (Ha¨nzelmann
et al., 2015). Additionally, it is also noteworthy that using
early HDF passages might be also less than ideal: during
the ﬁrst 3 divisions HDF cultures are not yet homoge-
neous (Auburger et al., 2012) and are undergoing adapta-
tion to the culturing conditions that result in both
transcriptome and epigenome remodeling (Antequera
et al., 1990; Nestor et al., 2015). Similarly, Akin et al.
(2004) suggest that patients’ dietary, hormonal and med-
ication eﬀects disappear after the 5th HDF passage.
Other, consistent reports suggest that body mass index
(BMI), smoking and medication use of the biopsy donor
do not inﬂuence the metabolome of HDF cultures past
several passages (Fournier et al., 2014). Therefore, it
appears that case-control HDF experiments produce the
most consistent and reproducible ﬁndings when per-
formed on HDFs between passages 5 and 15.
In addition, HDFs are as variable as the human beings
they originate from. HDF signal transduction (Gaspar et al.,
2014), mitochondrial function, circadian period length
(Brown et al., 2005) and cell size (Huang et al., 2005)
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all show individual variability, necessitating careful con-
sideration of experimental and control group size. How-
ever, as much as this individual variability represents an
experimental challenge in case-control studies, it also
allows assessment of individual, patient-speciﬁc
responses, opening the door to future personalized/preci-
sion medicine approaches.
Lastly and obviously, HDF cells are not brain cells,
and being aware of the diﬀerences between HDFs and
neurons is essential when considering the usefulness of
the HDF model for a speciﬁc experimental purpose: (1)
HDFs are much more robust and stress-resilient
(Auburger et al., 2012); (2) Unlike post-mitotic neurons,
HDFs can proliferate or enter into a reversible quiescent
state and then spontaneously regain proliferating capacity
(Lemons et al., 2010). (3) HDFs are self-suﬃcient, while
neurons live in a symbiotic relationship with glial cells
(Lundgaard et al., 2014); (4) neuronal energy homeosta-
sis relies almost exclusively on lactate oxidation
(Lundgaard et al., 2014) while HDFs utilize a much
broader range of substrates for metabolic activity
(Lemons et al., 2010). (5) There is an undeniable
divergence in functional specializations between HDFs
and neurons. Neurons are built to be excitable and rapidly
convey cell-to-cell signals, while HDFs are primarily
stromal cells with a prominent role in immune response
and regeneration (Glaros et al., 2009). The advantages
and drawbacks of the HDF model are summarized in
Table 2.
UTILITY OF FIBROBLASTS IN PSYCHIATRIC
RESEARCH
In summary, the selection of the right in vitro experimental
system should always depend on both the characteristic
features of the model and the experimental questions
asked. In the absence of human neural tissue, HDFs
are useful for examining genetically encoded and
conserved cellular functions and molecular pathways
(e.g. cycle, apoptosis, secretory and intracellular
signaling). HDF cultures are easily obtained using
minimally invasive skin biopsies; primary cell lines can
be established within 24 h and maintained for more than
20 passages without genetic or chemical manipulation
(Akin et al., 2004). Hence, the investigator can perform
controlled, reproducible, ‘personalized’ experiments
without a need to alter the individual patient’s genetic
background. Such a functional model can be used to
perform both state and trait experiments, focusing either
on the endophenotype at rest, and/or assess resilience
or maladaptation to various challenges (and compare
the response to that seen in HDF samples obtained from
matched controls) (Fig. 1).
Fibroblasts have been traditionally used to study
neurodegenerative disorders to investigate mitochondrial
dysfunction (Moreira et al., 2007), calcium dynamics
(Palota´s et al., 2002), membrane composition
(Evangelisti et al., 2014), autophagy and lysosomal
activation (Coﬀey et al., 2014), redox homeostasis
(Naderi et al., 2006), and amyloid precursor protein or
hyperphosphorylated tau- (Shahpasand et al., 2012)
related cell damage. In psychiatric research, the late
1980s were the golden age of HDF culture experiments,
followed by an extended period of decline in the utilization
of this model. This trend is recently changing: in the last
5 years HDFs have been rediscovered as useful patient-
derived models for studying CNS dysfunction (Fig. 2).
To better understand this trend and to deﬁne the areas
where HDFs can contribute most to understanding brain
disorders, we performed a critical review of the
Table 2. The advantages and limitations of human dermal ﬁbroblast (HDF) cultures as in vitro model of psychiatric disorders (based on Auburger et al.
(2012) and Connolly (1998))
Advantages
– easy to obtain, transport, culture and store
– high sample volume
– feasibility of well-matched case–control and within subject control studies
– trophic factors or genetic modiﬁcation are not necessary to maintain the cell line
– primary cell cultures with functional and genetic homogeneity (better signal/noise ratio)
– enables personalized/precision medicine studies and allows testing personalized drug treatment response
– express many of the same receptors and signaling pathways as neurons
– synthetize and respond to multiple auto-, para- and endocrine factors
– model amenable to stimulation and genetic manipulation
– lose epigenetic modiﬁcations and in vivo effects after 5 passages
– show natural in vivo and in vitro aging
– can be used for generation of iPSCs and iNCs
Limitations
– cultures are a mixture of keratinocytes/ﬁbroblasts in early passages (before P5) and proliferating/postmitotic cells in late passages (after
P20)
– proliferation rate, conﬂuent growing and cell senescent might bias inter- and intragroup variability
– susceptible to environmental inﬂuences
– cultured cells grow on artiﬁcial surfaces
– lack the variety of physiological, in vivo signals
– the age of the donor might affect cell viability
– HDFs differ from neurons in multiple relevant features, including synapse formation, division, ion channel expression, excitability, neuro-
transmitter release and glial interaction
iPSC: induced pluripotent stem cell; iNC: neural cell induced from iPSC or directly from postmitotic somatic cell.
S. Ka´lma´n et al. / Neuroscience 320 (2016) 105–121 109
published HDF literature to date. We searched the
PubMed database for publications from 1966 until
October 2015 using the following keywords: ‘‘ﬁbroblast
AND SZ” (221 items), ‘‘ﬁbroblast AND major depression
(MD)” (110 items), ‘‘ﬁbroblast AND bipolar disorder
(BD)” (81 items), ‘‘ﬁbroblast AND autism” (123 items),
‘‘ﬁbroblast AND attention deﬁcit” (27 items), ‘‘ﬁbroblast
AND alcohol dependency” (66 items). Case reports and
animal studies were excluded. We also excluded articles
when the abstracts did not contain information on study
subjects, measured parameters and main ﬁndings. It is
noteworthy that by design we limited our search to
psychiatric disorders and the HDF model – due to the
extent of the literature, our review cannot encompass
other models and diagnoses (Table 3).
UNDERSTANDING PATHOPHYSIOLOGICAL
PROCESSES USING HDFS
Signaling pathway studies
Understanding neurotransmitter systems enabled the
development of symptom-alleviating drugs in psychiatry,
yet it did not elucidate the full pathophysiology of these
disorders. This resulted in a shift from studies of
neurotransmitter levels to studies of intracellular
dysregulations underlying the neurochemical and
pathological changes. These studies were quite fruitful
and suggest that signal transduction disturbances can
lead to altered states of neuronal function and
predispose to cognitive and aﬀective disorders (Dwivedi
et al., 2002; Akin et al., 2005; Zhan et al., 2011).
The cell-type-speciﬁc response to stimuli depends on
a cascade of intracellular events, and encompasses
receptor and eﬀector expression, the presence of
co-regulatory factors, epigenetic modiﬁcations and ﬁnal
eﬀectors (most commonly a transcription factor).
However, it should be noted that second messenger
systems and intracellular signal transduction cascades
are highly conserved among many diﬀerent cell types.
Importantly, Rieske et al. (2005) proved that HDF
expressed transcription factors, signaling molecules and
receptors that are highly similar to cells of neuro-
ectodermal origin (Rieske et al., 2005).
The work of Shelton et al. is a good example of taking
advantage of the cellular/ molecular similarity between
HDFs and neuronal cells. Studying signal transduction
following adrenoreceptor stimulation in HDFs revealed
that cAMP-response element-binding protein (CREB)
can be activated both through the cAMP/protein kinase-
A (PKA) and phospholipase-C/protein kinase C (PLC/
PKC) pathways (Manier et al., 2001). Furthermore, HDFs
Fig. 1. Utility of human dermal ﬁbroblasts in neuropsychiatric
research (iPSC – induced pluripotent stem cell; iNC – induced neural
cell; ECM – extracellular matrix; G*E – gene * environment
interaction).
Fig. 2. Number of publications utilizing human dermal ﬁbroblast cultures for studies of psychiatric disorders between 1970 and October 2015. Note
the increased number of publications within the last ﬁve years.
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Table 3. Human dermal ﬁbroblast studies in psychiatric disorders
Research focus Psychiatric
disorder
Finding References
Receptor profile and signaling pathway
Muscarinic cholinergic receptors Aﬀective
disorders
Increased density of binding sites in patients and
their aﬀected or healthy relatives
Nadi et al. (1984)
ADHD Decreased Bmax Johansson et al. (2013a,b)
Serotonin 2A receptor MD Decreased receptor coupled phosphoinositide
response in melancholic MDD
Akin et al. (2004)
b2 receptor signaling BD NSD in receptor coupled cAMP synthesis Berrettini et al. (1987)
MD Decreased cAMP induced PKA activity Shelton et al. (1996)
cAMP/PKA signaling MD Decreased basal and cAMP-stimulated PKA
activity, especially in melancholic subgroup
Shelton et al. (1999)
MD Reduction in the Bmax of cAMP binding to PKA Manier et al. (2000)
MD Reduced PKC dependent CREB phosphorylation;
decreased PKA activity correlated with Hamilton-D
score
Akin et al. (2005)
BD Increased cAMP induced CREB response Gaspar et al. (2014)
Glucocorticoid receptor MD NSD in glucocorticoid binding Wassef et al. (1992)
Enzyme activity
Transketolase AUD and their
oﬀspring
Increased Km Mukherjee et al. (1987)
Kynurenine pathway SZ, BD Increased KYNA and 3-HK production;
increased 3-HK/KYNA ratio after cytokine;
NSD in enzyme levels
Johansson et al. (2013a,b)
Monoamine oxidase-A, -B and
catechol-O-methyl transferase
activity
SZ NSD Groshong et al. (1978),
Ramchand et al. (1995)
BD NSD Breakeﬁeld et al. (1980)
ASD
Tourette
syndrome
NSD Giller et al. (1980)
AUD NSD Giller et al. (1984)
Metabolism
Carbohydrate metabolism SZ Increased glucose oxidation Ramchand et al. (1995)
episodic
schizoaﬀective
disorder
NSD in one-carbon metabolism enzymes Bruinvels et al. (1988)
episodic
psychotic
patients
NSD in serine-folate metabolism enzyme set Fekkes and Bruinvels (1986)
Cell membrane phospholipid
composition
SZ Lower phospholipids, phosphatidylserine,
phosphatidylinositol, phosphatidylethanolamine,
cholesterol fraction
Mahadik et al. (1994a)
SZ Increase in polyamines Ramchand et al. (1994)
SZ Decreased total n-3 fatty acid;
NSD in arachidonic acid
Mahadik et al. (1996a)
SZ, BD Decreased eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA);
NSD in arachidonic acid
Ranjekar et al. (2003)
BD NSD in total n-3 fatty acids and arachidonic acid Mahadik et al. (1996a)
Utilization of essential fatty acids SZ NSD Mahadik et al. (1996b)
Mitochondria
Mitochondrial morphology and
distribution
BD Altered mitochondrial morphology and distribution;
abnormal cytochrome C distribution;
NSD in cytochrome C level and ATP production
Cataldo et al. (2010)
Membrane transport
Tyrosine SZ Decreased Vmax;
NSD in Km
Hagenfeldt et al. (1987),
Bongiovanni et al. (2013)
SZ Decreased Vmax and Km Ramchand et al. (1996),
Flyckt et al. (2001)
SZ Decreased transport due to the L-system Olsson et al. (2006)
BD Decreased Vmax;
NSD in Km
Persson et al. (2009)
(continued on next page)
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Table 3 (continued)
Research focus Psychiatric
disorder
Finding References
ADHD NSD Johansson et al. (2011a,b)
ASD Increased Km Fernell et al. (2007)
Tryptophan ADHD Decreased Vmax and Km Johansson et al. (2011a,b)
BD NSC Persson et al. (2009)
Serine, folate psychotic
patients
NSD in Vmax and Km Fekkes and Bruinvels (1986)
Alanine ADHD Increased Vmax Johansson et al. (2011a,b)
AD Increased Vmax Fernell et al. (2007)
Lithium BD, SZ NSD Hitzemann et al. (1988),
Breslow et al. (1985)
Cell growth, proliferation and apoptosis
Apoptotic susceptibility SZ Increased apoptotic susceptibility;
higher caspase-3 activity;
decreased BCL2
Gasso´ et al. (2014)
SZ Increased apoptotic susceptibility;
in vitro apoptotic markers correlate with volumetric
and metabolic brain measures
Batalla et al. (2015)
SZ More sub-G0 cells;
attenuated caspase-3 response
Catts et al. (2006)
BD NSD in apoptotic rate Cataldo et al. (2010)
Cell viability, proliferation and growth SZ NSD Cohen et al. (1987), Gasso´
et al. (2014)
SZ Reduced growth rate Mahadik et al. (1991)
SZ Cell-cycle associated transcriptome and proteome
changes;
decreased proliferation rate
Wang et al. (2010)
SZ Decreased adhesiveness and ﬁbronectin synthesis Mahadik et al. (1994b)
Cytoskeleton BD NSD in actin or tubulin cytoskeleton Cataldo et al. (2010)
Stress resilience and adaptation
Sensitivity to oxidative stress SZ Impaired capacity to synthesize GSH Gysin et al. (2007, 2009),
Tosic et al. (2006)
SZ 9 protein is aﬀected by the impaired antioxidative
protection in genetically predisposed SCZ patients
Gysin et al. (2009)
SZ NSD in SOD activity Cohen et al. (1986)
MD Increased GS reductase;
decreased antioxidant reserve capacity;
NSD in GSH
Gibson et al. (2012)
SZ Decreased SOD, CAT and GSH peroxidase;
NSD in membrane lipid peroxidation
Ranjekar et al. (2003)
BD Decreased SOD, CAT;
NSD in GP
Ranjekar et al. (2003)
Metabolic stress response MD 26–33% of the mRNA and
81–90% of the microRNA stress response were
MDD speciﬁc
Garbett et al., 2015a
Metabolome after oxidative stress Acute psychosis Extracellular matrix, arginine metabolism, plasma
membrane alterations;
deﬁcit of lysolipid response
Fournier et al. (2014)
Sensitivity to DNA-damaging agents SZ, MD, BD NSD Cohen et al. (1989)
Transcriptome
Transcriptome SZ 434 diﬀerentially expressed transcripts, NSD after
multiple comparison test
Matigian et al. (2008)
SZ 6 genes upregulated Cattane et al. (2015)
MD 139 genes aﬀected
(114 downregulated);
38 microRNAs changed
Garbett et al., 2015b
Fragile X
syndrome
Disease speciﬁc protein synthesis and
phosphorylation proﬁle
Kumari et al. (2014)
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from melancholic MD patients had decreased PKA and
PKC activity and reduced serotonin 2A receptor-speciﬁc
PLC response, conﬁrming previous post mortem and
platelet ﬁndings in MD patients (Shelton et al., 1999;
Akin et al., 2004, 2005).
This PKA/PKC-deﬁcit of CREB activation in MD
deserves more attention, considering that CREB plays
an essential role in activity-driven functional and
structural neural changes (Benito and Barco, 2015) and
that monoamines, stress hormones and antidepressants
aﬀect the CREB/BDNF pro-survival pathway (for a
comprehensive review see Dwivedi and Pandey, 2008).
Notably, some CREB-mediated cellular functions are
neuron-speciﬁc, but others – like the circadian rhythm reg-
ulation – are also present in peripheral cells (McCarthy
et al., 2013a; Druzd et al., 2014; Gaspar et al., 2014).
Circadian rhythm studies
Disruption of the circadian rhythm is a well-known
pathogenic factor for psychiatric disorders such as MD,
BD and SZ (Jagannath et al., 2013). During the last dec-
ade HDFs have been established as a valid model for
studying molecular oscillators, as: (1) cultured HDFs have
cell-autonomous circadian rhythm (average length of
24.5 h) that depends on the same clock genes found in
the pacemaker cells of the suprachiasmatic nuclei
(Nagoshi et al., 2004); (2) the circadian rhythm in HDFs
is stable, and donor-speciﬁc diﬀerences are preserved
even after multiple cell divisions (Brown et al., 2005;
Pagani et al., 2010); and (3) the HDF cellular clock can
be re-synchronized with a serum shock (50% serum treat-
ment) (Yagita et al., 2001).
In more recent experiments, Gaspar et al. examined
the diﬀerences in the cAMP/CREB pathway in ﬁbroblast
cultures from BD patients and healthy subjects (Gaspar
et al., 2014). They found that the cAMP-induced CREB
response was inversely correlated with light-stimulated
melatonin changes in the donors, and concluded that
light-induced melatonin suppression and resetting of the
circadian rhythm (Lonze and Ginty, 2002) is present in
HDFs. Importantly, BD cells showed approximately
3.3-fold higher CREB induction that control cells, suggest-
ing an increased sensitivity to phase-resetting in BD
patients (Gaspar et al., 2014).
Similarly, McCarthy et al. (2013a) found a longer
circadian period length in HDF cultures from BD patients.
Furthermore, lithium treatment augmented the resynchro-
nization of the circadian clock, with BD responding more
prominently to drug-induced resynchronization than the
matched control HDFs. Additionally, it was determined
that genotype can predict the lithium-induced rhythm
changes: increased period length in HDFs was associ-
ated with SNPs in the RORA and PER3 genes in a
diagnosis-independent fashion. Importantly, SNPs in both
of these genes have been previously identiﬁed as poten-
tial BD, anti-depressant response and post-traumatic
stress disorder-associated alleles (Benedetti et al.,
2008; Smith et al., 2009; Garriock et al., 2010; Logue
et al., 2013).
These experiments suggest that HDFs can be used in
studies bridging genetics and disease-associated
endophenotypes (i.e. the inherited sensitivity to light-
induced circadian rhythm disruption) (Saini et al., 2015).
Furthermore, such assays could sub-stratify aﬀective
patients based on circadian rhythm status, and thus open
the door for basic and clinical studies that speciﬁcally
target subgroups of patients.
Studies of stress and adaptation
Stressful life events contribute to the development of
psychiatric disorders (Walker et al., 2008; Musliner
et al., 2015). Maladaptive stress response can lead to
systemic immune, hormonal and metabolic dysregulation
in the body and aﬀective, behavioral and cognitive distur-
bances in the brain. According to the stress–diathesis or
G*E model of MD, the hereditary risk factors will manifest
in clinical symptoms when the environmental challenges
exceed the individual’s adaptation potential (Santarelli
et al., 2014).
In our recent studies, we used HDF cultures from MD
patients and matched controls to determine the
genetically encoded stress vulnerability to metabolic
Table 3 (continued)
Research focus Psychiatric
disorder
Finding References
Circadian rhythm
Period length BD NSD in period length and clock gene expression
rhythmicity
Yang et al. (2009)
BD NSD Bamne et al. (2013)
BD Longer period length;
NSD in amplitude
genotype-determined lithium response
McCarthy et al. (2013a)
AUD Period correlates inversely with symptom severity;
NSD in contrast with CNT
McCarthy et al. (2013b)
Lithium-response BD Calcium channel genes modulate the eﬀect of
lithium on the circadian rhythm
McCarthy et al. (2015)
Abbreviations used: 3-hydroxy-kynurenine (3-HK), attention deﬁcit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), alcohol use disorder (AUD), maximal
binding capacity (Bmax), bipolar disorder (BD), cyclic adenosyl monophosphate (cAMP), catalase (CAT), glutathione peroxidase (GP), control, healthy subjects (CNT),
glutathione (GSH), substrate aﬃnity (Km), kynurenic acid (KYNA), major depressive disorder (MD), no signiﬁcant diﬀerence (NSD), protein kinase A (PKA), schizophrenia
(SZ), superoxide dismutase (SOD), maximal transport velocity (Vmax).
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stimuli (Ka´lma´n et al., 2014; Garbett et al., 2015a,b).
mRNA and microRNA proﬁling analyses after metabolic
stress exposure revealed profound transcriptional diﬀer-
ences between the MD and control HDFs: the mRNA
signature of MD patients consisted of cell cycle, apoptosis
and immune function-related gene sets. Furthermore, the
metabolic stressors aﬀected MD HDFs diﬀerently than
controls, as 81–90% of the microRNA changes were
detected only in the MD biomaterial. These ﬁndings also
suggest that diﬀerent metabolic stressors lead to diﬀerent
transcriptome changes, thus culturing conditions and
stressors for HDFs have to be selected carefully in order
to appropriately study the pathophysiology of interest
(Ka´lma´n et al., 2014; Garbett et al., 2015a,b).
Redox state studies
Oxidative stress-related disturbances in SZ, BD and MD
are an integral part of these diseases, yet our
understanding of the underlying pathophysiology is quite
limited (Bajpai et al., 2014; Reyazuddin et al., 2014). As
free radicals are found in very low concentrations in
human biomaterials and have short half-life (Reyazuddin
et al., 2014), the majority of past experiments relied on
indirect measures of oxidative stress such as DNA dam-
age, lipid peroxidation, levels of antioxidants and enzyme
sets in the blood or the brain tissue (Reyazuddin et al.,
2014). Reliable, direct and meaningful measurements of
oxidative stress markers are challenging even in freshly
prepared plasma due to large diﬀerences between intra-
and extracellular concentrations and rapid molecular
transformations (e.g. rapid oxidation, disulﬁde exchange
and redistribution) (Gysin et al., 2011). Thus, functional
peripheral assays in HDFs are better suited to assess
both the oxidative status and the anti-oxidative reserve
capacities of the cells.
A good example of this is the research performed by
Do et al. who studied the redox homeostasis in SZ
patients by combining neuroimaging, blood and
cerebrospinal ﬂuid assessment, genetic testing and HDF
functional assays (Do et al., 2000; Tosic et al., 2006;
Gysin et al., 2007). Their study, using patient HDFs
expanded on previously reported ﬁndings that (1) gluta-
mate–cysteine ligase (GCL) is the rate-limiting enzyme
of reduced glutathione (GSH) synthesis, which is one of
the main antioxidant mechanism across various tissues
(Meister, 1995), (2) genetic variants of the GCLM-
subunit appear to be associated with greater risk to SZ
(Tosic et al., 2006), and (3) in vivo and postmortem
studies reported decreased GSH levels in the SZ brain
(Do et al., 2000; Yao et al., 2006). The redox homeostasis
of SZ HDFs (measured by GSH and GCL levels) was sub-
optimal even under standard culturing conditions and,
when exposed to oxidative stress, HDFs from SZ patients
were unable to appropriately adapt and increase GCL
activity in response to the environmental challenges
(Gysin et al., 2007). Notably, this antioxidant deﬁcit had
widespread consequences under stress (Gysin et al.,
2009; Fournier et al., 2014) and could also be observed
in the blood of patients carrying a high-risk GCL genotype
who also had plasma thiol alterations (Gysin et al., 2011).
Age-related studies
The combined data argue that oxidative stress and
inﬂammation, elevated stress hormones, subsequent
insulin resistance, dyslipidemia, premature telomere
shortening, mitochondrial dysfunction and multiple other
factors contribute to enhanced systemic and brain aging
(Wolkowitz et al., 2010; Liu, 2014). At a cellular level,
aging is associated with a loss of division potential
(replicative senescence) and increased apoptotic rate.
Unlike immortal and genetically modiﬁed cell line systems
the dividing HDFs show natural aging and reﬂect the
biological age of donors, providing a platform to study
the eﬀects of genetic and environmental factors on cellu-
lar senescence (Tigges et al., 2014).
Although the term ‘dementia praecox’ is no longer in
use (McGlashan, 2011), there are indications that SZ is
at least partially a systemic disorder accompanied by
accelerated molecular aging (Shivakumar et al., 2014).
During the course of the illness, the premature onset of
age-related pathophysiological changes mentioned above
appear to aﬀect both the brain and the peripheral tissues
(reviewed in Kirkpatrick et al., 2008; Shivakumar et al.,
2014). Previous results demonstrated accelerated
aging-related processes in HDF cultures from SZ
patients, which encompassed reduced growth and prolif-
eration rate (Wang et al., 2010), decreased adhesiveness
(Mahadik et al., 1994b), relative predominance of sub-G0
cells (Catts et al., 2006), increased apoptotic susceptibil-
ity, elevated pro-apoptotic caspase-3 reactivity and lower
anti-apoptotic Bcl-2 expression (Gasso´ et al., 2014).
These combined ﬁndings indicate that the observed
molecular similarities between SZ and aging could and
should be investigated in HDF cultures, as they may be
an important part of the disease pathophysiology
(Batalla et al., 2015).
Data-driven studies
Psychiatric disorders arise as an interplay between the
individual’s genetic makeup and environmental
inﬂuences. ‘‘Hypothesis-generating” or ‘‘data-driven”
approaches allow new, unanticipated discoveries,
potentially revealing the consequences of known and
unknown genetic factors and identifying the most
aﬀected pathways and cellular functions.
One example of HDFs used for this purpose is the
study by Garbett at al., which provided a detailed
description of the transcriptome alterations in HDFs
from patients with MD (Garbett et al., 2015a,b). Molecular
pathway analysis both on mRNA and microRNA levels
revealed that apoptosis, cell–cell communication, adhe-
sion and immune function-related transcripts were signif-
icantly altered in the MD samples. These results were
consistent with the previous postmortem and in vivo ﬁnd-
ings (Shelton et al., 2011; Hung et al., 2014), and pro-
vided further validation of transcriptome similarities
between the brain and peripheral tissue of patients with
MD.
The utility of HDFs in data-driven discovery eﬀorts is not
solely limited to studies of pathophysiological mechanisms
in MD. In a recent analysis, Cattane et al. (2015) performed
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transcriptome proﬁling of HDFs from SZ patients and con-
trols using DNA microarrays and
RT-qPCR. The study identiﬁed six diﬀerentially expressed
genes (Egr1, Fos, Fosb, Hist2h2be, Jun and Tcf4), ﬁve of
which have been previously implicated in the pathophys-
iology of SZ in postmortem brain, peripheral blood and
genetic studies (Kyosseva, 2004; Kurian et al., 2011;
Forrest et al., 2014). It is also notable that this study found
that EGR1 levels were correlated in the peripheral blood
cells and HDFs from the same donors.
Studies of pharmacological agents
To date, the majority of studies of psychotropic drugs
eﬀects utilized control, immortalized or non-human
ﬁbroblasts (e.g. De Filippi et al., 2007; Lauth et al.,
2010; Sugden et al., 2010). However, patient HDFs
deserve a much greater consideration as models for test-
ing pharmacological agents and responses: (1) In the
context of precision/personalized medicine, patient-
derived HDF lines could be successfully used to predict
treatment response to lithium in BP patients (McCarthy
et al., 2013a). (2) Self-sustaining HDF cell lines provide
a virtually unlimited source of experimental material,
enabling high-throughput screening assays for identiﬁca-
tion of novel therapeutic compounds (Bae et al., 2015;
Kubben et al., 2015). (3) This in vitromodel system is also
useful for identifying unwanted side eﬀects and toxicity of
known psychotropic drugs, such as antidepressant-
caused cellular damage (Cordero et al., 2009), lithium
and valproic acid-caused circadian clock alterations
(Johansson et al., 2011a), or antipsychotic agent-
modulated aminoacid transport (Bongiovanni et al.,
2013).
SIMILARITIES BETWEEN HDF AND CNS CELLS
Neurons and glia are both aﬀected in psychiatric
disorders and both can be considered valid therapeutic
targets (Eroglu and Barres, 2010; Sanacora and
Banasr, 2013). Interestingly, glia and HDF show striking
similarities in several aspects.
(1) Glia generate ECM consisting of hyaluronic acids,
glycoproteins and proteoglycans (Faissner et al.,
2010). Although ECM is tissue speciﬁc, the main
components and the cell-matrix dynamics show
high similarity throughout various tissues (Naba
et al., 2015). The roles of ECM are many: ECM
determines structural plasticity and adaptation,
modulates inter- and intracellular signaling, ion
levels and transmits survival or death/survival
signals (Gundelﬁnger et al., 2010). Postmortem,
neuroimaging and genetic studies of SZ, MD and
BD all suggest neurodevelopmental disturbances,
which might be highly dependent on the extracellu-
lar environment (Berretta et al., 2015; Gong and He,
2015; Gurung and Prata, 2015). It has been also
suggested that both the composition and the
turnover of ECM are likely contributors to the devel-
opment and progression of psychiatric disorders
(Lubbers et al., 2014). For example, the reelin/
Dab1 molecular pathway, which is triggered in the
ECM, is implicated in corticogenesis and the neuro-
biology of SZ and BD (Ovadia and Shifman, 2011;
Iafrati et al., 2014). Clearly, HDFs can provide
valuable information about reelin-induced signal
transduction (Leeb et al., 2014), and the similar
ECM-generating potential of HDFs and glia might
allow mechanistic ECM studies on HDF systems
that might provide important disease insights.
(2) Glia provide antioxidant defense in the CNS and
closely cooperate with neurons for GSH synthesis
(Be´langer et al., 2011). Postmortem and peripheral
biomarker studies reveal a diminished ability to
maintain redox homeostasis in psychiatric disorders
(Bajpai et al., 2014; Reyazuddin et al., 2014). In
addition, HDF cultures obtained from SZ and MD
patients show impaired GSH regeneration (Cohen
et al., 1986; Ranjekar et al., 2003; Tosic et al.,
2006; Gysin et al., 2007, 2009; Gibson et al.,
2012). Therefore, the decreased oxidative resili-
ence in HDFs is potentially mimicking a dysfunction
that occurs in glial cells in the brains of patients with
SZ and MD.
(3) Neurons have a narrow metabolic spectrum and
rely on glia in almost every metabolic process
(Brown et al., 2014; Lundgaard et al., 2014). Energy
storage and supply and lipid homeostasis of the
brain (fatty acid oxidation, cholesterol biosynthesis
and traﬃcking) are primarily driven by astrocytes
(Dietschy and Turley, 2004; Be´langer et al., 2011).
Recent study of HDF from patients with MD
revealed a disease-speciﬁc response to lipid depri-
vation (Garbett et al., 2015b), suggesting that this
molecular endophenotype might be related to glial
cell deﬁcits in subjects with MD.
(4) In addition to microglia, astrocytes also actively par-
ticipate in the inﬂammatory and immune response,
and they contribute to these processes by secretion
of many auto- and paracrine factors (reviewed by
Lee and MacLean, 2015). Prolonged neuroinﬂam-
mation with glial involvement is a key step in the
progression of multiple psychiatric diseases
(Leonard, 2007; Mu¨ller et al., 2012). Consequently,
altered expression of immune and cell–cell commu-
nication molecular pathways in HDFs from subjects
with MD and SZ (Cattane et al., 2015; Garbett et al.,
2015b), as well as BD-speciﬁc changes in the basal
and cytokine-induced tryptophan-kynurenine meta-
bolism (Johansson et al., 2013; Brown et al.,
2014) may reﬂect disrupted glial inﬂammatory func-
tions in the brains of diseased individuals.
(5) Growth factors coordinate cell proliferation, migra-
tion, survival and apoptosis, synapse formation
and axonal guidance (Terwisscha et al., 2013).
Additionally, two recent meta-analyses showed that
serum BDNF is decreased in ﬁrst episodic psychotic
patients (Toll and Mane´, 2015) and serum NGF
(nerve growth factor) is lowered in MD patients
(Chen et al., 2015). Importantly, recent HDF studies
by Palazzo et al. (2012) revealed that HDF express
BDNF, NGF, neurotrophin-3 (NTF3) and NTF4 and
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their respective receptors. Thus, HDF experiments
might allow testing for how genetic variants of
growth factors contribute to acquired vulnerability
to psychiatric disorders.
CONCLUSIONS
The expanding literature during the last several decades
suggests that the patient-derived HDF model is a
valuable platform for developing novel molecular biology
methods and represents a useful cellular system for
studying the molecular basis of psychiatric disorders.
The value of HDFs is based on ease of acquiring/
establishing of the cell lines from patients, sharing
molecular similarities with cells from the CNS, and the
ability to be propagated without additional genetic
manipulations. HDFs also facilitate our understanding of
brain disorders by allowing us to examine similarities
between the in vitro observations and pathophysiology
of the CNS, and by providing the arena for investigating
G*E interactions, signal transduction and metabolic
dysfunctions. Additionally, the HDF model can be
instrumental in identifying brain disease biomarkers and
thus emphasize the organic aspects of neuropsychiatric
disorders. Due to these characteristics, in the near
future HDFs might provide seminal contribution to
pharmacogenetics and individual therapeutic strategies
used in precision/personalized medicine.
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Neuronal differentiation of induced pluripotent stem cells and direct reprogramming represent powerful methods for modeling
the development of neurons in vitro. Moreover, this approach is also a means for comparing various cellular phenotypes between
cell lines originating from healthy and diseased individuals or isogenic cell lines engineered to differ at only one or a few
genomic loci. Despite methodological constraints and initial skepticism regarding this approach, the field is expanding at a fast
pace. The improvements include the development of new differentiation protocols resulting in selected neuronal populations
(e.g., dopaminergic, GABAergic, hippocampal, and cortical), the widespread use of genome editing methods, and single-cell
techniques. A major challenge awaiting in vitro disease modeling is the integration of clinical data in the models, by selection
of well characterized clinical populations. Ideally, these models will also demonstrate how different diagnostic categories share
overlapping molecular disease mechanisms, but also have unique characteristics. In this review we evaluate studies with regard to
the described developments, to demonstrate how differentiation of induced pluripotent stem cells and direct reprogramming can
contribute to psychiatry.
1. Challenges in Psychiatric Research
Schizophrenia (SCZ) and bipolar disorder (BPD) present
with overlapping clinical symptomatology and share many
environmental and genetic risk factors (for a review see
[1]). Additionally, extended literature argues on the neu-
rodevelopmental origin and neuroprogressive course of both
syndromes. Although psychotic disorders and BPD are not
the most frequent psychiatric conditions, they affected 8
million people in Europe and costed C125 billion for the
society in 2010 according to the report of the European Brain
Council [2].
As mental disorders are exclusively human conditions,
investigating and modeling these conditions raise several
problems and necessitate compromises. Animal models,
based on rare mutations of large effects, provide valuable
information on the cellular biology and behavioral endophe-
notypes of psychiatric disorders but obviously have their
limitations and validation difficulties. Indeed, 92% of drugs
that passed preclinical studies fail in the clinical phase due to
lack of efficacy or safety reasons [3].
In vivo brain sampling in psychiatric patients or control,
healthy subjects is ethically and technically problematic.
Postmortem tissue samples are widely used for assessment
of architectural and molecular alterations in brain disorders,
but the results must be evaluated circumspectly regarding
the variability in the sampled brain area, the pre- and
postmortem circumstances and the consequent degradation
of RNAs and proteins. In order to countervail these technical
issues, brain banks provide great sample sizes, standardized
methodology, and detailed clinical information; however,
these samples are not appropriate for functional assays or
diagnostic purposes and the observed changes might be
evoked by comorbidities or environmental factors over the
course of the disease.
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The heritability of SCZ, BPD, and autism spectrum
disorders (ASD) is above 80% [4–6], but neither candidate
gene nor genome-wide association (GWA) studies can fully
explain this magnitude. These hidden genetics substantiated
the theory of raremutationswith large effects versus common
alleles with low penetrance [7]. Accordingly, in most of the
cases psychiatric diseases are multifactorial and thus derive
from the constellation of (otherwise harmless) common
susceptibility alleles and environmental factors. Cases caused
by single mutations occur very rarely and remain undetected
in large-scale studies. Additionally, recent studies suggested
that de novo mutations may have a great impact on the
individual susceptibility [8, 9]. In vitro cell culture models
represent a system-oriented view, in which mental disorders
are the manifestations of the donor’s individual genetics, and
along this line they enable performing functional assays to
map gene × environment (G × E) and gene × gene (G × G)
interactions.
2. Manufacturing Neurons: Made in Dish
Since detailed description of the iPSC/iNC induction and
differentiation would extend the limitations of this paper and
several publications have been already written on this rapidly
developing field, here we will only briefly summarize the
main technical issues (Figure 1). For further information and
comparison of different protocols see [92–94].
Currently, there are three methods to generate human
neural cells in vitro: iPSCs can be differentiated into neuronal
progenitor cells (NPCs) and somatic cells can be transdif-
ferentiated into neural stem cells or directly into neurons.
Interestingly, transdifferentiation experiments have not yet
been performed in the context of psychiatric disorders, even
though four transcription factors or two microRNAs are
enough to convert human fibroblasts into functional neurons
within three weeks [95, 96]. Direct conversion has the advan-
tage of bypassing the prolonged, potentiallymutagenic phases
of reprogramming and intensive progenitor proliferation
[97]. On the other hand, the amount of experimentalmaterial
is limited by the number of somatic cells and the efficacy of
the transdifferentiation.
Somatic cells can be reprogrammed into pluripotent stage
with a set of transcriptional factors, namely, OCT4, SOX2,
KLF4, and c-MYC or OCT4, SOX2, NANOG, and LIN28
[98, 99]. These can be entered into the cells via integrating
(lenti- and retroviral) or non-integrative (adenovirus, Sendai
virus, episomal vector, and synthetic mRNA) vectors or
direct protein delivering tools [100]. After initial induction,
endogenousNANOG, SOX2, andOCT3/4 expression indicate
pluripotency which can be maintained via basic fibrob-
last growth factor (bFGF) supplementation for theoretically
unlimited time.
The differentiation of iPSCs is thought to follow in vivo
developmental pathways and require environmental cues.
During the past eight years several protocols have been
developed based on monolayer dual SMAD inhibition [101]
or embryoid aggregates [102] with an efficacy of 80% or
more than 85%, respectively. (For a comparative review see
[103].) Successfully differentiated or transformed cells can
be easily recognized by the detection of PAX6, an early
forebrain neuronal marker. Since embryonic aggregate-based
techniques reduce the variability of differentiation potential
among pluripotent cells, it results in a more homogenous
cell population. However, the culture always contains pro-
genitors, glial cells, and mature or immature neurons with
different neurotransmitter and receptor profiles and varying
electrophysiological properties [13].
During manufacturing specific neurons, two major
approaches are available. (1) High neurotransmitter speci-
ficity can be evoked by viral vectors or the combina-
tion of growth factors/small molecules. GABAergic cortical
interneurons [104, 105], dopaminergic midbrain neurons
[106, 107], dentate gyrus granule cells, and glutamatergic
pyramidal neurons were successfully generated according to
these protocols with an efficacy above 90%. (2) On the other
hand, one can address the investigation of region and layer-
specific neurons. Remarkably, NPCs emerging from neural
rosettes show self-organized spatiotemporal differentiation
pattern and model the six-layered cortical structure. Bene-
fitting from this, researchers are able to cultivate and isolate
early and late cortical progenitors, preplate neurons, deep (V-
VI) and superficial (II–IV) layer neurons in a definite tem-
poral manner [108]. Furthermore, advents of biotechnologies
already allow us to grow neural and glial cells in 3D cul-
tures, forming functional organoids which resemble certain
brain regions on the cellular and tissue level [109]. These
microphysiological systems could be especially valuable
tools for modeling neurodevelopmental or neuroprogressive
diseases.
The basic requirements against differentiation are as
follows: quick and efficient generation of homogenous cell
populations with physiological (or diseased) characteristics.
The main concern about currently existing protocols is that
they frequently result in heterogeneous, asynchronic cell pop-
ulations with varying phenotypes and maturation states [13].
Remarkable efforts are made to develop cost-effective, large-
scale generation of NPCs and matured, synchronized neu-
rons for high-throughput assays [14, 110].
3. Closer to Perfection or Just Misperception?
iPSC/iNC cultures as model systems have advantages and
disadvantages: (1) the cell lines can be initiated from easily
obtainable biospecimens, for example, blood sample, skin
biopsy, hair follicle, or urine, (2) but the reprogramming,
culturing, and differentiation are labor intensive and require
notable expertise [111]. (3) iPSCs and iNPCs have self-
sustaining capacity, (4) while differentiated neurons are in
postmitotic state; hence they provide restricted experimental
material. (5) During reprogramming and differentiation the
cells undergo epigenetic rearrangement, (6) and proliferating
iPSCs exhibit genetic instability which may result in popu-
lation diversity and biases in genetic assays [112]. (7) Neuro-
transmitter and brain region specific neurons provide unique
opportunity to study the pathophysiology and genetics of
neuropsychiatric disorders, (8) but every new protocol has to
be carefully validated regarding the cell type-specific markers
and the analogies and discrepancies compared to in vivo and
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Figure 1: Schematic illustration of induced pluripotent stem cell and neural cell line generation and further clinical and research applications.
(iPSC: induced pluripotent stem cell; iNPC: induced neural progenitor cell; iN: induced neuron).
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Represents the research articles only. Publications were reviewed until June, 2015.
animalmodel findings. (9) Finally, iPSC/iNC experiments are
time and money consuming.
4. Three Years’ Balance: Debits and Credits
In 2012, the National Institute of Mental Health (NIMH)
and the Foundation for the NIH organized a workshop on
the technological advances and challenges of patient-derived
iPSCs/iNCs research in psychiatry. Scientists and delegates
of industry and government and funding organizations
conceived recommendations and directions for the future
focusing on basic research, new target identification, and
drug development (for the meeting report see [10]). Since
stem cell biology and brain research are two of themost active
fields of life sciences, we decided to review systematically the
literature on iPSC/iNC in the context of psychiatric diseases
and strike a balance: Did we take our own advice? How far
have we got? What challenges do we face? (Table 1).
To give exact answers, we performed, first in the lit-
erature, a systematic review on iPSC/iNC based researches
in psychiatry. We searched PubMed with the following
keywords: “induced pluripotent OR reprogramming OR
transdifferentiation AND psychiatry OR schizophrenia OR
bipolar OR major depression OR autism” until 20 June, 2015.
First, we catalogued research papers, if (at least part of) the
experiment was conducted on human induced pluripotent
derived or transdifferentiated neural cell cultures and English
text was available. We excluded papers on neurodegenerative
disorders, dementias, and epilepsies (Table 2(a)). During the
survey, we noticed that review publications display outstand-
ing proportion of the literature (41%); thus we decided to list
the relevant reviews using the same criteria (Table 2(b)).
5. What Can (Should) Be Reviewed?
After categorizing the items, we found 80 relevant publi-
cations: 48 research articles and 33 reviews (Figures 2(a),
2(b), and 2(c)). Intriguingly, we did not find any papers with
iPSCs/iNCs targeting major depression. This is surprising,
since unipolar depression is the leading chronic disorder
in the WHO European Region, and the third cause of
disability-adjusted life-years (DALY) [113], while only half
of the patients receive adequate therapy with 70% long-
term efficacy [114]. Considering that major depression is
a multifactorial, neurobiological disorder with heritability
estimates between 40 and 60% [115] and peripheral cells
were traditionally used to model and study the diseased
endophenotypes [116–118], we can envisage that iPSCs/iNCs
hold great promise in this field.
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Table 1: Advancements and further challenges of the utility of induced pluripotent/neural cells in psychiatric research.The recommendations
were conceived on a meeting of the National Institute of Mental Health and the Foundation for NIH in 2012 [10].
Recommendations in 2012 Advancements in the past 3 years Challenges remain
Standardization of protocols
(i) Optimizing reprogramming and
differentiating methods
(ii) Efficient generation and validation of
specific neural cell types
(iii) The importance of region and
maturation state specific differentiation
(iv) Poorly defined regional identity
(i) Safe, integration-free, nonviral induction
(ii) Neurotransmitter and region specific
protocols with efficacy >80%
(iii) Multiple model based studies
(iv) Combination of GWAS databases with
iPSC/iNC observations
(i) Comparison of cells induced from
different peripheral tissues
(ii) Utility of induced glial cells in
psychiatric research
Improving homogeneity
(i) Detailed comparison of induced and
source cells to reveal de novo genetic
mutations
(ii) Multiple parallel cell lines from one
donor
(iii) Epigenetic mapping during
reprogramming and differentiation
(i) Vector integration-free, “safe” reprogramming
methods
(ii) Reassuring results on chromosomal mutations
(iii) Average 3 cell lines/donor
(iv) Experiments and reviews comparing the
available protocols
(i) Concerns on de novo CNVmutations
and the neuronal genome
(ii) Contradictions regarding epigenetics
(iii) Little is that known about
endogenous production of astrocytes
Increasing statistical power
(i) Increasing sample sizes
(ii) Careful selection and grouping of
subjects
(iii) Detailed clinical and genetic
characterization of subjects
(iv) Overthought diseased-control pairing
(i) Studies with whole genome sequencing and
whole transcriptome profiling
(ii) Isogenic case-control comparison (new DNA
editing techniques, twin studies)
(i) Increasing sample sizes
(ii) Reconsideration of patient grouping
(iii) Transparent, published case-control
matching
Improve reproducibility, resource sharing, and collaboration
(i) Establishing rigorous, transparent, and
reproducible methods
(ii) Detailed publication of protocols
(iii) Rapid sharing of cell lines, technologies,
and best practices
(iv) Improving public-private partnership
(i) iPSC banks combined with gene banks
(ii) Commercially available iPSCs, iCell neurons,
and knock-out cell lines with isogenic controls
(iii) Open access movements
(iv) Results usually correlated with postmortem
and animal model findings
(i) Guidelines for validation
(ii) Criteria for cell characterization
(markers, electrophysiological properties)
(iii) Poor publication of donor’s genotype,
clinical features
Towards large-scale studies
(i) Decreasing protocol diversity
(ii) Validation assays for phenotypic
comparison of derived cell lines
(i) Protocol diversity remains, but major steps
towards large-scale production
(ii) Commercially available cells provide enough
experimental material for high throughput assays
Personalized medicine requires
reprogramming and differentiation by
every single patient, which is still
remarkably time-consuming and money
consuming
Careful patient selection, case-control matching
(i) Subgrouping on the base of
comprehensive genetic and clinical
characterization
(ii) Linking genotype with molecular and
cellular pathophysiology
(i) Isogenic case-control pairs provided by DNA
editing techniques, twin studies
(ii) Pedigree-studies
(iii) DSM-5 reconsidered subcategories
Endophenotype-based subgrouping?
6. Evidence-Based Questions
iPSC/iNC studies are interpretable only in a multiscale
diseasemodeling paradigm; thus results fromawell-designed
experiment should raise more questions than those they
answer per se. Therefore, we examine the main issues
addressed at the 2012 NIMH workshop [10] and those which
emerged since via introducing some of the published studies
and focusing on answered and emerged future challenges.
6.1. Time Is Not Everything, but Timing! The 2012 work-
shop highly emphasized the need for effective, standardized
derivation and validation protocols for high-scale studies
and future clinical application of iPSC/iNC technologies [10].
The participants cautioned against proliferation of poorly
designed studies and recommended the establishment of
rigorous, transparent, and reproducible methodology.
Reviewing the literature, we can conclude that significant
progression was made in neural differentiation methods
during the past three years. Today, researchers are able to
generate neurons of regional and temporal identity, as well
as 3D organoids; however, the methods are still under intense
development formore efficient, time-sparing protocols. Since
we have to allow room for these innovations, validation
practices call for standardization.
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Table 2: (a) Research articles using induced pluripotent stem cells and/or induced neural cells in studying psychiatric disorders. (b) Review
articles on induced pluripotent stem cells and/or induced neural cells in modeling psychiatric disorders.
(a)
Author, publication
date Modeled disease(s) Main findings
Cell line,
differentiation protocol
Patient
derived
cell lines
Free
full text
Ananiev et al., 2011 [11] Rett syndrome Neurons exhibit smaller nuclear size Differentiatedglutamatergic neurons Y (3) Y
Bavamian et al., 2015
[12] BPD
miR-34a is associated with BPD and
neurodevelopment NPCs Y (1) N
Belinsky et al., 2014 [13] Neurodevelopment Electrophysiology and gene expressionduring neural maturation
Differentiated
glutamatergic neurons Y (1) Y
Boissart et al., 2013 [14] Psychopharmacology,ASD
Synchronous production of cortical
neurons for high-throughput assays
Glutamatergic cortical
neurons Y (2) Y
Brennand et al., 2011
[15] SCZ
Diminished connectivity, cAMP and
WNT signaling rescued by
antipsychotic treatment
Panneuronal
differentiation
protocol, glutamatergic
neurons
Y (4) Y
Brennand et al., 2015
[16] SCZ
Altered migration, mitochondrial
damage, and increased oxidative stress
NPCs, panneuronal
differentiation Y (4) Y
Brick et al., 2014 [17] ASD iPSC bank from ASD patients andcontrols
Differentiated
glutamatergic neurons
Y
(cell bank) Y
Bundo et al., 2014 [18] SCZ LINE retroelements show moreactivity in SCZ derived cells
Differentiated
glutamatergic neurons Y (3) Y
Chen et al., 2014 [19] BPD
BPD iNCs exhibit Ca-signaling and
neurodevelopment associated
transcription alterations
Differentiated neurons
(mixed glutamatergic-
GABAergic
populations)
Y (3) Y
Chen et al., 2013 [20] SCZ, BPD Transcriptional effects of zinc fingerprotein 804A silencing
Differentiated
glutamatergic neurons N Y
Cheung et al., 2011 [21] Rett syndrome Generation of MECP2 mutantiPSC/iNC lines and their isogenic pairs
Differentiated
glutamatergic neurons Y (1) Y
Chiang et al., 2011 [22] SCZ Introduction of an integration-freemethod for reprogramming iPSCs Y (2) Y
Corrales et al., 2012
[23] SCZ
Copy number variations in iPSCs,
iNCs NPCs Y
∗ N
Dage et al., 2014 [24] Psychopharmacology,ASD
Pharmacological and transcriptome
characterization of iNCs Forebrain neurons N N
DeRosa et al., 2012 [25] ASD iPSC and GABA neuron derivationfrom whole blood GABAergic neurons Y
∗ Y
Doers et al., 2014 [26] Fragile X syndrome iNCs show neurite outgrowth deficit Forebrain neurons Y (3) N
Germain et al., 2014
[27]
Neurodevelopmental
disorders
Gene expression analysis of iPSCs
from 15q11 variants
Differentiated
glutamatergic neurons Y (3) Y
Griesi-Oliveira et al.,
2014 [28] ASD TRPC6 gene is associated with ASD
Differentiated
glutamatergic neurons Y (1) N
Hashimoto-Torii et al.,
2014 [29] SCZ
Heat shock transcription factor 1
mediated stress response abnormalities
in a subpopulation of iNPCs
NPCs Y (4) Y
Hook et al., 2014 [30] SCZ Increased catecholaminerg neuralactivity in SCZ cell cultures
Panneuronal
differentiation protocol Y (4) Y
Chung et al., 2014 [31] Fragile X syndrome Development of a high-contentscreening assay NPCs Y
∗ N
Krey et al., 2013 [32] Timothy syndrome iNCs exhibit dendritic retractiondeficit
Differentiated
glutamatergic neurons Y (2) Y
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Author, publication
date Modeled disease(s) Main findings
Cell line,
differentiation protocol
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derived
cell lines
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Kumari et al., 2015 [33] Fragile X syndrome Development of a high-throughputscreening assay NPCs Y (3) N
Larimore et al., 2013
[34] Rett syndrome
MECP2 regulates synaptic expression
of dysbindin-BLOC1 pathway
Differentiated
glutamatergic neurons Y (2) Y
Lin et al., 2012 [35] SCZ Allele specific expression profile Differentiatedglutamatergic neurons Y (3) Y
Lin et al., 2014 [36] SCZ, ASD Heat shock alters SCZ, ASD-relatedgenes
3-dimensional
neuronal aggregates Y Y
Liu et al., 2012 [37] Fragile X syndrome FMR1 mutation linked phenotype andsignaling deficits Differentiated neurons
Risk
variant
carrier
Y
Madison et al., 2015
[38] BPD
Phenotypic alterations in BPD
progenitors rescued by WNT
inhibition
NPCs
Y (2)
(pedigree-
study)
N
Maekawa et al., 2015
[39] SCZ, ASD
Hair follicle is a potential biomarker
source
iPSC-derived
neurospheres Y Y
Marchetto et al., 2010
[40] Rett syndrome
Morphological and
electrophysiological anomalies
Panneuronal
differentiation protocol Y Y
Maschietto et al., 2015
[41] SCZ
Altered gene expression profile during
neurodevelopment NPCs Y (1) Y
Niedringhaus et al.,
2015 [42] Fragile X syndrome
Mobile raft minicultures developed for
high-throughput assays on neurons
Differentiated neurons
in microraft cultures Y (1) Y
Pas¸ca et al., 2011 [43] Timothy syndrome Disease-specific cellular phenotypeand differentiation
Cortical glutamatergic
neurons Y (2) Y
Paulsen et al., 2014 [44] SCZ Zinc and potassium imbalancereverted by valproate NPCs Y (2) N
Pedrosa et al., 2011 [45] SCZ 22q11.2 deletion delays differentiation Glutamatergic neurons Y (3) N
Robicsek et al., 2013
[46] SCZ
Impaired differentiation, maturation,
and mitochondrial dysfunction Dopaminergic neurons Y (3) N
Roussos et al., 2014 [47] SCZ CACNA1C variation disrupts generegulation through chromosome loops
Differentiated
glutamatergic neurons N Y
Shcheglovitov et al.,
2013 [48]
22q13.3 deletion
syndrome
SHANK3 and IGF1 correct excitatory
synaptic transmission deficit
Differentiated
glutamatergic neurons Y (2) N
Sheridan et al., 2011
[49] Fragile X syndrome Diminished neural differentiation
Differentiated neurons
and glia Y (3) Y
Shi et al., 2014 [50] Psychopharmacology Dopamine 2 receptor is mediated bymicroRNA-9 and microRNA-326 Dopaminergic neurons N Y
Tian et al., 2014 [51] Timothy syndrome Altered Ca
2+ signaling leads to
transcriptional dysregulation
Differentiated
glutamatergic neurons Y (3) Y
Topol et al., 2015 [52] SCZ Altered WNT signaling Forebrain patternedNPCs Y (4) N
Wang et al., 2014 [53] BPD Cell adhesiveness is associated withlithium response
Immature iNs,
lentiviral-based
transdifferentiation
Y (12) Y
Wen et al., 2014 [54] SCZ, MDD
DISC1 mutation causes synaptic
deficits and transcription
dysregulation
Glutamatergic
forebrain neurons Y (2) N
Williams et al., 2014
[55] Rett syndrome
MECP2 mutant astrocyte influences
negatively the morphology and
function of cocultured neurons
Astrocytes Y Y
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Author, publication
date Modeled disease(s) Main findings
Cell line,
differentiation protocol
Patient
derived
cell lines
Free
full text
Yoon et al., 2014 [56] SCZ 15q11.2 CNV results in neural stem celldeficit Neural rosettes, NPCs Y Y
Yu et al., 2014 [57] SCZ Deficit in hippocampal granule neurongeneration
Hippocampus dentate
gyrus granule cells Y (4) Y
Zeng et al., 2013 [58] Neurodevelopment
NRXN1 silencing impacts adhesion
and differentiation related
transcription
NPCs and
differentiated neurons N Y
∗ indicates data were not available.
ASD: autism spectrum disorders; BPD: bipolar disorder; iPSC: induced pluripotent stem cell; MDD: major depressive disorder; SCZ: schizophrenia; NPC:
neural progenitor cell.
(b)
Author(s) (31) Year of publication Disease(s)
Acab and Muotri 2015 [59] ASD
Aigner et al. 2014 [60] ASD
Ardhanareeswaran et al. 2015 [61] ASD
Brennand and Gage 2012 [62] Psychiatric disorders
Brennand et al. 2014 [63] SCZ
Buxbaum and Sklar 2011 [64] SCZ
Chailangkarn et al. 2012 [65] Neurodevelopmental disorders
Cheung et al. 2012 [66] Rett syndrome
Cundiff and Anderson 2011 [67] Neuropsychiatric disorders
Duan 2015 [68] SCZ
Freitas et al. 2014 [69] ASD
Ho et al. 2015 [70] Neuropsychiatric disorders
Cocks et al. 2014 [71] ASD
Kim 2010 [72] Psychiatric disorders
Kim et al. 2012 [73] ASD
Kim et al. 2014 [74] ASD
Ladran et al. 2013 [75] Neuropsychiatric disorders
Liu and Scott 2014 [76] ASD
Mackay-Sim et al. 2011 [77] Neuropsychiatric disorders
Muotri 2015 [78] ASD
O’Shea and McInnis 2015 [79] BPD
Pas¸ca et al. 2014 [80] Neuropsychiatric disorders
Paulsen et al. 2012 [81] SCZ
Paulsen et al. 2013 [82] Neurodevelopmental disorders
Prilutsky et al. 2014 [83] ASD
Qiang et al. 2014 [84] Neuropsychiatric disorders
Schadt et al. 2014 [85] Neuropsychiatric disorders
Tobe et al. 2013 [86] Psychopharmacology
Tran et al. 2013 [87] SCZ
Vaccarino et al. 2011 [88] Neuropsychiatric disorders
Viswanath et al. 2015 [89] BPD
Walsh and Hochedlinger 2010 [90] Rett syndrome
Wright et al. 2014 [91] SCZ
ASD: autism spectrum disorders; BPD: bipolar disorder; SCZ: schizophrenia.
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Key questions are as follows: What are we modeling?
(Which developmental and functional state of the in vivo
neurons?) What kind of indicators and assays should be used
for quality control? iPSCs are considered almost undistin-
guishable compared to human embryonic stem cells; and
iPSC derived NPCs form rosettes, analog to the neural tube,
the embryonic primordium of the central nervous system
[119]. Thus, it is reasonable to assume that we are modeling
fetal neurogenesis and neurodevelopment in cell cultures
under differentiation. Accordingly, Brennand et al. found
that the gene expression profile of NPCs and even 6-week-
old differentiated neurons resembles the first-trimester fetal
brain at the most [16]. Moreover, the electrophysiological
properties of stem cell derived neurons share common
temporal pattern with pyramidal neurons of the postnatal
animal neocortex [120].
However, we have to declare that our knowledge on pre-
and postnatal brain development is restricted and mainly
relies on animal and human fetal brain studies. This limited
insight and the in vitro observations underpin that iPSC
differentiation and iNC maturing follow the in vivo timeline
and stages and react to the same exogenous effects [93].
For instance, Boissart et al. demonstrated that the dif-
ferentiational potential of iNPCs follows a temporal manner
similar to what has been previously described in animal
models [14]. The group delayed cellular commitment with
high-mitogenic medium and sustained NPC proliferation for
passages 8–20. The prolonged proliferation period resulted
in a homogeneous late cortical progenitor population that
spontaneously differentiated into superficial cortical neurons.
Three weeks after withdrawal of mitogenic factors, more than
80% of the cells were glutamatergic. Importantly, the short,
synchronous, and highly productive differentiation period
makes this method amenable to high-throughput assays.
6.2. Doing Well in the Wells. Neurons, specified from pro-
genitor cells, are immature and require 4–12 weeks to reach
their definitive phenotype in vitro, which [119, 121, 122] is a
notable hampering factor of iNC studies. Literature proves
that detailed investigation of this period is crucial for the
following technical and validation reasons.
(1) First, transition from pluripotency to differentiated
neuronal state is attended by complex, pervasive gene expres-
sion changes. Fathi et al. analyzed the differentiation-related
transcriptome dynamics and revealed that 5955 transcripts
were modified during the 4-week-long protocol [123]. Of
note, 2589 transcripts were upregulated in the differentiated
neurons compared to pluripotent cells. On one hand, this
intensive, early period can be used to unveil and under-
stand neurodevelopmental disturbances and bridge between
disease-associated genotypes and endophenotypes. On the
other hand, experimental design, timing, and theories must
be set up circumspectly.
(2) Differentiation and maturation can be influenced
by the culturing conditions; therefore, several researches
proposed protocol modifications to shorten the “before-the-
experiment” period and improve synchronicity. For instance,
Tang et al. compared the neural maturation on two different
surfaces: the most frequently used artificial coating, laminin,
versus astrocyte layer [124]. Astrocytes promoted the differ-
entiation, soma and neurite growth, and dendrite arboriza-
tion. They supported functional maturation with regard to
ion channel and receptor expression and synaptic transmis-
sion. Still, even if cultured on astrocytes, neurons did not
exhibit matured synaptic activity before the third week, and
cells on laminin were further delayed. Astrocyte-conditioned
[125], ascorbic acid [126] and cAMP supplemented [123]
culturing medium or the application of graphene oxide
nanomaterial [127] also accelerates differentiation.
(3) We also cannot pass by the fact that the extended,
responsive maturation may lead to phenotypic heterogeneity
within the dish and result in a mix of progenitors and
immature, partially or fully matured neurons in different
ratios [13]. Additionally, NPCs and neurons display similar
appearance and NPCs express glutamate [128], GABA [129],
and dopamine [130] receptors.
6.3. Casting Neurons. Given the above-mentioned issues, we
suggest that every iPSC/iNC experiment should include the
developmental and functional characterization of the subject
cells. The main approaches for describing a neuron are as
follows: neural marker detection, receptor and ion channel
profiling, electrophysiological analysis, and the evaluation
of synaptic functions via enzyme activity, neurotransmitter
release, metabolism, and reuptake [131].
The methodology of neural marker detection developed
concomitantly with the differentiation protocols. Today, we
are able to generate and identify cortical excitatory gluta-
matergic pyramidal cells [102]; GABAergic inhibitory inter-
neurons [105]; cerebellar Purkinje cells [122]; or dopamin-
ergic neurons of the substantia nigra [131]. However, the
presence of the differentiationmarkers is not indicative of the
neuron’s maturation state.
The work of Dage et al. revealed that detailed pharmaco-
logical characterization of the differentiated neurons would
be much desired since the receptor and ion channel signature
of differentiated neurons may change almost day by day [24].
Furthermore, maturing iPSC-derived neurons do not display
NMDA receptor subunit switch, peculiar to the neonatal
brain [24], which might be a relevant difference between in
vitro and in vivo fashions.
Data suggest that electrophysiological assessment of
the cells might be the most potent approach for defining
maturation states. The electrophysiological development in
vitro resembles postnatal neocortical changes observed in
animal models. Namely, the resting membrane potential
becomes more negative, the duration of action potential
decreases, and the Na+, K+, and Ca2+ currents show time-
dependent changes [120]. The milestones are thought to
be the appearance of spontaneous excitatory postsynaptic
currents (sEPSC) and action potentials in fresh neurons [122]
and capability for repetitive action potentials in matured
neurons [13, 120, 131].
Belinsky et al. went further.They carried out patch clamp,
Ca2+ imaging, and PCR on single-cell level to correlate
the electrophysiological properties and the gene expression
pattern of differentiating and maturing neurons [13]. The
10 Stem Cells International
cells demonstrated action potential already from day 15,
but expression of several neuronal physiology and disease-
associated genes were delayed until day 29 (COMT, DISC1,
DTNBP1,GAD1, andPAX6).These thought-provoking results
press for multimethod validation. Recently, Chatzidaki et al.
[132] demonstrated the detailed pharmacological character-
ization of nicotinic acetylcholine receptors on iPSC-derived
human neurons. The exact time points of the functional and
developmental stages highly depend on the cell type and the
culturing protocol; therefore, an orientating timeline with the
defined, critical landmarks and minimally required valida-
tion assays could assist the interpretation and reproducibility
of in vitro findings. Furtherly, high-throughput assays offer
the possibility to monitor the cell cultures around the clock,
analyze structural and functional alterations (e.g., synaptic
activity), and capture the right time to run hundreds of tests.
6.4. Neurons, into Single File! Weare only beginning to realize
the magnitude of heterogeneity in neuronal cultures derived
from iPSCs. Earlier lines of evidence already highlighted the
fact that, despite the utilization of targeted differentiation
protocols, neuronal cultures remain heterogeneous and give
rise to mixed populations of glutamatergic, GABAergic, and
dopaminergic neurons, as well as astrocytes and undifferenti-
ated cells. Recently, the development of single-cell approaches
makes it possible to determine the ratio of neurons versus
astroglia, neuronal subpopulations, or neurons reaching a
specific stage of maturation, within a population of differ-
entiating neurons. Neuron-to-neuron variation seems to be
a general feature of in vitro as well as in vivo neuronal
populations. Moreover the degree of variation also casts
light on faulty neurodevelopment associated with neuropsy-
chiatric disorders. Shcheglovitov et al. [48] used single-
cell methodology to analyze neuronal cultures derived from
patients suffering from Phelan-McDermid syndrome, a rare
condition caused by 22q13.3 deletion. Besides other major
findings, this outstanding paper also points out that only
a small proportion of neurons express postsynaptic density
proteins SHANK1–SHANK3, indicating small fraction of
synaptically mature neurons. 20–60% of neurons expressed
TBR1, CTIP2, and SATB2 upper layer cortical markers, while
less than 10% of neurons expressed GABAergic markers. In
their methodological summary, Citri et al. [133] provide a
protocol for single-iN qPCR and present data indicating the
low proportion of VGLUT1 and VGLUT2 expressing iNs,
suggesting delayed synaptic maturation in this system [134].
The described single-cell methodology has been successfully
incorporated in several other studies. While neuronal differ-
entiation protocols are much better characterized in recent
years, the above findings illustrate that single-cell approaches
are on the rise and will be important and necessary tools in
the armamentarium of in vitro neuronal disease modeling
efforts.
6.5. Thinking Big. Theoretical concepts of psychiatric dis-
orders changed radically in the recent decades: the immune-
neurodevelopmental model of SCZ and ASD [135], neuro-
inflammation-degeneration theory of MDD [136], and the
need for G×E and network-based diagnostic and therapeutic
approaches became widely accepted. But the revolution is
still delayed in psychopharmacology. One detrimental factor
can be the lengthy, expensive, and animal model based
testing of potential new targets and compounds. Therefore,
robotic high-throughput assays on human cell lines could
be milestones in the paradigm shift towards human biology
based, in vitro drug development [137]. iPSC/iNCs can be
optimal subjects for these studies.
Fragile X syndrome is neurodevelopmental disorder
caused by a silencing mutation of the FMR1 gene. Recently,
two independent research groups developed and published
high-throughput screening methods for FMR protein detec-
tion and novel drug identification using patient-derived
iNPCs [33, 138]. Kumari et al. designed a time-resolved flu-
orescence energy transfer (TR-FRET) based assay to measure
FMRP levels in 1 536wells and screen 1 280 pharmacologically
active compounds parallel to identify those which increase
the expression of the silenced gene [33]. The most effective
molecules were retested in a secondary assay using qRT-
PCR and further confirmed by dose-response experiment.
Kaufmann et al. used high-content screening to observe cell
morphology and FMRP expression alterations and tested the
efficacy and toxicity of 50 000 compounds [138]. Importantly,
automated high resolutionmicroscopy andmachine learning
algorithms allow single-cell-based follow-up and data analy-
sis in living cultures; therefore the group was able to detect
that a remarkable subpopulation of the cells (40%) responds
to certain drugs, although the averaged measures did not
reach significance.
Both works demonstrated a sensitive, cost-effective
approach for drug development. However, we have to add
that the utility of progenitor cells is frequently subopti-
mal or invalid in psychopharmacology; and current high-
throughput methods are optimized for proliferating, easily
transferable cell lines and not for postmitotic neurons [42,
139]. To reduce the technical difficulties, Niedringhaus et al.
worked out a transferable raftminiculturing practice for neu-
ron cultures which provide sufficient experimental material
for microvolume reactions and appropriate sample sizes [42].
Notably, the cell viability, sample-to-sample reproducibility,
and screening potential proved to be higher than those on
conventional well-plates.
An additional hampering factor might be the time-
consuming derivation and characterization of neurons from
somatic cells accompanied by several technical pitfalls.
Research industry offers several genetically modified iPSC-
derived neurons which can be a faster model for drug
development after thorough validation [125].
6.6. Double Standard: Stable and Flexible. The iPSC/iNC line
generation requires stem cell-like, incompact chromatin and
multiple epigenetic rearrangements. Controversially, scien-
tists agree that a high-quality iPSC/iNC assay conserves the
donor’s genetic information (including parental imprinting).
The NIMH meeting participants, and many since then,
conceived a reasonable concern on the genetic (un)stability
of induced cell lines [10].
Previously, chromosome aberrations, gene deletions/
duplications, and point mutations were thought to be the
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main mechanisms responsible for de novo mutations during
the pluripotent state. However, multiple studies demon-
strated that iPSCs and iNPCs exhibit chromosomal stability
(one examined 1700 stem cell cultures [140]). Per contra,
copy number variations (CNVs) show significant incidence
[23, 112]. All of the investigated cell lines gained CNVs and
the CNV signature of the iPSCs differed from both somatic
parent cells and iNCs. This indicates that de novo mutations
may appear through the somatic cell-iPSC-NPC-neuron
transitions. On the other hand, mosaicism for CNVs is also
common in vivo: it represents 0.12–7.3% of intraindividual
genomic variability [141].
Keeping in mind that CNVs are known to influence
clonal selection in cell cultures [142] and participate in the
etiology of several human diseases, including neurodevelop-
mental disorders (SCZ [143], ASD [31], and ADHD [144]),
the iPSC/iNC quality control calls for reconsideration. It
was always supposed but, recently, Kang et al. proved that
genetic integrity is highly influenced by the reprogramming
technique, and DNA nonintegrating protocols are safer [145].
Thepreviously recommended karyotyping is not sufficient for
ensuring validity; instead, DNA sequencing of the source and
generated cells is desirable.
6.7. The Neuronal Genome: Imperfectly Imitable? Somatic
mosaicism affects the brain also: brain-only or brain region-
only somaticmutations, chromosome aneuploidy,microdele-
tions, or retrotransposon dynamics have been detected in
post mortem brain tissue. Presumably, these neural genomic
variations contribute to the functional heterogeneity of
brain cells and also to the development of neuropsychiatric
disorders [146]. For instance, L1 retroelements (the only
human retrotransposon with autonomous activity) exhibit
increased copy number in adult NPCs compared to non-
brain cells and are known to be associated with Rett syn-
drome [147]. Bundo et al. examined the L1 signature in
SCZ using multiple model systems [18]. First, they showed
that L1 copy number is increased in the prefrontal cor-
tical neurons of SCZ patients compared to controls and
autologous nonbrain cells. To answer the question whether
this ensues from hereditary or environmental factors, the
group assessed the L1 profile in an environment-induced
SCZ animal model and in iNCs derived from SCZ patients
with rare mutation of large effect (22q11 deletion). The
genomicDNAof themouse brain exhibited the consequences
of high L1 activity and they also detected increased L1
insertion rate during in vitro neurogenesis. Moreover, brain-
specific L1 insertion sites were near or in genes involved
in synaptic functions and neuropsychiatric disorders sup-
porting the possible pathognomic role of retrotransposition
events. For conclusion, we can speculate that increased
L1 dynamics by environmental and/or genetic factors may
increase the susceptibility to neurodevelopmental disorders
by disrupting synaptic and schizophrenia related genes in
neurons.
This outstanding experimental design reassures the valid-
ity of iPSCs/iNCs in modeling neurodevelopment and calls
for further studies on the neuronal genome.
6.8. Designation of Origin. Besides the above-mentioned
somatic mosaicism, cellular commitment and in vivo cell-
aging raise the following question: Does the source cell type
matter? Neuropsychiatric studies apply the most frequently
easy-to-obtain lymphocytes, fibroblasts, and keratinocytes;
but, theoretically, all somatic cells can be reprogrammed or
transdifferentiated into iPSCs and iNCs.
These somatic cells widely vary in their epigenetics,
proliferative potential, and the rate of cellular aging. Previous
studies found that the intrinsic properties of the source
cells, that is, stage of differentiation [148], senescence [149],
tissue type [150], and number of passages [151], influence the
efficacy of reprogramming. Furthermore, the generated cells
display a residual gene expression pattern of the source cell
type referring to “incomplete reprogramming” and result in
variability among iPSCs from different tissue samples [152].
Chen et al. speculated that induced cell lines may
retain and transmit transcriptional/epigenetic marks from
the source tissue to the differentiated cells; therefore, they
carried out whole transcriptome analysis in neurons gained
from fibroblasts or dental pulp [20]. Notably, they found
63 differentially expressed genes, including a glutamate
receptor, choline, GABA, and glycine transporter. Striking
differences were found in the expression of the SLITRK2
gene (associated with BPD and ASD), multiple HOX genes,
and a set of transcription factors. Pathway analysis revealed
that neurological disease/schizophrenia related gene sets are
the most affected [20]. Unfortunately, the interpretation of
the results might be problematic since the dental pulp was
obtained from a 12-year-old male subject, while fibroblasts
originated from a 30-year-old female and a 58-year-old male.
However, the experiment is highly noteworthy: even if we
conclude that the source cell type or the donor’s age passed
down through generations and affected the gene expression
of the iNCs, it urges for further research.
6.9. Patients Ill Sorted? One of the main research principles
is representativeness: the sample has to be an unbiased illus-
tration of the studied population. Psychiatric diagnostic cate-
gories cover a wide range of patients with great heterogeneity
in etiological factors, symptomatology, disease progression,
and therapy response. This diversity issued several difficul-
ties in experimental and clinical settings during the past
decades.
Now, the overlook is changing: DSM-5 omitted the pre-
vious SCZ subtypes defined by clinical symptoms [153]. Two
years later, the Consortium on the Genetics of Schizophrenia
(COGS) postulated that endophenotypes could provide a
more negotiable approach of patient categorization for clini-
cal and research purposes [154]. Endophenotypes, for exam-
ple, cognitive dysfunction, EEG-markers, or brain imaging
phenotypes, are quantitative laboratory based measures with
a same level of heritability as SCZ itself [155]. They can
be linked to certain genotypes, cellular phenotypes, psy-
chopathologies, and functional impairments and fill the gene
to phene gap. The NIMH workshop in 2012 also addressed
the critical step of patient selection and recommended subject
recruitment based on comprehensive clinical, genetic, and
cellular characterization.
12 Stem Cells International
6.10.The Art of Design. Disrupted in schizophrenia 1 (DISC1)
gene is known to be involved in fetal and adult neurode-
velopment and neuroplasticity, and its variations are highly
associated with a wide range of mental disorders: SCZ, BPD,
MDD, and ASD as well [156]. Presumably, it predisposes to
endophenotypes which can manifest themselves in different
clinical syndromes depending on the genetic and environ-
mental cofactors [157].
Wen et al. aimed to study cellular consequences of
the DISC1 mutation [54]. They derived iPSC lines from a
carrier pedigree: one SCZ and one MDD patient with a
DISC1 frameshift mutation, two unaffected family members
without the mutation, and one additional control: an unre-
lated healthy subject. The DISC1 mutation caused functional
synaptic transmission deficits in the glutamatergic neurons
via pervading transcriptome alterations. To challenge their
hypothesis on the primary pathognomic effect of the DISC1
mutation, the research group repeated the measures with
the isogenic pairs of the cell lines, generated by DNA
editing. Over and above the obvious values of their results
in understanding DISC1 related pathophysiology and filling
the gap between the genotype and the clinical picture with a
cellular endophenotype, this work provides a great example
for careful, overthought study design.
Considering that patient iPSC/iNC studies are usually
conducted on small sample sizes (1–5 persons/group) and
advancements are trending towards personalized medicine,
careful case-control matching in iPSC/iNC research is crucial
tomaintain validity and reliability.Whenmonogenic diseases
(e.g., Rett and Fragile X syndrome) are investigated, the
gender, age, and/or genotype based selection of healthy
individuals is sufficient. Per contra, in case of polygenic neu-
ropsychiatric disorders with intermediate heritability (30–
70%) other designs are noteworthy since the combined effect
of all disease-related and irrelevant alleles manifests itself in
the dish [158].
For instance, pedigree-studies allow identifying heri-
tability factors. Inclusion of affected and unaffected family
members reduces the genetic noise (heterogeneity) and thus
the risk of type I error. While a second, independent control
group from out-of-pedigree healthy subjects helps to oversee
the potential effects from family genetic background. Iso-
genic pairs produced by genetic correcting technologies (e.g.,
TALE nuclease [159], zinc finger nuclease [160], homologous
recombination [161], or CRISPR [162]) allow a cell line to be
its own control and enables the targeted testing of single gene
effects via excluding (epi)genetic diversity. In some cases (e.g.,
CNVs, trinucleotide repeats, and X-linked disorders), in vivo
or in vitromosaicism provides isogenic controls [26].
6.11. Psyche in the Dish? The question is not sceptic by all
means. How can we validate a specific iPSC/iNC line for
modeling a psychiatric disorder? Chromosomal and cellular
marker characterization and evaluation of genetic stability
are only the base of quality control. Having differentiated
neurons does not evidence a model for neurophysiology or
disease neuropathology.
Two research groups aimed the validation of a commer-
cially available neural cell line for further studies on ASD and
neurodegenerative diseases [1, 24, 125]. The corroboration
included whole transcriptome analysis, receptor and ion
channel profiling, and detailed electrophysiological charac-
terization. According to their results, the cells display early
developmental neural phenotype and express the majority of
ASD associated genes and thus this cell line might be utilized
as control in comparison to patient-derived cells or suitable
for isogenic mutant—wild type pair generation.
Interestingly, many of the ASD-related genes showed
changes along the culturing process [24], and Belinsky et
al. also detected specific temporal manner in the genes of
interest (DISC1, DTNBP1, GAD1, PAX6, FOXP1, FOXP2,
vGLUT1, and COMT) [13]. This sounds reasonable since the
mentioned genes are linked to neurodevelopment, synaptic
transmission, and intracellular signaling, functions highly
implicated during neural maturing. However, these obser-
vations are worthy of note, suggesting that timing can
easily enhance or undermine the validity of the experi-
ment, especially when the most frequently used early neural
and forebrain markers (PAX6 and vGLUT1 and GAD1) or
canonical disease genes (DISC1 and COMT) are the subjects.
Concordantly, Wen et al. found that DISC1 mutation caused
structural anomalies and synaptic dysfunction attenuate
around postdifferentiation weeks 4–6 [54].
Usually, experimental data can be embedded into pre-
vious results and legitimized by the cited literature. Con-
sidering the novelty of the field and the limited number of
research papers, iPSC/iNC researchers can rarely expect their
model’s validation from preceding experiments. Comparing
the results with animal model and human postmortem
findings can offer pivots; however, dissimilaritiesmight ensue
from differences between species and cell types since we are
matching pure neuron cultures with tissues [41].
6.12. Grafting Neurons for Psychiatric Treatment? Three
future applications of iPSCs and iNCs are most commonly
predicted [24]. As model systems, they can help us under-
stand the cellular pathophysiology of neuropsychiatric dis-
orders and reveal genotype-phenotype correlations. High-
throughput cellular screening assays may provide novel
targets in drug development; and, finally, iPSC-derived cells
may play a role in regenerative medicine.
Induced or embryonic PSC-based replacement therapy
research is one of the most expeditiously developing fields
of medicine. Currently, clinical trials are in progress in
macula degeneration, type I diabetes mellitus, ischemic
heart failure, and spinal cord injury [163]. Preclinical results
are also promising in Parkinson’s and Alzheimer’s disease,
neurodegenerative disorders with well-defined pathological
and functional alterations and cellular loss (recently reviewed
in [163, 164]). And what about other psychiatric disorders?
Animal models can provide us with hints about this appli-
cation.
For instance, SCZ has multifactorial origin which per-
vades the whole connectivity during neurodevelopment
and results in poorly understood brain pathology. Human
and animal research suggest that cortical and hippocampal
inhibitory interneuron deficit contributes to the dopamin-
ergic system dysfunction, thus the positive symptoms of
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SCZ [165]. In rodents, embryonic and induced human and
nonhuman NPC grafts survive, proliferate, migrate, and
differentiate spontaneously into pyramidal or GABAergic
neurons [166–168]. The integration of these inhibitory neu-
rons into the host neural circuits successfully modulated
the hyperactive dopaminergic system and the behavior
analogous of positive symptoms in a mouse SCZ model.
While these engraftment experiments are perplexing and can
contribute substantially to our understanding of the neurobi-
ology of psychiatric disorders, they donot necessarily forecast
engraftment of in vitro differentiated neurons as a feasible
approach for the treatment of psychiatric disorders in the
near future. Disease pathology remains poorly understood
and the clinical hurdles are also numerous.
6.13. Open Access in Stem Cell Based Disease Modeling. The
NIMH workshop addressed one more intensively discussed,
still actual issue: information and resource sharing which
is especially meaningful in the rapidly developing scientific
fields such as iPSC/iNC research [10].The participants argued
that open sharing of data and standardization of iPSC/iNC
generation and validation protocols are essential for improv-
ing experimental reproducibility.
It is well known that open sharing and collaborative
environment empower knowledge circulation and thus fuels
innovation and discovery. Therefore, decision-makers took
significant steps to implement the open access policy: in
2015, both the European Commission and the US Congress
supported the proposal that articles on publicly funded
researches have to be freely available for anyone [169, 170].
We were curious if this open access movement is observable
in the iPSC/iNC literature.We found that 73%of the reviewed
research papers are freely accessible (35 from48 articles, listed
in Table 2(a)).
The other basis of open science is resource sharing.
Growing number of cell banks collect somatic cells and/or
iPSCs from patients with neuropsychiatric disorders and
assure accessibility for the scientific community on request
[17, 171]. Such (inter)national consortiums and collaborations
provide standardized databases and methodology, increased,
homogenous sample quality, and possibility to study rare
genetic or phenotypic variations, affected families, or—as
seen in Sweden—isogenic cell line pairs from monozygotic
twins [172].
7. Tools in Our Hands:
We Have Nothing to Fear
The ideal cell culturemodel for in vitro experimentsmeets the
following requirements: (1) it is easily obtainable via minimal
invasive intervention; (2) the initiation and maintenance of
the cell culture are not extremely labor intensive or time-
consuming; (3) the fact that differentiation, if necessary,
can be directed and monitored; (4) the cell line reserves
proliferative, self-sustaining capacity over passages; (5) and
this is done with genetic stability; (6) it exhibits similar (or
identical) pathophysiological features to the diseased tissue in
vivo; and (7), last but not least, the method provides enough
experimental material at reasonable expenses.
Revising the currently available in vitro systems, the
words of Salvador Dali flash on: “Have no fear of perfection
– you’ll never reach it.” Ideal in vitro model cannot exist,
but depending on the concept of the research and the
accessible resources one can choose the most optimal from
the following.
Extended literature discusses peripheral cells, such as
blood leukocytes and dermal fibroblasts, as potential in
vitro models and biomarker sources of mental disorders.
They are relatively easy-to-obtain, robust cell lines and
share receptor and signaling pathway similarities with CNS
cells [173–175]. Fibroblasts have self-maintaining capacity
ab ovo and maintain homogeneity between passages 5 and
20 [176]. Freshly isolated leukocytes are appropriate even
for bedside functional assays or can be immortalized for
culturing but represent poor genetic stability [177]. Finally,
we cannot disregard that peripheral cells do not permit the
examination of specific neural phenomena (e.g., electrophys-
iology, microarchitecture, and neurodevelopment).
Human primary neural cultures, initiated from brain
biopsies, are barely applied to neuroscience.They require spe-
cial conditions and lack self-maintaining capacity; therefore,
the amount of experimental material is restricted. Furtherly,
the cells are already tainted with life-long in vivo effects,
which balks the expression of the na¨ıve endophenotype.
Since 2006, when Takahashi and Yamanaka showed that
the expression of four transcription factors can reprogram
adult somatic cells into an earlier ontogenic state [98],
induced pluripotent stem cells (iPSCs) and iPSC-derived cell
lines became one of the most studied and advancing fields of
medicine; but, as seen above, we still face numerous technical
or theoretical issues.
8. Can We Make a Long Story Short?
The main concerns about iPSC-research, that is, time and
resource demands, genetic instability, epigenetic changes, and
populational heterogeneity, might be partially overcome by
omission of the pluripotent state and direct transdifferen-
tiation of somatic cells into completely different cell types.
After Takahashi and Yamanaka introduced the method of
cellular reprogramming, researchers started to work on new
protocols to establish neural cultures from somatic cells by
direct cell lineage conversion. Vierbuchen et al. were the
first who successfully transdifferentiated mouse fibroblasts
into functional neurons [95]. Since then, they and others
showed that human somatic cells (e.g., fibroblasts [134], blood
cells [178], and hepatocytes [179]) can be transdifferentiated
into neural progenitor cells [180] or postmitotic neurons
via forced expression or exogenous addition of transcription
factors,microRNAs, or smallmolecules.Moreover, one single
factor is enough to induce neural cell fate [181] and cell
type-specific factors allow the generation of dopaminergic
[182], motor neurons [183] or oligodendrocytes [184]. The
induced neural cells resemble in vivo neurons in their
functional, electrophysiological, translational characteristics
and form functional synapses; thus, they can be valuable
in vitro models of neuropsychiatric disorders. However, as
of yet only one experiment has been published on direct
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reprogramming in the context of psychiatric disorders.Wang
et al. [53] used lentiviral transduction with a construct
expressing miR-9/9∗-124, NEUROD2, ASCL1, andMYT1L to
transdifferentiate fibroblasts from bipolar patients responsive
or unresponsive to lithium medication, the gold standard
of mood-stabilizing treatments. iNCs derived from lithium-
responders and lithium-nonresponders demonstrated differ-
ent cell adhesion characteristics. This innovative approach
demonstrates the translation potential and “nearly bedside”
application of transdifferentiation-based assays.
The greatest advantage of direct lineage conversion is
bypassing pluripotent states and avoiding potential onco-
genicity as a consequence. On the other hand, this stability,
that is, lack of self-renewal and potential amplification,
might be a drawback in laboratory research and regenerative
medicine. Besides, the possibility of residuals from in vivo
cellular senescence and epigenetic memories inherited from
the parental tissue deserves further considerations [185].
9. The Undeservedly Neglected:
Glia-Associated Pathologies
Vast majority of psychiatric research deals with neurons but
they account for only about one-third of human brain cells.
Glial cells are responsible for maintaining brain homeostasis
and neural well-being. They provide lactate as source of
energy, regulate the redox balance, metabolic clearance, and
CNS immunology [186, 187], and play crucial role in directing
neuronalmigration, neurite outgrowth, and synaptic pruning
[188]. Additionally, astrocytes are in bidirectional cross talk
with neurons, and glial neurotransmission has been proposed
to be involved in several mental functions (e.g., memory,
motor control, and decision making) and neuropsychiatric
disorders [189]. Postmortem human and animal studies
proved that glial cells contribute to the development and
progression of psychiatric disorders and can be potential
therapeutic targets [190, 191].
NPCs derived from iPSCs can be differentiated into glial
precursors and mature astrocytes and oligodendrocytes [192,
193]. Microglial-like cells are even more easily obtainable
due to their mesodermal origin, and circulating monocytes
can be transdifferentiated within 14 days [194]. These cell
lines are underrepresented in psychiatric research, only used
as a feeder/supporting layer for the neurons. Per contra,
they are intensively studied as potential disease models and
therapeutical targets in neurological disorders, for example,
Huntington disease [195], amyotrophic lateral sclerosis [196]
or congenital hypomyelination [197], and intellectual disabil-
ity [198].
Yet, we can find a great example: how neuron-glia cocul-
tures can help to answer whether certain glia-associated
pathologies are pathognomic factors, additive part of the
endophenotype, or reactive (beneficial) response to the neu-
ral dysfunction. Williams et al. differentiated astrocytes and
neurons from iPSCs of Rett syndrome patients and demon-
strated that mutant astrocytes have non-cell-autonomous
adverse effects both on cocultured mutant and on healthy
neurons [55]. The group also proved that this impact is
directed by the extracellular environment since the astroglia-
conditioned media took the same detrimental effect on the
morphology and function of wild type and mutant neuronal
cultures. The adverse effects could be rescued by IGF-1
supplementation which underpins the ongoing IGF-1-based
clinical trials in the treatment of Rett syndrome. Surprisingly,
the efficiency of IGF-1 supplementation depended on the
genotype of the astrocyte, which calls for further pharma-
cogenetic studies. According to these findings, the effects of
the mutations in the astrocytes and neurons appear to be
additive. Similar innovative studies will unravel the complex
association of human neurons and glial cells in healthy and
diseased brains.
10. Limitations
On the whole, results are reassuring.Those who reported dif-
ferentiation and maturation anomalies in iNCs from patients
with neurodevelopmental disorders [37, 41, 43, 45, 46, 49]
are more than those who could not detect alterations during
differentiation [14] or in electrophysiological properties [13,
54]. However, there are some noteworthy study design and
publication biases.
(1) Scalability represents a central issue for stem cell based
disease modeling. Ideally, the number of cell lines derived
from specific patients could be scaled up to numbers typical
for clinical studies, meaning tens or hundreds of patients.
Realistically seen, today this is not feasible. However wemust
keep in mind that this method is in its infancy and the task
remains the exploration of cell lines derived from genetically
and clinically well characterized individuals.
(2) A priori hypotheses influence the objectives and the
measured parameters. Differentiation is intensively moni-
tored in these diseases; therefore, such small-scale variations
like 12% nuclear size differences can be detected [11], but less
is known about the transcriptome or receptor profile alter-
ations. (3) Majority of the studies examined the iPSC/iNC
lines at rest in monotonous environments which might be
detrimental during neurodevelopment, that is, specialization
for signal detection and transmission.Therefore environmen-
tal challenges could enhance and reveal additional differences
as showed in [29, 36]. (4) Great proportion of these differ-
ences might affect synaptic transmission which is understud-
ied in iPSC/iNC models; however, novel visualization and
high-content screening technologies might bring advances to
this field. For instance, functional assays of DISC1 mutant
cells, namely, spontaneous synaptic current measurement
and synaptic vesicle staining in living cells, revealed synaptic
vesicle release defect which were also observable in the
transcriptome [54].
(5) Similarly, there is a rate shift towards pervasive,mono-
genic neurodevelopmental syndromes with early-childhood
presentation and well-defined clinical and genetical picture.
The nature of these syndromes differs substantially from
the most frequent adult psychiatric disorders which are
multifactorial with less robust pathology and might show
themselves in the connectome and not on the single-cell level.
(6) Additionally, in case of polygenic disorders, the discrete
phenotypic alterations might be very small, presented on a
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continuous spectrum. In contrast, iPSC/iNC studies usually
recruit psychiatric patients with rare mutations of large
effects. Selection of severe cases based on the polygenic
score method could be a possible approach to overcome this
limitation.
11. Take Home Messages
This review demonstrates the unprecedented possibilities
offered by iPSC based in vitro disease modeling in psychiatry,
a field ofmedicine awaitingmajor developments. It is striking
how fragmented our understanding is about molecular dis-
ease pathways underlying SCZ, BPD, and ASD and how high
the level of unmet needs is among patients suffering from
these disorders. Incomplete therapeutic response, therapy-
resistance, and cognitive deterioration are all major hurdles
in the treatment of psychiatric patients. In vitro disease
modeling will help us with diagnostics by demonstrating
the heterogeneity within clinical disease groups in terms
of molecular disease mechanisms. This question, whether
similar clinical phenotypes share molecular foundations or
are rather determined by a final common pathway, remains a
central idea in psychiatry. Stem cells could also contribute to
treatment by paving theway to personalized pharmacological
treatment and drug screening as detailed in the review.
The prospects of stem cell based disease modeling cannot
be exactly foreseen; however, based on the past few years’
developments we can envisage major breakthroughs in stem
cell based psychiatry for the benefit of our patients.
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